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Abstract 
 
Mathematical models of physiological processes can be used in critical care and 
anaesthesia to improve the understanding of disease processes and to guide 
treatment. This thesis provides a detailed description of two studies that are 
related through their shared aim of modelling different aspects of brain 
physiology. 
 
The Relationship Between Transcranial Bioimpedance and Invasive Intracranial 
Pressure Measurement in Traumatic Brain Injury Patients (BioTBI) Study 
describes an attempt to model intracranial pressure (ICP) in patients admitted 
with severe traumatic brain injury (TBI). It is introduced with a detailed 
discussion of the monitoring and modelling of ICP in patients with TBI alongside 
the rationale for considering transcranial bioimpedance (TCB) as a non-invasive 
approach to estimating ICP. The BioTBI Study confirmed a significant 
relationship between TCB and invasively measured ICP in ten patients admitted 
to the neurological intensive care unit (NICU) with severe TBI. Even when using 
an adjusted linear modelling technique to account for patient covariates, the 
magnitude of the relationship was small (r-squared = 0.32) and on the basis of 
the study, TCB is not seen as a realistic technique to monitor ICP in TBI. 
 
Target controlled infusion (TCI) of anaesthetic drugs exploit known 
pharmacokinetic pharmacodynamic (PKPD) models to achieve set concentrations 
in the plasma or an effect site. Following a discussion of PKPD model 
development for the anaesthetic drug propofol, the Validation Study of the 
Covariates Model (VaSCoM) describes a joint PKPD study of the Covariates Model. 
Pharmacokinetic validation of plasma concentrations predicted by the model in 
forty patients undergoing general anaesthesia confirmed a favourable overall 
bias (3%) and inaccuracy (25%) compared to established PKPD models. The first 
description of the pharmacodynamic behaviour of the Covariates Model is 
provided with an estimated rate constant for elimination from the effect site 
compartment (ke0) of 0.21 to 0.27 min-1. 
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1 Introduction to Mathematical Modelling in 
Neurological Intensive Care and Anaesthesia 
 
1.1 The Need for Modelling 
In anaesthesia and critical care medicine, patients undergo continuous 
monitoring of their physiological systems. Developments in healthcare 
information systems mean that increasingly vast quantities of physiological data 
are being stored. There is mounting recognition that despite the significant time 
and resources that are consumed to collect these data, they are not being used 
to their full potential(1). In the ideal situation, data can be used to guide 
clinical management, predict outcomes and improve understanding of disease 
processes. To achieve this ideal, there is a need to utilise the advances in 
methods for the study of dynamic systems and in particular the techniques of 
mathematical modelling(2).  
 
1.2 The Principles of Modelling 
A model is a representation of reality and can only ever be an approximation of 
that reality(3). Mathematical models can be described in terms of their purpose 
or in terms of the approach to the modelling process (Figure 1.1).  
 
The approach to mathematical modelling can be to either model the data or to 
model the system(4). In a data driven approach there is no need for existing 
knowledge of the physiological system of interest. Instead, these models can be 
considered as a “black box” where statistical modelling techniques are used to 
describe available experimental data. In contrast, for a physiologically derived 
model there is a requirement for existing knowledge of the system and the 
model is developed to represent this knowledge. 
 
The purpose of mathematical modelling of physiological systems can be 
considered as predictive, explanatory or both. A predictive model aims to 
predict the future behaviour of the system under investigation. Meanwhile, an 
explanatory model aims to improve the understanding of the system of interest. 
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Figure 1.1: The relationship between modelling approach and modelling purpose. 
The process of mathematical modelling involves the stages of model building, 
model identification, model simulation and model validation. The details of this 
process will vary significantly depending on the specific model being developed 
(Table 1.1). 
 
Model Type Model Features Model Type Model Features 
Deterministic Fixed model inputs 
provide fixed model 
outputs 
Stochastic 
 
Model outputs account for 
randomness observed in 
physiological systems 
Static Model describes system 
at single point in time 
Dynamic Model describes system as it 
changes in time 
Discrete Model samples 
physiological data at 
distinct time points 
Continuous Model of physiological system 
is allowed to change at any 
point in time 
 
Table 1.1: Categorisation of physiological models. 
1.3 Modelling of the Brain 
The clinical settings of the two studies presented in this thesis were firstly the 
neurological intensive care unit (NICU) and secondly the operating theatre, 
specifically in patients undergoing general anaesthesia to facilitate surgery. In 
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both of these settings there is a need to model either the effects of disease 
processes or of specific therapies on the physiology of the brain.  
 
The NICU provides the facilities and expertise to care for patients who suffer 
severe brain injuries with a variety of aetiologies ranging from trauma and 
vascular events to infection and malignancy. In these patients, specialised 
devices, such as the intracranial pressure monitor, can be used to monitor the 
disease process and thus inform treatment decisions. Modelling of the data 
provided by these devices has led to an improved understanding of the 
pathological processes following brain injury. There is an increasing demand to 
develop “non-invasive” monitoring and so avoid the potential complications of 
devices that require placement within the brain parenchyma. 
 
The first study (BioTBI) is a pilot study to model the relationship between 
transcranial bioimpedance (TCB) and invasively measured intracranial pressure 
(ICP) in patients with traumatic brain injury (TBI). Without existing knowledge of 
the relationship between TCB and ICP the model derived is primarily data 
driven. It is an example of a stochastic, static, discrete model. The ultimate aim 
of this study was to begin development of a non-invasive technique to estimate 
ICP. 
 
General anaesthesia can be regarded as a triad of hypnosis (or unconsciousness), 
analgesia (or pain relief) and muscle relaxation. The target sites of drugs used to 
achieve the hypnotic component of general anaesthesia are within the brain. 
There is therefore a call for models that can predict the dosing requirements to 
achieve adequate delivery of drugs to the brain and then to predict the clinical 
effects of these drugs. 
 
The second study (VaSCoM) is a validation study of a three compartment 
pharmacokinetic (PK) model for the intravenous anaesthetic drug propofol. The 
“Covariates Model”(5) is an update to a model (The Marsh Model(6)) in wide 
clinical use that was previously adapted to account for the observed 
pharmacokinetic data. It is an example of a deterministic, dynamic, continuous 
model. The dual aims of this study were to firstly validate the pharmacokinetic 
component of the model and secondly to expand the model to account for 
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pharmacodynamic behaviour. This involved the use of processed 
electroencephalography (pEEG), a non-invasive brain monitoring technique, to 
quantify the effect of propofol on the brain. 
 
A narrative review of the literature and discussion of existing models relevant to 
the two studies is provided in this thesis. The BioTBI and VaSCoM studies are not 
only related by their shared aim of modelling aspects of the brain, but also 
through the approach taken to the modelling process. All of the data collected 
were converted into standardised non-proprietary formats, while all of the 
analyses were performed using the open source statistical programming 
environment “R”(7). The consequence of this is that all data and models can be 
shared with interested research groups with diverse expertise in fields ranging 
from medicine to mathematics and clinical physics to computing science.  
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2 Monitoring and Modelling of Intracranial Pressure in 
Patients with Traumatic Brain Injury 
 
2.1 Overview 
Since Monro published his observations on the nature of the contents of the 
intracranial space in 1783 there has been investigation of the unique relationship 
between the contents of the skull and the intracranial pressure (ICP). This is 
particularly true following traumatic brain injury (TBI), where it is clear that 
elevated ICP due to the underlying pathological processes is associated with a 
poorer clinical outcome. Consequently, there is considerable interest in 
monitoring and manipulating ICP In patients with TBI.  
 
The two techniques most commonly used in clinical practice to monitor ICP are 
via an intraventricular or intraparenchymal catheter with a microtransducer 
system. Both of these techniques are invasive and are thus associated with 
complications such as haemorrhage and infection. For this reason, significant 
research effort has been directed towards development of a non-invasive 
method to measure ICP. In this introduction there will be a detailed review of 
the existing non-invasive ICP monitoring technology. The final section will then 
be an overview of the theory underlying the BioTBI study.  
 
The principle aims of ICP monitoring in TBI are to allow early detection of 
secondary haemorrhage and to guide therapies that limit intracranial 
hypertension and optimise cerebral perfusion. However, information from the 
ICP value and the ICP waveform can also be used to assess the intracranial 
volume-pressure relationship, estimate cerebrovascular pressure reactivity and 
attempt to forecast future episodes of intracranial hypertension.  
 
The following introduction to monitoring and modelling of intracranial pressure 
in patients with traumatic brain injury is an updated and extended version of a 
previously published review article(8). 
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2.2 Introduction to Traumatic Brain Injury 
The pathophysiology of TBI can divided into primary and secondary injury. The 
primary injury may include focal haematomas, contusions or diffuse injury that 
leads to a cycle of hypoxic ischaemic injury associated with inflammatory and 
neurotoxic processes (Figure 2.1). This secondary injury is exacerbated by 
secondary physiological insults such as hypoxia, hypo or hypercarbia, 
hypotension, hyperthermia and hypo or hyperglycaemia. A rise in ICP, or 
intracranial hypertension (ICH), is a secondary insult that can result from the 
primary injury, vascular engorgement, obstruction to cerebrospinal fluid (CSF) 
flow or cerebral oedema. It is known to be associated with poorer outcomes(9), 
which has led to considerable interest in its monitoring and manipulation in 
patients who have suffered TBI. 
 
Figure 2.1: The inter-relationship between primary and secondary injury in TBI. 
Secondary physiological insults can potentiate ischaemia and lead to exacerbation of 
secondary injury. ICP = intracranial pressure. Adapted from Maas et al(10). 
Normal ICP in healthy adults is usually regarded as 5 to 15 mmHg(11) and in TBI 
an ICP of >20 mmHg is widely accepted as ICH(12). The principle aims of ICP 
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monitoring in TBI are to allow early detection of secondary haemorrhage and to 
guide therapies that limit ICH. In addition, measurement of ICP and mean 
arterial pressure (MAP) allows calculation of cerebral perfusion pressure (CPP):  
 
𝐶𝑃𝑃 = 𝑀𝐴𝑃 −𝐼𝐶𝑃 (2.1) 
            
Attempts can then be made to optimise cerebral perfusion pressure with the aim 
of preventing cerebral ischaemia. 
 
There is ongoing debate over the central role of ICP monitoring in the clinical 
management of TBI. This is particularly relevant in the context of a recent 
randomised controlled trial (RCT) that did not show an outcome benefit in 
patients undergoing ICP monitoring with a treatment threshold of 20 mmHg 
when compared to patients that were not monitored(13). The purpose of this 
review is therefore to reconsider some of the basic science underlying ICP 
monitoring and the intracranial pressure-volume relationship in adults. With this 
pretext there will then be support for the arguments of other authors for the use 
of ICP as “more than a number” or a generic treatment threshold(14). Instead, 
the information within ICP trends and the ICP waveform can be used to provide 
individualised treatment thresholds and forecast future episodes of ICH. 
 
2.3 Concepts and Historical Perspectives 
2.3.1 Intracranial Contents 
The Monro-Kellie hypothesis describes the relationship between the contents of 
the skull(15). In 1783, Monro published his observations that: the brain was 
enclosed in a non-expandable case of bone; the substance of the brain was 
nearly incompressible; the volume of the blood in the cranial cavity was 
therefore constant or nearly constant; and a continuous outflow of venous blood 
from the cranial cavity was required to make room for the continuous incoming 
arterial blood. Experiments performed by Kellie and Abercrombie supported 
these observations but they, like Monro, did not account for the role of CSF. 
 
As the important role of CSF was recognised, the Monro-Kellie hypothesis was 
revised to its current form where with an intact skull, the sum of the volumes of 
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the brain, intracranial blood and CSF are constant. Therefore an increase in one 
necessitates a decrease in one or both of the remaining two. As the brain 
parenchyma is essentially non-compressible, compensation is achieved through 
extrusion of CSF or venous blood. 
 
2.3.2 Intracranial Pressure Measurement 
Lundberg systematically described the technique of continuous ICP monitoring 
using an intraventricular catheter in a series of 130 patients with suspected 
intracranial space occupying lesions(16). He then went on to confirm the 
feasibility of the technique in a series of 30 patients with TBI(17).  
 
In his seminal paper, Lundberg identified three typical patterns of ICP 
fluctuation which have come to be known as “A”, “B” and “C” waves. A waves 
are steep rises in ICP to a plateau of 50 mmHg or more and are sustained for 5 – 
20 minutes before falling rapidly. They represent a critical reduction in 
intracranial compliance. B waves occur with a frequency of 0.5 to 2 waves per 
minute and are rhythmic oscillations to 20-30 mmHg above the baseline but 
without a sustained period of intracranial hypertension. C waves are not thought 
to be of pathophysiological importance, probably a reflection of Traube-Hering 
waves originating in the arterial pressure and are of much smaller amplitude to 
B waves. 
 
While Lundberg and colleagues were developing the role of ICP monitoring in 
man, Langfitt’s group were examining primates to carefully characterise the 
transmission of pressure across the intracranial compartments(18, 19). The 
phenomenon of pressure underestimation was fully defined in experimental 
studies of extradural brain compression where progressive loss of transmission of 
ICP across the tentorial hiatus occurred, with the pressure in the posterior fossa 
and lumbar subarachnoid space progressively under-reading the ventricular 
pressure and eventually returning to normal pressure. 
 
2.3.3 The Intracranial Volume-Pressure Relationship 
The intracranial volume-pressure curve demonstrates how small increases in 
volume of one of the intracranial components can be compensated by a 
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reduction in CSF or blood volume (Figure 2.2). However, these compensatory 
measures are quickly exhausted and any subsequent increase in volume leads to 
an exponential increase in ICP. Measurement of this volume-pressure 
relationship is most often incorrectly referred to as intracranial compliance. 
According to conventional terminology it should be referred to as elastance 
(change in pressure per unit change in volume, 'P/'V)(20, 21). Due to the 
exponential nature of the volume-pressure relationship as depicted in Figure 
2.2, being able to quantify elastance is attractive clinically as in theory it will 
increase during the volume compensation phase more rapidly than ICP and 
should therefore be predictive of impending volume decompensation.  
 
Figure 2.2: Cerebral volume-pressure curve showing the exponential relationship 
between ICP and an increase in volume of one of the intracranial components. The 
red line marks the point of decompensation. 
The first full mathematical description of the craniospinal volume-pressure 
relationship was published by Marmarou in 1973(22). Since then, several 
research groups have contributed physiological simulation models of ICP 
dynamics of varying complexity. These models aim to improve understanding of 
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ICP pathophysiology and thus assist in the development of appropriate treatment 
strategies. A detailed comparative review on this subject has been provided by 
Wakeland and Goldstein(23). The early work of Marmarou and colleagues shall 
be discussed below as it provides an introduction to many important concepts 
surrounding ICP dynamics.  
 
Through his interest in the pathological state of hydrocephalus, Marmarou 
developed a mathematical model of the CSF system that produced a general 
solution for the CSF pressure(22). The model parameters were verified in a 
series of experiments on adult cats(24). In these studies, the CSF pressure was 
measured both intracranially at the cisterna magna and in the lumbar 
subarachnoid space in response to bolus injections (Figure 2.3).  
 
Figure 2.3: Demonstration of intracranial pressure changes following a bolus volume 
injection V0  where: Pb is the baseline ICP, Pp is the peak pressure and P2 refers to 
the pressure point on the return trajectory at time t. 
Of particular note in this work, was the introduction of the pressure-volume 
index (PVI). Marmarou confirmed the non-linear relationship between changes in 
craniospinal volume and pressure. However, by plotting changes in volume 
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against the log to the base ten of pressure, a straight-line relationship could be 
defined (Figure 2.4). The slope of this line is termed the PVI and is the notional 
volume required to raise ICP tenfold. Unlike elastance or compliance, the PVI 
characterises the craniospinal volume-pressure relationship over the whole 
physiological range of ICP and can be calculated from: 
 
𝑃𝑉𝐼 =
𝑉଴
𝑙𝑜𝑔ଵ଴൬
𝑃௣
𝑃௕
൰
 
(2.2) 
 
where V0 is the bolus injection volume, Pp is the peak pressure and Pb is the 
baseline ICP. 
 
Figure 2.4: Log10 ICP vs intracranial volume relationship defined by Marmarou(22). 
The pressure volume index (PVI) is the notional volume which when added to the 
craniospinal volume causes a ten-fold rise in ICP. 
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Marmarou's mathematical model developed an improved understanding not only 
of craniospinal elastance but also of the inter-relationships of the static and 
dynamic processess of formation, storage and absorption of CSF. Previously, 
Davson had demonstrated that by withdrawing CSF at the estimated rate of CSF 
production (approximately 0.3 ml/min), it was possible to determine the 
cerebral venous pressure(25). This value could then be substituted into the 
steady-state ICP equation: 
 
𝐼𝐶𝑃 = 𝑃௦௦௣ + ൫𝐼௙ × 𝑅௢൯ (2.3) 
 
where Pssp is sagital sinus pressure, If is CSF formation rate and Ro is CSF outflow 
resistance. Marmarou extended Davson’s work and his general solution for ICP 
allowed the derivation of an equation for CSF outflow resistance based on the 
bolus injection technique (Figure 2.3)(22, 24): 
 
𝑅௢ = 𝑡 ×
𝑃௕
(𝑃𝑉𝐼)𝑙𝑜𝑔ଵ଴ቊ
൫𝑃ଶ/𝑃௣൯൫𝑃௣ − 𝑃௕൯
(𝑃ଶ −𝑃௕)
ቋ
 
(2.4) 
 
In TBI management, it is useful to know CSF outflow resistance when 
determining the aetiology of raised ICP. In general terms, causes of ICH can be 
categorised into "vascular" and "non-vascular" mechanisms. Vascular mechanisms 
include active cerebral vasodilation due to stimuli such as increased arterial 
carbon dioxide levels or decreased CPP with intact pressure autoregulation, 
passive distension of cerebral vessels in the absence of autoregulation or venous 
outflow obstruction. Non-vascular mechanisms include increased brain mass due 
to cerebral edema or an expanding extradural, subdural or intracerebral mass.  
A further non-vascular mechanism is an increase in CSF outflow resistance 
secondary to obstruction of the normal CSF pathway. 
 
The importance of vascular factors and the state of cerebral blood flow (CBF) 
autoregulation as a determinant of craniospinal elastance was shown clearly by 
the work of Gray and Rosner(26, 27). The autoregulation of CBF will be discussed 
later, however, through a series of studies in adult cats, Gray and Rosner 
demonstrated that with CPP levels greater than 50 mm Hg, there was a linear 
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increase in PVI with increasing CPP.  Similarly, with CPPs below 50 mmHg, 
further reduction in CPP was also associated with increased PVI, as well as 
reduced CBF.  This work illustrated that the PVI is a complex function of CPP and 
that the direction of the CPP-PVI relationship is dependent on whether CPP is 
above or below the autoregulatory range for CBF. The importance of the state of 
autoregulation on PVI has been supported recently by Lavinio et al(28). In a 
series of brain injured patients admitted to the intensive care unit (ICU), PVI 
results were significantly different if a transcranial Doppler (TCD) derived 
assessment of middle cerebral artery (MCA) flow velocity (FV) revealed defective 
cerebral autoregulation.  
 
Despite the potential for providing valuable information on the intracranial 
pressure-volume relationship, the PVI is not routinely measured in clinical 
management of severe TBI. Variability between measurements is high because of 
the difficulty in rapid manual injection at a constant rate.  As a result, an 
average of repeated measures is usually required. In addition, there is an 
infection risk associated with injecting fluid into the subarachnoid space via an 
intraventricular catheter(29-31) and a risk of provoking secondary ICP rises 
following injection as a consequence of vasodilation(32). Thus, an interest in 
deriving estimates of the intracranial pressure-volume relationship indirectly 
through analysis of the ICP waveform has become a research focus. 
 
2.3.4 The ICP Waveform 
The ICP waveform has three consistent peaks that are related to the arterial 
pulse waveform (Figure 2.5), although their exact aetiology is the subject of 
some debate(33). Avezaat and van Eijndhoven systematically studied the ICP 
waveform pulse amplitude (ICPplse) as a measure of craniospinal elastance(32, 
34). In recognition of the limitations of the PVI related to the need for volume 
injection or withdrawal, they exploited the fact that with each cardiac cycle 
there is a pulsatile increase in cerebral blood volume. This is the equivalent of a 
small intracranial volume injection (dV), and the ICPplse is the pressure change 
(dP) in response to that volume increment and should consequently be directly 
related to the craniospinal elastance (dP/dV) (Figure 2.6). Therefore, as 
craniospinal elastance increases (compliance decreases) the ICPplse should 
increase. The observation that as ICP increases so does the amplitude of the 
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intracranial pressure pulsations is not a new one, having been first described in 
1866 by Leyden(35). 
 
 
Figure 2.5: ICP waveform recorded from a Raumedic intraparenchymal catheter and 
displayed beneath an arterial waveform recorded from the radial artery in a patient 
with TBI. CRAN = intracranial pressure, ABP = arterial blood pressure, P1 = 
percussion wave, P2 = tidal wave, P3 = dicrotic wave. 
The mathematical description of the exponential craniospinal volume-pressure 
relationship was extended by Avezaat and Van Eijndhoven: 
 
𝐼𝐶𝑃 = 𝑃௘௤𝑒ாభௗ௏ + 𝑃଴ (2.5) 
 
where Peq is intracranial equilibrium pressure, E1 is the elastance coefficient and 
determines the elastance at a given pressure and P0 is ICP at zero elastance. The 
term P0 was introduced into the pressure-volume equation primarily for 
mathematical convenience. It allows the volume-pressure curve as a whole to 
shift up or down its axis, which allows for correction of pressure transducer 
reference position and postural changes.  Mathematically, P0 is the pressure at 
zero elastance and must therefore have physiological significance as a 
determinant of the normal intracranial equilibrium pressure (Peq).  Löfgren 
showed that alterations in central venous pressure (CVP) can shift the pressure-
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volume curve up or down its axis(36), which would suggest CVP may be a factor 
determining P0. 
 
Figure 2.6: Craniospinal volume–pressure relationship demonstrating that for the 
same increase in craniospinal volume (dV) the ICP response (dP) increases when 
total craniospinal volume increases. Peq = intracranial equilibrium pressure, Veq = 
intracranial equilibrium volume. Adapted from Avezaat and Van Eijndhoven(32). 
To allow validation of ICPplse as a measure of elastance, Avezaat and Van 
Eijndhoven compared the relationship of ICPplse versus ICP and elastance, as 
invasively measured by volume injection, versus ICP. This was performed in a 
series of 58 patients undergoing ICP monitoring for a variety of neurosurgical 
indications. A linear relationship between both ICPplse and ICP and invasively 
measured elastance and ICP was confirmed, supporting the mono-exponential 
relationship between intracranial volume and ICP. However, the correlation 
between these relationships was weak. 
 
Of particular note in the above study, was the observation that there was a 
disproportionate increase in ICPplse during plateau waves, which was thought 
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secondary to an increase in dV due to defective cerebral vascular muscle tone. 
To explore this phenomenon further, they monitored ICPplse while manipulating 
ICP in adult dogs by inflating an epidural balloon. They found the ICPplse 
increased linearly with ICP up until a pressure of around 60 mmHg (Figure 2.7). 
At this pressure a breakpoint occurred and the ICPplse increased more rapidly 
with increasing ICP. It was postulated that the breakpoint marked the loss of 
CBF autoregulation, which will be dealt with in more detail below.  
 
Figure 2.7: ICPplse plotted against ICP, demonstrating a direct linear relationship. A 
breakpoint occurs at an ICP of approximately 60 mmHg where the slope of the 
relationship increases. Adapted from Avezaat and van Eijndhoven(32). 
The major limitation of using ICPplse as a measure of craniospinal elastance 
(dP/dV) is the need to assume that the volume of pulsatile blood (dV) is 
constant. This is unlikely to be the case in severe brain injury because of the 
associated cardiovascular complications. Therefore, the clinical utility of this 
technique is limited unless the pulsatile blood volume can be controlled for.  
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2.3.5 Cerebral Autoregulation 
2.3.5.1 Principles of Cerebral Autoregulation 
As suggested earlier, one of the principle clinical reasons to monitor ICP is to 
allow calculation of cerebral perfusion pressure. This is useful because, in 
theory, maintenance of a CPP within the limits of cerebral autoregulation will 
result in maintenance of adequate cerebral blood flow to meet the metabolic 
demands of the brain(37). Regulation of flow is achieved by active dilation and 
constriction of cerebral arterioles in response to changes of CPP and is 
illustrated in Figure 2.8. A number of physiological mechanisms are known to be 
involved in this process and Hamner and Tan have recently quantified the 
relative contributions of sympathetic, cholinergic and myogenic 
mechanisms(38). By measuring CBF while manipulating CPP, and utilising 
pharmacological blockade of the three mechanisms, they were able to 
demonstrate the effect that each had on cerebral autoregulation in healthy 
volunteers. Of note, they found that 38% of the pressure-flow relationship was 
unexplained by these mechanisms, implying that others must also be important. 
 
The physiological range of autoregulation, is regarded as 50 to 150 mmHg in 
healthy adults(37). When CPP is below the lower limit of the autoregulatory 
range, vessels within the arterial-arteriolar bed tend to passively vasoconstrict. 
Conversely, when CPP is above the upper limit, passive vasodilation occurs. 
Using measures of CBF including intra-arterial xenon clearance(39) and 
transcranial Doppler flow velocity of the MCA(40), it has been demonstrated that 
disordered cerebral autoregulation occurs after severe TBI and is associated with 
worse outcome. 
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Figure 2.8: Illustration of the maintenance of cerebral blood flow across a range of 
cerebral perfusion pressures.  
2.3.5.2 Mathematical Models of Autoregulation 
As discussed above, there is an extensive literature on the mathematical 
modelling of ICP dynamics. Several of these models incorporate descriptions of 
cerebral autoregulation. The models can be primarily physiology based, and aim 
to improve our understanding of the interaction between ICP dynamics and 
autoregulation, or they can have a more statistical basis and aim to provide an 
index of the state of autoregulation. Examples of each type of model shall be 
considered in turn below.  
 
2.3.5.3 Physiological Models of Autoregulation 
Ursino and Lodi published a simplified mathematical model of the interaction 
between ICP and cerebral haemodynamics that is a cut down version of Ursino’s 
earlier work(41-43). The model is a two compartment model which incorcopates 
the hemodynamics of the arterial-arteriolar cerebrovascular bed, CSF production 
and reabsorption processes, the pressure-volume relationship of the craniospinal 
compartment, and a Starling resistor mechanism for the cerebral veins (Figure 
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2.9). Importantly, it includes a parameter to account for the maximum 
autoregulatory gain. Using this model in a series of 20 patients with severe TBI, 
Ursino et al were able to classify the state of cerebral autoregulation and 
predict the response of ICP to PVI testing(42). 
 
 
 
Figure 2.9: Reproduction of the Electrical Equivalence Circuit of the Ursino 
Model(43). Capacitors are used to represent physiological compartments, resistors 
restriction to flow of blood or CSF and diodes unidirectional flow. CBF (q) enters the 
intracranial space at systemic arterial pressure (Pa). It is subject to arterial 
resistance (Ra) and the cerebrovascular bed has some storage capacity (Ca). CBF is 
then through proximal (Rpv) and distal (Rdv) venous resistance. Venous pressure (Pv) 
is assumed to equal ICP (PICP). PICP is dependent upon the volume stored in 
intracranial compliance (CIC). This is dependent upon blood volume in Ca, CSF inflow 
(qf) through inflow resistance (Rf) and CSF outflow (qo) through outflow resistance 
(Ro), which is itself dependent upon venous sinus pressure (Pvs). The system can be 
disturbed by mock CSF injection (Ii). 
Czosnyka has also proposed compartment model of CBF and CSF circulation(44). 
It is a three compartment model that consists of two vascular storage 
compartments (arterial and venous) and one CSF storage compartment (Figure 
2.10). Again, this model is able to simulate the state of autoregulation. Using 
data taken from 82 patients admitted to ICU with moderate and severe TBI, 
comparison was made between measured clinical responses and simulated model 
responses to events such carotid artery compression, systemic arterial 
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hypotension and ICH. The mathematical modelling results were found to be 
helpful with interpretation of the clinical phenomena. In particular, the model 
demonstrated that the correlation between arterial blood pressure (ABP) and ICP 
is dependent on the state of autoregulation. Czosnyka exploited this fact in 
development of the pressure reactivity index (PRx), which will be discussed in 
the following section.  
 
 
 
Figure 2.10: Reproduction of the Electrical Equivalent Circuit of the Czosnyka 
model(44). Capacitors are used to represent physiological compartments and 
resistors restriction to flow of blood or CSF. The model illustrates the presence of 
three storage compartments (Ca = compliance of the great cerebral arteries, Cv= 
compliance of capillaries and small veins, Ci = compliance of the CSF containers). 
Other parameters are arterial blood pressure (ABP), cerebral arterial pressure in the 
small arteries (Pa), pressure in the cortical veins (Pv), ICP (Pi), sagital sinus pressure 
(Pss), resistance of great cerebral arteries (Ra), cerebrovascular resistance (CVR), 
resistance of cortical and bridging veins (Rb), CSF outflow resistance (RCSF) and CSF 
secretion (If).  
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An example of a model bridging the gap between physiological and more 
statistical or data driven models of autoregulation is provided by Daley et al(45). 
The high frequencies of cerebrovascular pressure transmission of ABP to ICP are 
reduced by vasoconstriction and increased by vasodilation. The highest modal 
frequency (HMF) at which energy is transferred from ABP to ICP can be 
calculated from digitised ABP and ICP waveforms. Pairs of ABP and ICP values 
are processed using an autoregressive moving average (ARMAX) technique to 
numerically define a difference equation representing the change of ICP relative 
to ABP at 4 millisecond sampling epochs. The difference equation can be 
converted to a continuous description of cerebrovascular pressure transmission. 
The constants of this continuous model can then be used to determine HMF. 
 
In a piglet model of raised ICP it was found that when cerebral autoregulation 
was intact (as assessed by measurement of pial artery diameter), a rise in CPP 
led to a decrease in HMF.  In contrast, when there was autoregulatory 
impairment, a rise in CPP was met with an increase in HMF (Figure 2.11). Similar 
results have been seen in patients admitted to ICU with severe TBI(46). 
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Figure 2.11: Examples of the relationships between HMF and CPP during challenge 
with norepinephrine before and after fluid percussion injury (FPI). A) Before FPI (in 
blue): challenge with norepinephrine resulted in a response consistent with active 
vasoconstriction with a negative correlation value (R = −0.77) and negative slope 
(m) of the regression line (m = −0.317 Hz/mm Hg) between HMF and CPP were 
demonstrated. B) After FPI (in red): challenge with norepinephrine resulted in a 
response consistent with passive vasodilation with a positive correlation value (R = 
0.34) and positive slope of regression line (m = 0.325). Adapted from Daley et 
al(45). 
2.3.5.4 Data Driven Indices of Cerebral Autoregulation 
The most systematically investigated of the statistical approaches to 
autoregulatory assessment, using ICP as an input parameter, is the Pressure 
Reactivity Index (PRx) described by Czosnyka et al(47). It is based on the 
hypothesis that naturally occurring slow oscillations of arterial blood pressure 
can be used to evaluate the cerebrovascular reactivity. In theory, when pressure 
reactivity is intact, an increase in ABP would result in cerebral vasoconstriction 
and a reduction in ICP (negative PRx). Conversely, when pressure reactivity is 
absent, an increase in ABP would result in a passive rise in ICP (positive PRx). 
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Pressure reactivity has a complex relationship with cerebral autoregulation 
rather than the expressions being analogous. 
 
The PRx is a moving correlation coefficient between 40 consecutive samples of 
values for ABP and ICP averaged over a period of five seconds. By employing this 
averaging interval, most of the frequency changes above 0.2 Hz in the ABP and 
ICP recordings are filtered out. In addition, Nyquist’s sampling theorem dictates 
that the highest frequency that can be represented by a signal sampled every 
five seconds is 0.1 Hz or 6 oscillations per minute. As a result, the dynamical 
system relationship between ABP and ICP cannot be precisely defined by PRx. 
 
Nevertheless, PRx has been found to be a very useful tool in clinical research. In 
TBI it has been demonstrated to provide a reliable index of cerebral 
autoregulation as validated by TCD(47) and PET(48) derived measurements. 
Clinical observations show that the PRx is high both during the occurrence of 
plateau waves and also during refractory raised ICP(49). In addition, the PRx has 
been used to guide proposed therapies and calculation of an “optimal CPP” for 
the management of patients with TBI(50). 
 
2.3.5.5 Comparison of Models of Cerebral Autoregulation 
Despite illustrating a number of the approaches that can be taken, this is by no 
means an exhaustive list of models of CBF autoregulation. It is not clear which 
approach is most clinically practical or useful. The models take different input 
parameters and yield different output indices, thus making comparison difficult.  
In an attempt to address this issue, Shaw et al re-worked and normalized three 
of the models so that a fair evaluation could be made on a standardized dataset 
of ABP, ICP and MCA flow velocity readings taken from piglets pre and post fluid 
percussion injury(51, 52). The state of autoregulation predicted by the models 
could then be compared to changes in pial artery diameter as a direct measure 
of autoregulation. One of the interesting conclusions from this work was that 
before application of a number of optimization approaches, none of the models 
performed particularly well. Overall, Ursino’s physiological model performed 
best and after optimization of the data driven models, Daley’s HMF 
autoregulatory index performed marginally better than Czosnyka’s PrX. This 
work is limited by the use of only one small dataset for comparison. What is 
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certain, however, is that further studies comparing autoregulatory methods and 
optimization approaches are warranted before widespread clinical adoption of a 
standarised autoregulation model is possible.  
 
In recognition of this challenge, an international group of those working in both 
experimental and clinical autoregulation research have setup a new consortium 
called the “Cerebral AutoRegulation Network” or CAR-Net(53). 
 
2.4 Current Controversies 
2.4.1 Should ICP be Monitored in Severe TBI? 
Monitoring of ICP has become a standard of care in severe TBI and its use is 
supported by internationally applied guidelines. The Brain Trauma Foundation 
makes a level IIb recomendation that patients with severe TBI should be 
managed using information from ICP monitoring to reduce in-hospital and 2-
week post-injury mortality(54). Further, Treating ICP >22 mm Hg is 
recommended because values above this level are associated with increased 
mortality.  
 
The evidence for and against ICP monitoring in TBI has been appraised in several 
excellent reviews(55-57). Supporting the use of ICP monitoring are retrospective 
comparisons of historical cohorts at the same centre suggesting that protocols 
incorporating ICP monitoring improve outcome(58, 59). Similarly, there has been 
an association between centres monitoring ICP more frequently and better 
outcome(60). In contrast, a retrospective comparison of 2 trauma centres 
revealed an increase in therapy levels without an improvement in outcome in 
the centre that monitored ICP(61).  
 
On the basis of the wealth of conflicting evidence, there was demand for a 
randomised controlled trial (RCT) to assess the impact of ICP monitoring on 
clinical outcomes. An RCT of 324 patients with severe TBI was subsequently 
performed in Latin America(13). Patients were assigned to protocolised therapy 
directed by either ICP monitoring or clinical examination and imaging. There was 
no difference between groups in the primary outcome of a composite of survival 
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time, impaired consciousness, and functional status at 3 months and 6 months 
and neuro-psychological status at 6 months.  
 
This study has been subject to extensive discussion and editorial review(62-65) 
including by the lead investigator(66). Irrespective of the applicability of the 
findings to the routine practice of ICP monitoring in severe TBI, the results 
certainly strengthen the argument for more clearly defining the use of ICP 
targeting strategies as part of an individualised and multimodal approach to this 
patient group. 
 
2.4.2 What Modality Should be Used to Monitor ICP? 
2.4.2.1 Introduction 
The two techniques most commonly used in clinical practice to monitor ICP are 
via an intraventricular or intraparenchymal catheter with a microtransducer 
system. Both of these techniques are invasive and are thus associated with 
complications such as haemorrhage and infection. For this reason, significant 
research effort has been directed towards development of a non-invasive 
method to measure ICP.  
 
2.4.2.2 Intraventricular Catheter 
Following Lundberg’s description of the use of intraventricular catheters for the 
continuous measurement of CSF pressure(16), the technique has remained the 
gold standard for ICP monitoring(67). It is performed by inserting a catheter into 
either lateral ventricle through a frontal burr hole. In 1960, Lundberg was 
already using electronic measurement equipment by connecting the ventricular 
cannula via a strain gauge transducer to a potentiometer recorder. In modern 
practice, the ventricular catheter can similarly be connected to an external 
strain gauge or the ICP waveform can be transduced via fibreoptic or micro 
strain gauges within the catheter itself. 
 
An advantage of measuring ICP using an intraventricular catheter is the 
opportunity to perform drainage of CSF as an ICP lowering therapy. It is also 
possible to recalibrate the monitor while in situ and thus retain accuracy for 
several days of monitoring. However, as suggested above, the technique is not 
without risk. It can be technically difficult in the case of ventricular effacement 
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or midline shift. There is a risk of CSF infection but this can be kept to as low as 
10% with a “Bundle” based approach to care(68). The incidence of haemorrhage 
following ventriculostomy is around 1%, although the number requiring surgical 
evacuation is likely to be lower(67). 
 
2.4.2.3 Intraparenchymal Catheter 
In cases where intraventricular ICP monitoring is not possible, or in many centres 
as the preferred technique, an intraparenchymal device can be placed. The 
principle difference with the intraparenchymal devices is the inability to 
recalibrate them following insertion with the consequent problem of zero drift. 
Bench testing of devices using both fibreoptic tips (Camino OLM ICP monitor; 
Camino Laboratories, San Diego, CA) and micro strain gauges (Codman 
Microsensor ICP Transducer; Codman & Shurtlef Inc., Randolph, MA) have shown 
24 hour zero drift of <0.8 mmHg(69). Similarly, laboratory testing of an 
intraparenchymal device incorporating a micro strain gauge with complete 
Wheatstone bridge circuit incorporated into the tip (Raumedic AG, Helmbrechts, 
Germany), demonstrated a mean zero drift of 0.6 mmHg at 5 days(70). However, 
in the more demanding clinical environment, a multicentre evaluation concluded 
that the zero drift rate remained a concern and catheter performance was 
similar that of other manufacturers(71). 
 
Intraparenchymal ICP monitoring devices are typically placed via a small burr 
hole into the white mater of the non-dominant frontal hemisphere. These 
devices measure a compartmentalised local pressure and significant 
supratentorial pressure gradients have been demonstrated between monitoring 
ipsi and and contralateral to the side of focal haematomas(72). 
 
2.4.3 Non-invasive ICP Monitoring 
For a non-invasive measure of ICP to replace the commonly used invasive 
measures above it must provide an accurate absolute measure of ICP that can be 
performed continuously at the bedside. There is no current technique that 
satisfies these criteria. An in depth review of all of the available technologies is 
outwith the scope of this article and has been covered in detail elsewhere(73-
75). Techniques considered include imaging based studies using CT and magnetic 
resonance imaging (MRI), transcranial Doppler sonography (TCD), near-infrared 
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spectroscopy (NIRS), tympanic membrane displacement (TMD), visual-evoked 
potentials (VEPs), measurements of optic nerve sheath diameter (ONSD) and 
other measurements of the optic nerve, retina and pupil. Of these, approaches 
using TCD and ONSD have perhaps received the most clinical interest. 
 
Using low frequency TCD, it is possible to measure flow velocity in the middle 
cerebral artery (MCA)(76). Several authors have published equations using the 
MCA flow velocity metrics of peak systolic velocity (PSV), mean flow velocity 
(mFV), end diastolic velocity (EDV) and pulsatility index (PI, PSV-EDV/mFV) to 
estimate ICP and CPP.  
 
Schmidtt et al examined 25 patients admitted with severe TBI and calculated 
non-invasive CPP (nCPP) as MAP x EDV/mFV +14 mmHg(77). For these patients, 
81% of 1 minute averages of nCPP (n = 12 275) were different from invasively 
measured CPP (iCPP) by <10 mm Hg. In 81 brain injured patients, including 21 
with TBI, Bellner et al calculated non-invasive ICP (nICP) as 10.93 x PI – 1.28(78). 
Bland and Altman analysis of all measurements (n = 658) revealed that the 
difference between nICP and invasively measured ICP was less than 4.2 mmHg 
for 95% of measurements. Edouard et al calculated nCPP as [mFV/(mFV-EDV)] x 
(MAP-DAP) in patients with severe TBI and bilateral injury(79). In 10 patients, 
repeated measurements were made during their clinical course (n = 89) and a 
significant correlation was found between nCPP and iCPP. However, in a further 
10 patients in whom hypercapnoea was induced, the strength of this correlation 
was reduced. 
 
The performance of the above three equations in estimating ICP was compared 
in 45 patients with severe TBI by Brandi et al(80). Under standardised 
conditions, including continuous sedation, normocapnoea and normothermia, 
daily nICP measurements were compared to ICP measured using an 
intraparenchymal device. On the basis of Bland and Altman analysis, the authors 
concluded that the equation by Bellner et al(78) was superior in assessing nICP. 
However, as has been noted elsewhere(55), the Bellner equation failed to 
predict all cases of ICH in this series and is therefore not likely to be clinically 
useful as a screening test in TBI. 
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Like TCD measurements, assessment of ONSD using ultrasound potentially 
provides a simple bedside screening test for ICH in TBI. The technique exploits 
the fact that the optic nerve is part of the central nervous system and therefore, 
a rise in ICP will be transmitted through the CSF surrounding the nerve. Several 
studies comparing ultrasound derived ONSD assessment to iICP(81-86) have been 
included in a recent meta-analysis(87). This was limited by the fact that it 
included only 231 patients, 89 of whom had suffered TBI. However, using the 
ONSD thresholds reported in the individual studies, the pooled sensitivity and 
specificity to detect ICH were 0.9 and 0.85 respectively. Dubourg et al are now 
collecting data for an individual patient data meta-analysis with the objective of 
defining the cutoff value for ultrasound derived ONSD in the detection of 
ICH(88). 
 
2.4.4 Should ICP or CPP be the Target? 
Whatever modality is chosen to monitor ICP in severe TBI, the clinician must 
then decide whether to primarily target therapy at attempting to optimise CPP 
or lower ICP.  CPP oriented therapy, as proposed by Rosner et al(89), requires 
pressure autoregulation and the ability to manipulate CPP within the 
autoregulatory range.  During intact pressure regulation, increases of CPP cause 
constriction of the arterial-arteriolar vascular bed and lowering of ICP by a 
reduction in cerebral blood volume.  In addition, the result ing reduction of pre- 
and post-capillary pressure decreases fluid filtration and increases absorption, 
thus reducing brain oedema. However, the application of CPP oriented therapy 
when autoregulation has been lost may result in an imbalance of Starling forces 
at the capillaries leading to increased net fluid filtration and further brain injury 
by increased production of vasogenic oedema.  
 
Avoiding vasogenic oedema is one of the underlying tennets of the “Lund” 
approach to management of severe TBI based on lowering ICP(90, 91). Asgeirsson 
et al, working at the University Hospital of Lund, described a protocol aimed at 
inducing transcapillary fluid absorption through reduction of hydrostatic 
capillary pressure and preservation of normal colloid osmotic pressure. This 
included pharmacological interventions such as the reduction of systemic 
hypertension with metoprolol and clonidine, and precapillary vasoconstriction 
with dihydroergotamine. 
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In an attempt to determine whether an ICP or CPP based approach was 
preferable, Roberston et al conducted an RCT in 189 patients admitted with 
severe TBI(92). Patients were randomised to an ICP based protocol or a CBF 
based protocol. The major differences between the protocols were the CPP 
targets (>50 mmHg in the ICP group and >70 in the CBF group) and the option to 
treat ICH with hyperventilation in the ICP group. In terms of the primary 
outcome of this study, cerebral ischaemia as measured by jugular venous 
desaturations, the CBF based protocol was associated with a lower risk of 
ischaemia. However, this did not translate into improved neurological outcome 
and indeed was associated with an increased frequency of systemic 
complications such as adult respiratory distress syndrome (ARDS).   
  
It is likely that the choice of ICP or CPP based approach to ICU management of 
severe TBI should be made on an individual patient basis. For this to be possible, 
the state of autoregulation needs to be assessed. 
 
Support for the clinical utility of a pressure reactivity index has been provided 
by Howells et al(93). The approach of two neurosurgical ICUs to ICP management 
in TBI was compared using a PRx based index, averaged over many hours per 
day, and a machine learning Bayesian Neural Network (BANN) model, which 
predicted the probability of good or bad clinical outcome. In one centre, the 
predominant management approach was CPP targeted therapy and in the other, 
the approach was ICP targeted therapy.  The model showed  that not only was 
pressure reactivity related to clinical outcome but also that it’s relationship to 
outcome was management approach dependant (Figure 2.12).  From these data, 
a principally CPP targeted approach was more successful when pressure 
reactivity was intact, while a principally ICP targeted approach was more 
successful when pressure reactivity was impaired. Of course, there could be 
other factors influencing clinical outcome that were not considered in the 
analysis. Nevertheless it is compelling evidence for what appears to be common 
sense: a management strategy that considers the brains ability to regulate its 
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blood flow is more successful than one that does not.
 
Figure 2.12: Representation of BANN generated probability distribution plots for the 
mean likelihood of a favourable clinical outcome for patient populations managed in 
two different centres. In these data, the optimal point at which to switch from one 
treatment strategy to the other in a given patient is at an MABP/ICP trend with a 
slope of approximately 0.13. Adapted from Howells et al(93). 
2.5 Future Directions 
2.5.1 Introduction 
The field of ICP research is a wide ranging one and, to date, has been the 
subject of 16 international symposia embracing such diverse disciplines as 
neurosurgery, intensive care, anaesthesia, radiology, biophysics, electronic and 
mechanical engineering, mathematics and computer science(94). This 
multidisciplinary and collaborative approach is highlighted by research groups 
such as International Mission for Prognosis and Analysis of Clinical Trials in TBI 
(IMPACT)(95), Brain Monitoring with Information Technology (BrainIT)(96) and 
the recently funded CENTER-TBI project(97).  
 
At present, there is no level 1 evidence to support the targeting of a specific ICP 
or CPP using clinical interventions. Indeed the recently reported RESCUEicp 
study, which evaluated the role of decompressive craniectomy in treatment of 
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uncontrollable ICH, concluded that the rates of good recovery were not 
improved by the intervention(98). Similarly Eurotherm3235, which appraised the 
role of targeted temperature therapy (32 to 35qC) for the management of ICH, 
suggested that outcomes were worse with hypothermia than with standard care 
alone(99). 
 
In the face of these negative results, there is considerable effort to extract more 
information, rather than simply a generic threshold value, from the ICP signal 
and use this to provide patient specific targets and to forecast secondary ICP 
insults. In addition, there is ongoing effort to develop novel non-invasive 
techniques to measure ICP and thus widen its clinical application. Some key 
areas of current research shall be discussed below.  
 
2.5.2 Individualised ICP and CPP Targets 
As an alternative to using a universal CPP threshold for all TBI patients, a more 
dynamic patient tailored CPP target, based upon the autoregulation capacity of 
the cerebral vasculature, has been proposed. In retrospective analysis, Steiner 
et al(50) demonstrated that by plotting PRx against CPP for the entire 
monitoring period, a “U-shaped” curve could be produced in about 60% of 
patients. The CPP corresponding to the minimum PRx was taken to represent the 
optimal CPP (CPPopt) for each patient. Patients who were managed with CPPs 
closer to CPPopt were more likely to have a good outcome. 
 
The feasibility of using PRx to prospectively calculate CPPopt in TBI patients in a 
clinical environment has subsequently been demonstrated by Aries et al(100). 
Using a four hour moving window, updated every minute, CPPopt could be 
calculated for 55% of the monitoring period. Again, patients were more likely to 
have a good outcome if their actual CPP deviated less from CPPopt. 
 
In similar work, Lazaridis et al(101) have used PRx to identify patient specific 
ICP thresholds in TBI. By plotting PRx against ICP for the entire monitoring 
period, the threshold ICP was taken to be that at which the PRx was consistently 
>0.2. It was possible to calculate a threshold ICP in 68% of patients. Time spent 
above an individually calculated ICP threshold was more strongly predictive of 
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mortality than using a generic threshold of 20 or 25 mmHg. This further supports 
the concept of patient specific targets of ICP or CPP in the management of TBI. 
 
However, calculation of PRx and most other measures of autoregulation require 
high frequency data (> 50 Hz) sampling.  Capturing and processing this data 
frequency is not routine in many NICUs.  Consequently, Depretiere et al have 
developed a new index of cerebrovascular reactivity that requires only minute 
by minute data sampling(102). Known as LAx, the index is the moving median of 
minute-by-minute ICP/MAP correlation coefficients over different time intervals 
(3-120 min). They demonstated that not only does it correlate with PRx and GOS 
but also is able to produce a CPPopt recommendation. DATACAR (Dynamic 
Adaptive Target of Cerebral Autoregulation) combines different LAx values and 
time windows in a weighted manner to issue a CPPopt recommendation. They 
observed significant differences between PRx-based and LAx-based CPPopts. 
DATACAR was able to issue a CPPopt recommendation in 92% of monitoring time, 
as opposed to 44% for PRx-based CPPopt.   
 
Certainly, a method for continuous and robust determination of a patient’s 
optimal CPP, that can work with normal NICU data capture rates, is an attractive 
concept. A prospective study comparing a number of these indices is warranted. 
These developments show clearly the benefits possible through the combination 
of sharing and analysis of large ICU datasets with the development and 
application of mathematical models.  
 
2.5.3 Prediction of Secondary ICP Insults 
An interesting approach to forecasting ICH is based on preceding changes to 
waveform morphology. In recognition that most clinical decision making only 
takes into account the mean ICP, Hu and colleagues have proposed a technique 
for automatically extracting useful information from the ICP waveform(103). 
Morphological clustering and analysis of continuous intracranial pressure 
(MOCAIP) detects the P1, P2 and P3 peaks within the ICP waveform. The 
technique was developed and validated using an annotated database of ICP 
waveforms collected from 66 patients admitted to an adult hydrocephalus 
centre. For every 3 minute section of ICP recording, the MOCAIP algorithm 
performs beat-by-beat pulse detection followed by pulse clustering to generate 
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a dominant ICP pulse. Artifactual pulses are removed prior to the detection and 
optimal designation of pulse peaks. This process has been generalized as 
MOCAIP++ and validated on a larger dataset collected from 128 patients(104). 
 
The application of MOCAIP to ICP monitoring in TBI has been demonstrated(105). 
In a dataset from 66 patients, including 23 admitted with TBI, ICP pulse 
morphological metrics were correlated with low CBF as measured by an 
intravenous 133Xenon clearance technique. Of particular interest, was the 
association of an elevated P3 peak and low CBF. However, in this study, the 
correlation of pulse morphological metrics to low CBF was less in the TBI 
patients than in those admitted with other diagnoses such as subarachnoid 
haemorrhage. 
 
In the first efforts to use MOCAIP analysis to forecast episodes of elevated ICP, 
an ICP waveform dataset recorded from 34 patients presenting with suspected 
idiopathic intracranial hypertension, CSF shunts and Chiari malformation was 
evaluated(106). Using 24 metrics of the ICP waveform it was possible to classify 
recording segments as either control or pre-IH prior to episodes of elevation of 
ICP to >20 mmHg over a period of at least 20 minutes. This was done with a 
sensitivity of 37% and 21% and specificity of 99% and 99% for 5 and 20 minutes 
respectively. These results are encouraging but may not generalise to TBI 
because of the difference in underlying pathophysiological mechanisms. 
 
An alternative approach to prediction of ICH, which has been developed using 
data collected from patients admitted to NICU with TBI, is through the use of 
Gaussian processes(107). Using 4 hour windows of minute-by-minute recordings 
of ICP and MAP, Guiza et al generated over 1000 potential dynamic predictors 
from which a subset of 73 was selected. These included median values for non-
overlapping time intervals, measures of variability, clustering of values based on 
their trajectory, frequency domain analysis and correlation of ICP with MAP. 
Gaussian processes are a machine learning algorithm that generate a 
probabilistic prediction based on the known outcomes of similar data instances. 
The model was developed in a cohort of 178 patients to predict 30 minutes in 
advance of an elevation of ICP to >30 mmHg over a period of at least 10 
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minutes. It was then evaluated in a further cohort of 61 patients achieving a 
sensitivity of 82% and specificity of 75%. 
 
Future predictive models may incorporate both ICP waveform features and 
dynamic predictors to optimise their predictive capacity. The value of these 
predictions would then need to be assessed by providing them to clinicians and 
formally assessing the impact on patient management and outcome. 
 
2.5.4 Innovative Non-Invasive ICP Monitoring 
As suggested above, no methodology in current clinical use provides an accurate 
absolute measure of ICP. A novel technique, which provides an absolute value of 
ICP, has recently been described by Ragauskas et al(108). A two-depth TCD 
device is used to identify the intracranial and extracranial components of the 
ophthalmic artery (IOA and EOA). Following the assumption that the Doppler 
waveform of the IOA is dependent on compression by ICP and that of the EOA by 
externally applied pressure (Pe), a ring cuff is applied to the orbit and 
automatically inflated from 0 to 28 mmHg in 4 mmHg steps. The Pe at which the 
waveforms of the IOA and EOA are identical is taken to represent the ICP. A 
comparison study of this technique to CSF pressure measured by lumbar 
puncture was performed in 62 patients presenting to a neurology clinic, 
including 37 with suspected IIH and 20 with multiple sclerosis. For invasively 
measured CSF pressures in the range of 4 to 24, the non-invasive technique 
achieved a 98% confidence interval for the absolute error of r4 mmHg. 
 
In a study of a similar group of patients, the two-depth TCD technique was 
compared to the ONSD technique in its ability to predict raised CSF pressure as 
measured by LP(109). Using a CSF pressure threshold of 14.7 mmHg, and an 
ONSD cut-off of 5 mm, the two-depth TCD technique outperformed the ONSD 
technique with sensitivities of 0.68 and 0.37 and specificities of 0.84 and 0.59 
respectively.  
 
Further work is required to confirm the safety of the innovative two-depth TCD 
technique in terms of pressure effects on the globe and exposure of the lens to 
Doppler US. The applicability of the technique to the TBI population and across a 
wider range of ICP values has yet to be demonstrated.  
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2.6 Summary of the Current State of Intracranial Pressure 
Monitoring in Traumatic Brain Injury 
Despite the fact that ICP monitoring in TBI has become a standard of care, there 
is no level I evidence to support its use in targeting generic ICP thresholds. 
However, there can be little doubt that investigation of ICP and the intracranial 
pressure-volume relationship has led to an improved understanding of cerebral 
physiology. It is now time to exploit this knowledge and integrate ICP monitoring 
into a multimodality and individualised approach to care. Future RCTs of ICP 
monitoring should utilise autoregulatory assessment to provide patient specific 
thresholds for ICP and CPP. The use of non-invasive monitors of ICP is an 
attractive prospect but not yet supported by the technology.  
 
2.7 Transcranial Bioimpedance Measurement 
2.7.1 Introduction 
A study investigating the relationship between transcranial bioimpedance and 
invasive intracranial pressure measurement in patients with traumatic brain 
injury (BioTBI) is presented in the following three chapters of this thesis. It is 
therefore necessary to consider the principles of transcranial bioimpedance 
(TCB) measurement and the rationale for its consideration as a surrogate 
measure of ICP.  
 
As has already been discussed in detail, elevated ICP is associated with poor 
outcome following traumatic brain injury(9) and The Brain Trauma Foundation 
recommends that ICP should be monitored in patients with a severe traumatic 
brain injury(54). ICP is typically measured using invasive pressure monitors that 
are associated with specific complications and can generally only be inserted in 
specialist centres. To provide ICP monitoring to a wider clinical population, 
multiple attempts have been made to develop a non-invasive technique. 
Transcranial bioimpedance measurement was considered to be a potential 
approach to non-invasive ICP monitoring. 
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2.7.2 Fundamentals of Bioelectrical Impedance Analysis 
Bioimpedance is the ability of biological tissue to impede electric current. 
Techniques are available to measure bioimpedance from whole or part of the 
body in a process known as bioelectrical impedance analysis (BIA). The principles 
and methods of BIA have been extensively reviewed by Kyle et al(110) and shall 
be summarised below. 
 
Bioimpedance is the sum of capacitive resistance (or reactance) and resistive 
resistance (simply called resistance). The capacitive effect arises principally 
from charge distributed across cell membranes (acting like the plates of a 
capacitor) and the resistance from the conductance of current through the ionic 
solutions in extra and intracellular fluid paths. Electric current of low frequency 
will tend to be conducted through the extracellular space when the cell 
membrane is acting as an insulator, whereas electric current of high frequency 
will be conducted through both the extra and intracellular spaces. An electrical 
circuit model of the two current paths is shown in Figure 2.13. 
 
Figure 2.13: A parallel electrical circuit model demonstrating extra and intracellular 
current paths where R(ECW) is resistance through extracellular water, Xc is impedance 
from the cell membrane and R(ICW) is resistance through intracellular water. 
The equation relating the different factors is: 
 
𝑍 = 𝑅+ 𝑖𝑋௖ (2.6) 
 
where Z is overall impedance, R  is resistance and iXc is reactance. The 
magnitude of bioimpedance can be calculated by: 
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|𝑍| = ൫𝑅ଶ + 𝑖𝑋௖ଶ൯
ଵ
ଶ 
(2.7) 
    
In whole body measurements, two cutaneous electrodes are placed on the 
patient’s foot and another two on the ipsilateral hand. Resistance is proportional 
to length and inversely proportional to cross-sectional area of the conducting 
body (Figure 2.14). This means that whole body impedance measurements are 
corrected according to height (a surrogate of path length) for use in body 
composition analysis. 
 
Figure 2.14: Illustration of the cylinder model relating resistance to geometry. 
2.7.3 Bioelectrical Spectroscopy  
Bioimpedance measurement obtained using devices capable of delivering a 
broad band of frequencies (typically around 1 to 1000 kHz) is known as 
bioelectrical spectroscopy. Under these circumstances it is possible to plot the 
reactance and resistance measurements made at each frequency to construct a 
Cole-Cole plot (Figure 2.15), (111). Using the impedance values extracted from 
the Cole-Cole plot, body composition analysis can subsequently be performed. 
Equations exist to relate resistance, reactance and impedance at a variety of 
frequencies to fat free mass, body fat, total body water, extracellular water and 
intracellular water. 
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Figure 2.15: A graphical representation of a Cole-Cole plot with reactance plotted 
against resistance, where R0 represents resistance measured with a direct current 
and Rinf the resistance measured with an infinitely high frequency alternating 
current. Zc is the impedance measured at maximum reactance and T is the phase 
angle. 
In body composition analysis, the assumptions of homogeneous composition and 
uniform distribution of current across a fixed cross-sectional area are required. 
These assumptions are reasonable in healthy subjects, but are unlikely to apply 
in the context of disease. In this context, the phase angle has been the most 
extensively studied index of BIA. It is calculated as: 
 
𝜃 = 𝑡𝑎𝑛ିଵ + ൬
𝑋௖
𝑅 ൰ 
(2.8) 
 
where T is the phase angle (PhA). Calculation of PhA is typically performed at 50 
Hz in single frequency BIA and at Zc in bioelectrical spectroscopy. Higher values 
of PhA are thought to represent higher cellularity and efficient cell membrane 
and intracellular functioning(112). Lower phase angles have been correlated 
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with poor outcome and markers of increased disease severity in a number of 
pathological processes including renal failure(113, 114), cardiac failure(115, 
116) and several malignancies(117, 118). 
 
2.7.4 Bioimpedance Measurements of the Brain 
Application of bioimpedance measurements to the human brain is not a new 
development. Indeed rheoencephalography (REG), or electrical impedance 
measurement of brain circulation, has been investigated for several decades 
without transitioning into clinical practice(119). The principle of REG is based on 
the assumption that blood is a better conductor of electrical current than brain 
parenchyma. Therefore as arterial blood flows into the cranial cavity, there is a 
pulsatile reduction in continuously measured bioimpedance. 
 
As well as REG there have been several studies using intermittent measures of 
TCB in the detection of brain pathology. In a study of 100 healthy controls and 
50 patients with a variety of brain pathologies, Grasso et al made TCB 
measurements using a single frequency bioimpedance device(120). The 
pathologies studied were tumours, intraparenchymal haemorrhage and 
hydrocephalus. TCB measurements were made using pairs of cutaneous 
electrodes placed on the closed eyelids and at the base of the occiput. The 
relationship between resistance (R), brain water content (V) and head 
circumference (HC) was modelled as: 
 
𝑉 =
𝐻𝐶ଶ
𝑅  
(2.9) 
 
A significant increase in V was detected between the patients with brain 
pathology and the healthy controls. This supported their hypothesis that TCB 
could be used to detect pathological processes associated with brain oedema 
secondary to both extracellular and intracellular mechanisms. 
 
More recently Liu et al have compared TCB measurements made in 200 healthy 
controls to those made in 78 patients with haemorrhagic stroke and 51 patients 
with ischaemic stroke(121). Cutaneous electrodes were placed in frontal and 
occipital positions and a 50 Hz current applied using their “non-invasive 
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cerebral-edema monitior”. TCB was measured and then converted into a 
“perturbative index”. Unfortunately there are no details of how this index is 
calculated in this paper or related publications using the same device(122-124). 
The authors reported an increased perturbative index measured from the 
pathological side in both haemorrhagic and ischaemic stroke. 
 
Of particular relevance to the BioTBI study, Seonne et al have reported TCB 
measurements made using the same Impedimed SFB7 Bio-impedance 
Spectroscopy Unit (125). In their study of ten patients with ischaemic or 
haemorrhagic stroke, they compared TCB measurements made from each 
cerebral hemisphere using silver EEG electrodes. Nine out of the ten patients 
demonstrated either asymmetry or values outside those measured in control 
patients. It was not possible to differentiate between ischaemic and 
haemorrhagic stroke. 
 
Other authors have investigated the use of TCB measurements in TBI. Harting et 
al used a controlled cortical injury rat model of TBI to demonstrate a difference 
in brain impedance measurement made both post mortem and in vivo between 
sham and injured animals(126). In these experiments the measurements were 
made using bipolar electrodes in direct contact with the brain. Impedance 
measurements were found to correlate with brain water content, supporting the 
theory that bioimpedance could detect cerebral oedema following TBI. 
 
Previous attempts have been made to determine the relationship between TCB 
and ICP. Using a neonatal piglet model of brain hypoxia, Lingwood et al were 
first able to demonstrate that non-invasive TCB measurements correlated well 
with invasive measurements(127). They focussed on the bioimpedance 
parameter of R0 on the basis that the pathophysiology of brain hypoxia was likely 
to lead to intracellular oedema with a consequent reduction in the size of the 
extracellular space. The reduction in the extracellular space would lead to a 
significant increase in the impedance to a direct current. The presumed cerebral 
oedema was also associated with an increase in the invasively measured ICP. 
There was a strong correlation between the change from baseline of the non-
invasive measurements of TCB and ICP in the six animals subjected to severe 
hypoxia (correlation coefficients between 0.72 and 0.97). 
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In subsequent neonatal piglet experiments, Lingwood et al were able to 
demonstrate that the significant changes from baseline of non-invasive TCB 
measurements associated with severe hypoxia correlated well with clinical and 
histological markers of poor neurological outcome(128). They suggested that TCB 
measurements could therefore be used to help in prognosticating the degree of 
neurological impairment following severe perinatal asphyxia. Unfortunately it 
was not possible to confirm the association in a study of 24 human newborns 
with evidence of severe acute intrapartum hypoxia and encephalopathy(129). 
 
Other attempts have been made to explore the relationship between TCB and 
ICP using an animal model. Shaw et al performed a series of experiments in 
sheep, again using the Impedimed SFB7 device(130). TCB measurements were 
made via 21G needles inserted into the scalp on either side of the head. ICP was 
invasively measured with an intraventricular catheter and manipulated via the 
injection of a mock CSF injection to cause a stepwise increase in ICP up to 50 
mmHg. It was demonstrated that when Zc was normalised against a baseline 
value for each animal, there was a clear relationship between the log of ICP and 
the inverse of Zc: 
 
𝐼𝐶𝑃 = 𝑒𝑥𝑝൬
𝑎
𝑍௡௢௥௠
+ 𝑏൰ (2.10) 
 
where Znorm is the normalised Zc. In parallel with this animal study, Shaw et al 
performed a study in healthy human volunteers to determine the normal values 
for TCB recorded using transcutaneous electrodes.  
 
In terms of previous work that has investigated TCB measurements of the brain, 
it is finally necessary to mention the evolving technique of electrical impedance 
tomography (EIT)(131).  Using an array of surface electrodes, multiple electrical 
impedance measurements can be made between rotating electrode pairs. 
Advanced signal processing is then required to construct a cross sectional image 
of the object being measured. An adaptation of the technique has been applied 
to a porcine model of traumatic brain injury using a combination of cutaneous 
electrodes and an EIT electrode incorporated onto an intraparenchymal ICP 
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monitoring device(132). As a proof of concept study, it was possible to some 
degree, to detect intracranial injuries in real time. 
 
2.7.5 Postulate 
It is clear that multiple studies have demonstrated a potential role for 
bioimpedance measurements of the brain in clinical practice. Indeed there is 
some evidence from the animal studies above that TCB measurements are 
related to invasively measured ICP. As stated above, development of a reliable 
non-invasive ICP monitoring technique would have wide clinical applicability in 
TBI. It was therefore postulated that TCB measurements could provide an 
estimate of ICP in patients admitted following a TBI.  
 
Following TBI intracranial compliance is dependant upon the degree of 
intracellular swelling and the size of the extra cellular space. Similarly in TCB 
measurement, brain impedance depends upon intracellular swelling and the size 
of the extra cellular space. As there is a well-defined exponential relationship 
between ICP and intracranial compliance, it was proposed that there should also 
be a definable relationship between ICP and TCB.  
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3. Materials and Methods for the BioTBI Study 
3.1 Overview 
This chapter describes in detail the materials and methods for the Relationship 
Between Transcranial Bioimpedance and Invasive Intracranial Pressure 
Measurement in Traumatic Brain Injury Patients (BioTBI) Study. The study 
protocol and related documents are available on request.  
 
3.2 Objective 
The primary objective of this study was to define the relationship between non-
invasive bioelectrical impedance measurements of the brain and skull and 
intracranial pressure (ICP) in traumatic brain injury (TBI) patients. This would 
act as a pilot project to assess the feasibility of transcranial bioimpedance (TCB) 
as a non-invasive estimate of ICP. 
 
3.3 Ethical Approval 
Ethical approval was granted for the study by Scotland A Research Ethics 
Committee following the meeting on 23rd June 2011 and chaired by Dr Ian 
Zealley (Reference Number: 11/AL/0320). The study was sponsored by NHS 
Greater Glasgow and Clyde and supported by funding from The Association of 
Anaesthetists of Great Britain and Ireland/ Anaesthesia via the National Institute 
of Academic Anaesthesia (WKR0-2011-0039). 
 
3.4 Summary of Study Design 
This was a single centre pilot study comparing TCB measurements to invasively 
monitored ICP in patients with TBI. The aim was to enrol 15 patients with a view 
to performing 300 individual TCB measurements.  
 
3.5 Patient Recruitment 
Study participants were prospectively recruited from patients admitted to the 
Neurological Intensive Care Unit (NICU) at the Institute of Neurological Sciences. 
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Included patients were over 16 years of age, admitted with a traumatic brain 
injury and undergoing invasive ICP monitoring as part of their routine clinical 
care. 
Due to the nature of their injuries and ongoing intensive care, patients were 
unable to consent to inclusion in the study. For this reason, the nearest relatives 
were approached on their behalf. The nearest relatives were provided with a 
Relative’s Information Sheet and a verbal description of the study procedure. 
They were allowed time to ask questions and for consideration prior to 
consenting to their relative’s participation in the study.  
 
Patients were excluded from participation in the study if their relative refused 
consent or if there was soft tissue injury preventing application of the TCB 
electrodes. 
 
3.6 Patient Monitoring 
As part of their routine clinical care on the NICU, all participants were 
undergoing measurement of their physiological vital signs through the Philips 
IntelliVue MX700 bedside patient monitor (Philips Healthcare, Netherlands). 
Vital signs recorded included, but were not limited to, pulse oximetry (SpO2), 
end-tidal carbon dioxide (ETCO2), electrocardiogram (ECG), invasive arterial 
blood pressure (IABP) and core temperature.  
 
As stated in the inclusion criteria, all patients were undergoing invasive ICP 
monitoring. This was done through a Neurovent-P catheter-tip pressure sensor 
(Raumedic, Germany). The sensor was typically placed in the intraparenchymal 
compartment through a cranial bolt-housing overlying the frontal cortex. 
Interface to the Philips IntelliVue MX700 was provided by the NPS2 Philips/HP 
adapter cable.  
 
Minute by minute summaries of all vital signs, including ICP, were recorded and 
archived to the local patient management database (Microsoft SQL Server, 
2008). 
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3.7 Study Procedure 
3.7.1 Transcranial Bioimpedance Measurement 
Transcranial bioimpedance measurements were performed using the Impedimed 
SFB7 Bio-impedance Spectroscopy Unit (ImpediMed, Australia). The device is a 
single channel BIA unit that acquires 256 separate measurements between 4 and 
1000kHz. The SFB7 device was connected through application of 3M Red Dot 
Paediatric Monitoring Electrodes (3M, USA) to the scalp. In a previous study of 
healthy volunteers, our group had demonstrated the ease of obtaining TCB 
measurements using this device and have established a normative data set with 
varying electrode position, age and gender(130). From this it was concluded that 
temporal to temporal or frontal to occipital electrode positions were likely to 
give equally reliable data. The temporal to temporal position was anticipated to 
be the easiest to perform in TBI patients and was thus chosen as the primary 
configuration (Figure 3.1). 
 
Following patient recruitment to the study, TCB measurements were made with 
at least one hour intervals so that they could be considered as discrete 
measurements. There was a target of 20 measurements per participant, but this 
was subject to continuation of invasive ICP monitoring and ongoing feasibility of 
TCB measurement. At each measurement time point the device was programmed 
to perform 40 separate TCB recordings. This process took approximately one 
minute and ensured that any variation of instantaneous readings through 
pulsatile changes in either brain or scalp could be accounted for at the analysis 
stage. 
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Figure 3.1: SFB7 device connected with electrodes in the temporal position. An 
identical pair of electrodes are on the opposite side. 
3.7.2 Whole Body Bioimpedance Analysis 
Whole body bioimpedance measurements were anticipated to be an important 
variable when modelling TCB against ICP. To enable this, whole body 
bioelectrical impedance analysis (BIA) was performed six hourly during the study 
period using the SFB7 device and the standard technique.  
 
3.7.3 Waveform Data Capture 
In addition to routine clinical monitoring of participants, high frequency capture 
of physiological vital signs was performed throughout the study period. This was 
achieved by continuously streaming data from the Philips Intellivue MX700 
Medical Interface Bus (MIB) to a Dell Inspiron laptop (Dell Inc., USA) using 
ixTrends software(133). The purpose of this high frequency data capture was to 
allow better inspection of data for artifact and to allow future comparison of 
TCB against features of the ICP waveform. 
 
3.7.4 Additional Clinical Data 
A number of participant variables were recorded in the clinical record form 
(CRF) to allow data stratification for the process of modelling TCB against ICP. 
These variables included age, gender, body weight and height. Additional 
variables extracted from the participants computed tomography scan (CT) of 
their brain for consideration in the modelling process included brain diameter 
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and measurements of soft tissue swelling. To ensure that the population of 
patients studied was an appropriate representation of patients admitted with 
TBI, details of aetiology of TBI, primary diagnosis and any surgical procedures 
were also collected in the clinical record form (CRF). 
 
3.8 Analysis 
3.8.1 Introduction 
As stated in the introduction, data processing and analysis were performed using 
the “R” statistical programming environment(7). Specifically R Studio Version 
0.98.1102 running R Version 3.1.2 (R Core Team, 2014) was used. Individual R 
Packages used for each stage of analysis are detailed in the appropriate 
sections. All data visualisation was done using the package ggplot(134). 
 
3.8.2 Data Preparation 
3.8.2.1 Bioimpedance Data 
TCB and whole body BIA data were downloaded from the SFB7 device using the 
BioImp Body Composition Analysis Software provided with the device. The 
capabilities of this software in terms of Cole-Cole plotting and body composition 
estimates were not used. Instead the downloaded comma separated value (csv) 
files were imported into R for subsequent analysis. An annotated example of an 
SFB7 output file is shown in Figure 3.2. 
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Figure 3.2: Excerpt from a SFB7 data file, which includes header information and 
resistance and reactance measurements across 256 frequencies. 
Manipulation of TCB data into a standardised format for ease of repeatable 
analysis was performed using the packages dplyr(135) and stringr(136). Cole-
Cole plots were then constructed for each TCB and whole body bioimpedance 
measurement using a circle fitting function used in previous work(51). Summary 
values for Zc, R0 and Rinf were created by performing a composite fit using data 
from all of the 40 measurements made at each time point. Data were excluded 
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if the circle fitting function was unable to successfully calculate all of Zc, R0 and 
Rinf. 
 
3.8.2.2 ICP Data 
The ICP data necessary for modelling against TCB data were extracted from the 
high frequency data collected by the ixTrends software. These waveform data 
were stored with a resolution of 128 Hz and were output to a csv file. The 
processing of waveform data was done using techniques developed by Martin 
Shaw as part of a parallel project to which the BioTBI study contributed pilot 
data(137, 138). In brief, the waveform data underwent pulse detection and 
subsequent summarisation to 1 Hz frequency. ICP data were then extracted and 
imported into R. As for TCB data, manipulation of ICP data into a standardised 
format for ease of repeatable analysis was performed using the packages 
dplyr(135) and stringr(136). 
 
In preparation for modelling their relationship, a unique ICP value was needed 
for each TCB measurement. As a pragmatic sample, median ICP was calculated 
for the five minutes following each TCB measurement. 
 
3.8.3 Modelling ICP Using TCB Data 
3.8.3.1 Sample Size 
When calculating the appropriate sample size for the study, the range of ICP was 
assumed to be 0 to 50 mmHg. In the first instance, we expected to detect a 
minimum correlation between ICP and impedance of 0.2 (or 10 mmHg). 
Therefore a sample size of 280 was required to achieve a power of 0.9. We 
anticipated that this number of samples could easily be collected if 15 patients 
were recruited and TCB measurements made every hour for 24 hours. 
 
3.8.3.2 Modelling Process  
Attempts were made to model ICP using both absolute and normalised values of 
Zc and R0. In the animal studies referred to in the introduction, Zc had an inverse 
relationship with ICP, while R0 had a direct relationship(127, 130). An 
unadjusted linear modelling approach was first taken to confirm some degree of 
relationship between TCB and ICP.  
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An adjusted linear modelling approach was subsequently taken to explore which 
patient specific variables could be used to further define the relationship 
between ICP and Zc or R0. Each of the patient variables of gender, age, weight 
and height, along with CT derived measurements of soft tissue swelling and 
brain diameter, as well as whole body bioimpedance measurement and 
temperature, were included in linear models. Patient variables that did not 
significantly contribute to the model were sequentially removed. The simplified 
model was then compared against the original using analysis of deviance testing 
to confirm that they were not significantly different.  
 
The final modelling approach was to use the Akaike information criterion (AIC) in 
backward stepwise regression to select the models with the best balance of 
goodness of fit and low complexity. All modelling was done using the stats 
package in R(7). 
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4 Results for the BioTBI Study 
 
4.1 Overview 
The principle results of the transcranial Bioimpedance in Traumatic Brain Injury 
study are presented. There is first a description of patient demographics and 
measurements made, followed by a description of the attempts to model 
intracranial pressure using transcranial bioimpedance measurements. These 
results were presented in June 2016 at the 16th International Symposium on 
Intracranial Pressure and Neuromonitoring, Boston, Massachusetts. 
 
4.2 Data Collection 
4.2.1 Data Collection Period 
The initial plan for the BioTBI study was to recruit 15 patients to achieve a data 
set of 300 independent TCB measurements. Data were collected over the period 
17/12/2011 to 21/01/2014. TCB data were collected from a total of 11 patients 
during this period. In one of these patients, a technical problem with the 
neurological intensive care unit network led to a failure to store sufficient ICP 
data to model against TCB measurements. Consequently there were 10 patients 
with data suitable for inclusion in the study. 
 
In an audit of admissions to NICU at the Institute of Neurological Sciences in 
2010 there were 17 patients with TBI who underwent ICP monitoring. For this 
reason, it had been felt that recruiting the sample size of 15 patients in a two 
year period would be achievable. There were a number of reasons that meant 
that this was ultimately not the case. These ranged from a higher than expected 
number of relatives refusing consent, the unavailability of relatives to conduct 
the consent process, coincident admission of patients when there was only 
sufficient equipment to recruit one and short ICP monitoring periods meaning 
adequate data collection would not be possible.  
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4.2.2 Patient Demographics 
All patients met the inclusion criteria of age over 16 years, admitted to NICU 
with a traumatic brain injury and were undergoing ICP monitoring as a routine 
part of their clinical care. Table 4.1 summarises the demographic characteristics 
of each of the 10 final participants. There were nine male patients and one 
female and the median age was 51 (29 – 61) years.  
 
ID Gender Age 
(Yrs) 
Aetiology Primary 
Diagnosis 
Hospital Survivor 
001 m 45 Fall ASDH y 
003 m 54 Fall  EDH y 
004 f 61 Fall  EDH y 
005 m 51 Fall ASDH y 
007 m 48 Fall ASDH y 
009 m 59 Fall Contusions y 
010 m 61 Fall Contusions y 
011 m 41 Assault EDH y 
013 m 53 Fall Contusions y 
018 m 29 MVC DAI n 
 
Table 4.1: Demographic summaries for each of the ten patients included in the 
BioTBI study, where MVC = motor vehicle crash, ASDH = acute subdural haematoma, 
EDH = extradural haematoma, DAI = diffuse axonal injury. 
The aetiology of TBI was a fall in eight cases, with one assault and one motor 
vehicle crash. Most patients had several abnormalities identified on their 
admission CT brain scan, but the primary diagnosis was subdural haematoma, 
extradural haematoma or contusions in three cases each, with a single case of 
diffuse axonal injury. Four patients underwent craniotomy for haematoma 
removal prior to the period of TCB measurement. Subsequent to the study 
period, one further patient underwent craniotomy, two underwent burr hole 
drainage of chronic subdural haematoma and a further patient underwent 
insertion of an external ventricular drain followed by decompressive 
craniectomy. The extent of mixed pathology within and between patients is 
likely to have been significant in terms of the ability to model ICP using TCB and 
will be considered in detail later.  
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Nine out of the ten patients survived until discharge from hospital. The median 
length of stay in ICU was 8.6 (4.2 – 18.6) days, while the median length of acute 
hospital stay was 24.6 (16.2 – 143.5) days.  
 
4.2.3 Transcranial Bioimpedance Measurements 
In the ten patients who were ultimately included in the study, 168 valid 
temporal to temporal TCB measurement episodes were available. Preliminary 
Cole-Cole plots could be displayed on the SFB7 device and it was therefore 
possible to reject any clearly invalid measurements and repeat. In some patients 
it was impossible to achieve a valid measurement and the reasons for this will be 
explored in the discussion section. In the first five patients, initial attempts 
were made to measure TCB in alternative electrode positions (for example 
frontal to mastoid). It became clear however, that these measurements could 
often not be made due to the presence of a cervical collar or due to the risk of 
head position changes impacting on ICP. For each of the 168 episodes, there 
were 40 separate TCB measurement sweeps across the frequency spectrum. 
 
The TCB measurements from each measurement episode underwent Cole-Cole 
analysis to fit a single composite curve as a summary measure of the data. An 
example of the Cole-Cole plots for one patient is shown in Figure 4.1 and an 
example of the curve fitting has already been shown in Figure 2.15. 
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Figure 4.1: An example of composite Cole-Cole plots for one patient (ID = 011). 
4.2.4 Whole Body Bioimpedance Measurements 
A total of 39 whole body bioimpedance measurements were made. This 
represented at least one measurement for every six hour period for the patients 
included in the study. As for the TCB measurements, for each of the 39 
episodes, there were 40 separate measurement sweeps across the frequency 
spectrum. 
 
4.2.5 Intracranial Pressure Measurements 
ICP was calculated as a summary measure of two time windows surrounding each 
TCB measurement. The first time window was the five minutes immediately 
following the measurement, when the median value across the study period for 
all patients was 16.3 (9.5 – 28.9) mmHg. Boxplots showing the distribution of ICP 
for each patient are shown in Figure 4.2. The median ICP value using a second 
time window from 15 minutes before to 15 minutes after each TCB measurement 
was 16.2 (9.5 – 29.4) mmHg. The distributions of ICP values for each patient 
were essentially identical between the first and second time windows. For this 
reason, the decision was made to use only the ICP values calculated during the 
first time window during the process of modelling ICP using TCB. 
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Figure 4.2: Boxplots showing the distribution of ICP values measured across the 
study period for each patient. 
4.3 Modelling of ICP Using TCB Data 
4.3.1 Introduction 
A number of modelling approaches were taken in an attempt to find the most 
effective technique to predict ICP using TCB measurements. The results of these 
analyses shall be discussed in turn below. TCB measurements entered the 
models either as the raw measured value or as a value normalised against the 
overall median value for the individual patient. 
 
4.3.2 Unadjusted Linear Models 
ICP was first plotted against measured Zc and normalised Zc to allow visual 
inspection for any obvious relationship (Figure 4.3). From these plots there was 
no clear relationship between TCB and ICP, so the plots were then repeated for 
each individual patient (Figure 4.4). In the absence of any clear visual 
relationship the decision was made to use an unadjusted linear modelling 
approach to explore the relationship between both measured Zc and normalised 
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Zc and ICP. On the basis of the previously discussed sheep study(130), the inverse 
relationship between normalised Zc and the log of ICP was also explored. 
 
On the basis of the previously discussed neonatal piglet study(127), the 
relationship between ICP and R0 was also explored. Combined and individual 
patient plots are displayed in Figures 4.5 and 4.6. Again there was no clear 
relationship between TCB and ICP, so on the basis of the piglet experiment a 
direct relationship between R0 and ICP was assumed. 
 
Figure 4.3: Plot of ICP against measured (A) and normalised (B) Zc for the entire 
study population. 
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Figure 4.4: Plots of ICP against normalised Zc for each patient. 
 
Figure 4.5: Plot of ICP against measured (A) and normalised (B) R0 for the entire 
study population. 
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Figure 4.6: Plots of ICP against normalised R0 for each patient. 
There was no significant relationship between ICP and Zc or R0. There was a 
significant relationship between ICP and normalised Zc (p < 0.001), a significant 
inverse relationship between the log of ICP and normalised Zc (p < 0.01) and a 
significant relationship between ICP and normalised R0 (p < 0.001). The adjusted 
r-squared value for each of these relationships was small (0.09, 0.06 and 0.18 
respectively). Attempts were therefore made to explore the relationship 
between ICP and TCB parameters by adjusting the linear models for patient 
specific variables.  
 
4.3.3 Adjusted Linear Models 
To explore which patient specific variables could be used to further define the 
relationship between ICP and Zc or R0, each of the patient variables of gender, 
age, weight and height, along with CT derived measurements of soft tissue 
swelling and brain diameter, as well as whole body bioimpedance measurement 
and temperature, were included in linear models. Patient variables that did not 
significantly contribute to the model were sequentially removed. The simplified 
model was then compared against the original using analysis of deviance testing 
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to confirm that they were not significantly different. The following models were 
considered: 
 
𝐼𝐶𝑃 = 𝑎ଵ𝑍௖ + 𝑎ଶ𝑉ଶ…𝑎௡𝑉௡ + 𝑏 (4.1) 
  
𝐼𝐶𝑃 = 𝑒𝑥𝑝൬
𝑎ଵ
𝑍௖
+ 𝑎ଶ𝑉ଶ…𝑎௡𝑉௡ + 𝑏൰ 
(4.2) 
  
𝐼𝐶𝑃 = 𝑎ଵ𝑅଴ + 𝑎ଶ𝑎ଶ… 𝑎௡𝑉௡ + 𝑏 (4.3) 
  
𝐼𝐶𝑃 = 𝑎ଵ𝑍௡௢௥௠ + 𝑎ଶ𝑉ଶ…𝑎௡𝑉௡ + 𝑏 (4.4) 
  
𝐼𝐶𝑃 = 𝑒𝑥𝑝൬
𝑎ଵ
𝑍௡௢௥௠
+ 𝑎ଶ𝑉ଶ…𝑎௡𝑉௡ + 𝑏൰ 
(4.5) 
  
𝐼𝐶𝑃 = 𝑎ଵ𝑅௡௢௥௠ + 𝑎ଶ𝑉ଶ…𝑎௡𝑉௡ + 𝑏 (4.6) 
 
where Znorm and Rnorm are normalised Zc and R0, V1…Vn are patient specific 
variables and a1…an and b are constants. To assess whether or not the inclusion 
of both Zc and R0 strengthened the relationship between TCB parameters and 
ICP, the following models were considered:  
 
𝐼𝐶𝑃 = 𝑎ଵ𝑍௖ + 𝑎ଶ𝑅଴…𝑎௡𝑉௡ + 𝑏 (4.7) 
  
𝐼𝐶𝑃 = 𝑒𝑥𝑝൬
𝑎ଵ
𝑍௖
൰+𝑎ଶ𝑅଴…𝑎௡𝑉௡ + 𝑏 
(4.8) 
  
𝐼𝐶𝑃 = 𝑎ଵ𝑍௡௢௥௠ + 𝑎ଶ𝑅௡௢௥௠…𝑎௡𝑉௡ + 𝑏 (4.9) 
  
𝐼𝐶𝑃 = 𝑒𝑥𝑝൬
𝑎ଵ
𝑍௡௢௥௠
൰+ 𝑎ଶ𝑅௡௢௥௠…𝑎௡𝑉௡ + 𝑏 
(4.10) 
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Using measured TCB parameters, the simplified model with the greatest r-
squared value was:  
 
𝐼𝐶𝑃 = 𝑎ଵ𝑅଴ + 𝑎ଶ𝐺 +𝑎ଷ𝑊+ 𝑎ସ𝐻+ 𝑎ହ𝐵𝐷+ 𝑎଺𝑊𝐵𝑍௖ + 𝑏 (4.11) 
 
where G is gender,  W is weight, H is height, BD is brain diameter and WBZc is 
whole body bioimpedance (p < 0.0001, r-squared = 0.19, estimates in Table 4.2). 
 
 Estimate 95% Confidence Intervals P-value 
a1 0.20 0.12 to 0.29 < 0.0001 
a2 -5.68 -7.51 to -3.85 < 0.0001 
a3 0.08 0.01 to 0.15 < 0.05 
a4 0.28 0.16 to 0.40 < 0.0001 
a5 -0.41 -0.65 to -0.17 < 0.001 
a6 -0.02 -0.03 to -0.01 < 0.0001 
b 15.03 -4.92 to 34.98 0.14 
 
Table 4.2: Estimates for model 4.11. 
The simplified model with the greatest r-squared value using normalised 
bioimpedance measurements was: 
 
𝐼𝐶𝑃
= 𝑒𝑥𝑝൬
𝑎ଵ
𝑍௡௢௥௠
൰+ 𝑎ଶ𝑅௡௢௥௠ + 𝑎ଷ𝐺 + 𝑎ସ𝑆𝑇+ 𝑎ହ𝑇+ 𝑎଺𝑊𝐵𝑍௡௢௥௠+ 𝑏 
(4.12) 
 
where ST is soft tissue thickness and T is temperature (p < 0.0001, r-squared = 
0.32, estimates in Table 4.3).  
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 Estimate 95% Confidence Intervals P-value 
a1 2.92 1.07 to 4.78 < 0.01 
a2 9.60 6.10 to 13.09 < 0.0001 
a3 -3.81 -5.40 to -2.22 < 0.0001 
a4 0.13 0.08 to 0.19 < 0.0001 
a5 0.90 0.29 to 1.51 < 0.01 
a6 12.12 2.21 to 22.03 < 0.05 
b -48.50 -74.51 to -22.49 < 0.001 
 
Table 4.3: Estimates for model 4.12. 
4.3.4 Backward Stepwise Regression 
The models selected and their r-squared values calculated using a backward 
stepwise regression approach were essentially the same as those selected using 
the adjusted linear modelling approach. 
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5 Discussion and Conclusions for the BioTBI Study 
 
5.1 Overview 
A discussion of the results of the BioTBI Study is presented below. Limitations of 
the study are addressed and the results are considered in terms of those of 
similar studies attempting to model intracranial pressure (ICP) using a non-
invasive technique. There is then a description of work performed as a direct 
result of the BioTBI Study with suggestions for future directions of research into 
the modelling of ICP in patients with traumatic brain injury (TBI). 
 
5.2 Rationale for the Study 
Monitoring of ICP is well established in the clinical management of TBI and the 
practise is supported by international guidelines(54). ICP monitoring is typically 
performed using an intraventricular or intraparenchymal catheter with a 
microtransducer system. Both of these techniques are associated with significant 
complications such as bleeding and infection and their availability in TBI is 
largely restricted to specialist neurosurgical centres. A safe, simple and accurate 
non-invasive device would therefore increase the clinical availability of ICP 
monitoring. 
 
Transcranial bioimpedance (TCB) has been considered for the early detection of 
multiple brain pathologies in humans(120, 121, 125). In addition, previous 
animal experiments have shown a relationship between TCB and ICP(127, 130). 
Based on the known relationship between bioimpedance and the volume of the 
intracellular and extracellular spaces, the potential use of TCB was investigated 
as an estimate of ICP in TBI. 
 
5.3 Data Collection 
5.3.1 Study Population 
All study patients were recruited from the neurological intensive care unit 
(NICU) and had been admitted with severe TBI. The patients were representative 
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of the typical population of patients suffering a TBI in terms of age range and 
the diverse pathologies identified on computed tomography (CT) scanning of the 
brain. While the range of pathologies was a strength of the study in terms of its 
clinical applicability it may have limited the prospects of successfully identifying 
a relationship between TCB and ICP. 
 
In the animal studies that had previously defined a relationship between TCB 
and ICP, the experimental models resulted in a uniform pathological process 
that would effect TCB measurements in a predictable manner. In the neonatal 
piglet model described by Lingwood et al(127), brain hypoxia was presumed to 
lead to intracellular swelling and a consequent decrease in the extra-cellular 
fluid space that was associated with a rise in ICP. In the sheep model described 
by Shaw et al(130), intracranial hypertension (ICH) was induced by injection of 
mock cerebrospinal fluid (CSF) into the ventricle. The nature of the brain 
injuries in the patients recruited to the BioTBI study meant that there were 
likely to be multiple pathological processes evolving, even within an individual 
patient. The aetiology of increases in ICP could include intracellular or vasogenic 
oedema, expansion of intra or extra-axial haematoma or a disruption to CSF 
flow. All of these pathologies are likely to have had different influences upon 
TCB measurements that complicated the process of modelling ICP.  
 
A failure to translate promising animal research into successful human studies 
has been a very well recognised problem in TBI(139) and over the past 30 years 
more than 20 large phase III trials have failed to show a significant treatment 
effect of a neuroprotective agent(140). Many of the issues related to therapeutic 
trials relate equally well to monitoring studies. One of the primary problems in 
converting positive findings in animal models of TBI into positive findings in the 
clinical environment is believed to be the heterogeneity of human TBI compared 
to that in controlled animal models(141). The International Mission on Prognosis 
and Clinical Trial Design in TBI (IMPACT) study group was initiated in 2003(142). 
They were given access to individual patient data from several large randomised 
controlled trials (RCTs) with the aim of optimising the design and analysis of 
trials in TBI. Proposed techniques for dealing with heterogeneity in TBI have 
been to maintain broad inclusion criteria but to pre-specify covariate 
adjustment into analyses(143). 
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As already detailed in the results section, recruitment to the BioTBI Study was 
slower than had been anticipated. Although the intended sample size was not 
achieved, the number of patients and individual TCB measurements should have 
been sufficient to detect a strong relationship between TCB and ICP if it existed. 
 
5.3.2 TCB Measurements 
Measurement of TCB proved to have a number of technical difficulties in the 
population of TBI patients studied. The presence of rigid collars to immobilise 
the cervical spine in a number of patients meant that positioning the electrodes 
in mastoid or occipital positions was not feasible. Similarly the risk of 
undiagnosed cervical spine injury in this patient population means that the head 
and neck can only be moved with caution to allow electrode attachment. 
 
In several patients the application of electrodes was complicated by the position 
of dressings following cranial surgery or because of associated maxillo-facial 
injuries. Indeed the presence of significant soft-tissue swelling in some cases 
made the successful measurement of TCB difficult. In these cases there was the 
concern that a significant portion of the current path would be extra-cranial and 
therefore impedance would not necessarily reflect intra-cranial pathology. 
Attempts were made to mitigate this risk by measuring soft tissue thickness and 
brain diameter on CT scan and including these measurements in the adjusted 
models.  
 
5.3.3 ICP Measurements 
In the BioTBI Study, only patients who were undergoing ICP monitoring as part of 
their routine clinical care following severe TBI were recruited. In these patients, 
one of the principle aims of NICU care is to prevent ICH and thus intervene when 
ICP is rising. As can be seen from Figure 4.2, the vast majority of ICP summary 
measures from all patients were in the range of 10 to 25 mmHg. Therefore there 
were a limited number of extreme ICP values to facilitate model building. All 
studies investigating non-invasive ICP devices in the real clinical environment 
face a similar problem. For example in the study by Brandi et al, comparing 
multiple transcranial Doppler sonography (TCD) derived models of ICP, across 
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601 measurements in 45 patients, there were only four values above 25 
mmHg(80). 
 
ICP values used for modelling purposes were taken as a median of ICP in the five 
minutes following a TCD measurement. This time window was chosen as being 
long enough to provide a stable value but short enough to reflect any changes in 
pathophysiology. The R code used to provide the summary measure would allow 
the window length to be easily adjusted in any future studies.  
 
5.4 Modelling of ICP Using TCB Data 
5.4.1 Unadjusted Linear Models 
The TCB parameters selected for modelling were based upon the animal studies 
referred to above. Shaw et al had demonstrated an inverse relationship between 
the log of ICP and Zc(130), while Lingwood et al had demonstrated a direct 
relationship between ICP and R0(127). Visual inspection of plots of ICP against 
the Zc and R0 (Figures 4.3 and 4.5) did not suggest any strong relationship. Given 
the low sample size, plots were performed for each individual patient (Figures 
4.4 and 4.6) but even on an individual patient basis there was no clear trend 
between either Zc or R0 and ICP.  
  
The lack of a strong relationship was then supported by the results of the linear 
modelling approach, where there was no demonstrable relationship between the 
measured values of either Zc or R0 and ICP. When TCB variables were normalised 
per patient (as was done in the previous animal studies) there was a small but 
significant relationship. 
 
5.4.2 Adjusted Models 
In an attempt to account for some of the patient heterogeneity in the study 
population, a number of patient specific variables were used in adjusted linear 
models and backward stepwise regression. Using measured values, the TCB 
parameter R0 in combination with the variables of gender, age, weight, height, 
brain diameter and whole body Zc provided the adjusted linear model of ICP 
(4.11) with the largest adjusted r-squared value (0.19). Using normalised values, 
the TCB parameters of 1/Zc and R0 in combination with the variables of gender, 
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soft tissue thickness, temperature and whole body Zc provide the model of ICP 
(4.12) with the largest adjusted r-squared value (0.32).  The models and values 
calculated using backward stepwise regression were almost identical.  
 
The relatively low r-squared values in the above models mean that a large 
component of ICP is unexplained by the model incorporating TCB measurements. 
This is particularly relevant given that there is a significant risk of model over 
fitting to the small study population. Therefore the likelihood that either of the 
models could be generalised to provide clinically meaningful estimates of ICP in 
a population of patients admitted with severe TBI is low. 
 
5.4 Results in the Context of Similar Studies 
5.4.1 Non-Invasive ICP Measurement 
The two most extensively investigated non-invasive techniques to estimate ICP 
are TCD and optic nerve sheath diameter (ONSD) derived measures, as already 
discussed. The complexity of TCB measurements and the training required to 
perform them would be less than either of these ultrasound-derived measures. 
On the basis of the BioTBI study however, TCB does not show more potential 
overall.  
 
It is not possible to perform an exact comparison of the techniques, but the r-
squared value of 0.19 achieved by modelling ICP using measured values of TCB 
suggests the technique would be far inferior to either TCD or ONSD. The TCD 
technique proposed by Bellner et al(78) and recommended by Brandi et al(80) 
was initially demonstrated to detect an ICP of over 20 mmHg with a sensitivity of 
0.83 and specificity of 0.99. It is worth mention that in the comparative study by 
Brandi et al, the technique failed to detect all cases of intracranial 
hypertension. In the meta-analysis of ONSD techniques performed by Dubourg et 
al, the pooled sensitivity and specificity to detect ICH were 0.9 and 0.85 
respectively(87). 
 
The TCB, TCD and ONSD techniques all share the disadvantage of providing a 
surrogate measure of ICP, rather than an absolute measure. The technique 
described by Ragauskas et al(108), based on detecting ophthalmic artery pulse 
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waveforms following increments of intra-occular pressure, provides an 
interesting alternative. The safety and applicability to a wide range of clinical 
situations are yet to be demonstrated for this technique.  
 
5.4.2 Clinical Application of TCB 
The BioTBI study suggests that TCB techniques will require considerable 
development before application to estimation of ICP in TBI. Other authors have 
proposed the use of TCB to detect alternative pathologies. Both of Liu et al(121) 
and Seonne et al(125) have studied the use of TCB measurement in the early 
detection of stroke. The use of TCB in this population does not face the same 
difficulties in terms of movement of the head and neck or electrode application 
in the context of soft tissue injury that are encountered in TBI.  
 
There is no detailed description of the TCB measurements made by Liu et al. In 
the study by Seonne et al, comparison was made between TCB measurements 
made with central and lateral electrode positions and with left and right 
electrode positions. The ratios of resistance in these electrode positions was 
found to be outside the range of healthy controls in nine out of ten stroke 
patients. This is an interesting result and does support the hypothesis that TCB 
measurements can help to identify a patient with brain injury. It is difficult 
however to envisage how TCB would be applied in the acute care of stroke, 
where the requirement for early diagnostic imaging is already established in 
national guidelines(144).  
 
5.5 Related and Future Work 
5.5.1 Introduction 
Despite disappointing results in terms of modelling ICP, the ICP and ABP 
waveform data collected as part of the BioTBI Study have been a valuable 
research resource. They have been used as pilot data to test some of the models 
described in the introductory chapter and bring them closer to implementation 
in clinical practice. Examples of recent and ongoing projects that are using the 
data to develop novel ICP analysis, address issues related to artifact in high 
volume data capture and embed these complex analyses into the clinical 
environment are provided below.  
  
68 
5.5.2 Multi-resolution Convolution Analysis of the ICP Waveform 
From the database of ICP waveforms collected as part of the BioTBI Study, 
examples of the recognised ICP states of high and low compliance and ‘a’ and 
‘b’ waves were selected(145). Multi-resolution convolution analysis was used to 
identify features of the ICP waveform associated with each of the clinical states 
that could then be used to create an impulse function. It was then possible to 
identify these waveform features in a separate study dataset. These pilot results 
require further optimisation on a larger ICP waveform dataset. As with the 
previously discussed work on morphological clustering and analysis of continuous 
intracranial pressure (MOCAIP)(103), they do suggest that automated analysis of 
the ICP waveform may be able to identify clinically important ICP states. 
 
5.5.3 Calculation of Optimal CPP 
There has already been detailed discussion of the potential use of indices of 
cerebral autoregulation (CA) to calculate optimal cerebral perfusion pressure 
(CPPopt) in TBI. One of the potential limitations of this approach is the fact that 
the most established techniques to calculate CPPopt fail to successfully find a 
value in a significant percentage of monitoring episodes(100). Arterial blood 
pressure (ABP) and ICP waveforms collected during the BioTBI Study have been 
used to compare indices of CA(146) and explore alternative methods of 
estimating CPPopt(147). If targeting of CPPopt in the management of TBI is to be 
tested by RCT, there will need to be consensus agreement on the most 
appropriate means of its estimation. 
  
5.5.4 Detecting Artifact in Physiological Waveforms 
The BioTBI Study tested a new system for high frequency data capture on the 
NICU (ixTrends(133)). One of the well recognised problems with automatic high 
frequency data capture is the inadvertent collection of artifactual data(148). 
The ABP data collected during the BioTBI Study were used as pilot data for a 
Chief Scientist Office (Scotland) funded project (CHZ/4/801) into the automatic 
detection of artifactual events in vital signs monitoring data(149, 150). As high 
frequency data capture becomes the norm in ICU there will be a requirement for 
systems to ensure the quality of these data. 
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5.5.5 Embedding Automatic Data Analysis into the NICU 
At around the same time that the IMPACT Group were addressing issues 
surrounding the failure of multiple large RCTs to confirm the efficacy of 
promising therapies in TBI, the Brain monitoring with Information Technology 
(BrainIT) Group were suggesting an alternative solution(96). As a collaboration 
across 22 NICUs in 11 European countries (coordinated from the Institute of 
Neurological Sciences in Glasgow), the group have worked towards development 
of more information technology based tools for collection and analysis of 
standardised high resolution data in TBI. By sharing and analysing these high 
resolution data it is expected that a better understanding of variations in patient 
physiology and treatment will lead to more targeted therapies in the future. 
 
In the BrainIT projects, the data collection frequency was 1 Hz. In the BioTBI 
project, the data collection frequency of the ICP and ABP waveforms was 128 
Hz, while the frequency for the electrocardiogram (ECG) signal was 512 Hz. The 
collection of this resolution of data means that analyses of brain physiology, for 
example the assessments of cerebral autoregulation mentioned above, can be 
performed. However, the vast quantities of data generated require specialised 
infrastructure for transfer, storage and analysis. The Connecting Healthcare and 
Research Through A Data-Analysis Provisioning Technology (CHART-ADAPT) 
Project has been funded by Innovate UK (Reference: 102113) to address these 
issues along with the unique challenge of returning results to the patient bedside 
in a clinically useful timeframe(151). 
 
5.5.6 Alternative Monitors of Brain Physiology 
In the context of managing TBI, the importance of ICP monitoring relates to the 
information it can provide clinicians in terms of indicating the extent of the 
pathological process and guiding interventions. The interventions can be 
targeted at reducing ICP and optimising CPP as a means of ensuring adequate 
cerebral blood flow (CBF) and consequently maintaining oxygen and nutrient 
delivery to the injured brain. Direct measures of these endpoints exist but a 
review of their function and efficacy is outwith the scope of this thesis. The 
Brain Trauma Foundation (BTF) guidelines acknowledge the current low level of 
evidence surrounding devices designed to monitor CBF, brain oxygenation and 
the metabolic state of the brain. Despite this, the future of TBI care will 
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potentially involve integrating ICP measurement with multiple additional 
monitors of brain physiology.  
 
5.5.7 Alternative Applications for TCB Measurement 
All of the applications of TCB measurement described above have been in the 
monitoring and investigation of acute pathologies. As an estimate of ICP it may 
be more appropriate in future studies to consider a role for TCB in monitoring 
more chronic conditions. For example, idiopathic intracranial hypertension (IIH) 
is a syndrome of raised intracranial pressure without identifiable aetiology(152) 
and hydrocephalus is a disorder of excessive accumulation of CSF with multiple 
aetiologies(153). In both of these clinical conditions there is often an indication 
for measurement of CSF pressure in individuals over a long period of time, 
frequently resulting in multiple invasive procedures. Therefore the need for new 
techniques to assist with the diagnosis of hydrocephalus is recognised as an 
opportunity for hydrocephalus research(154). In IIH and hydrocephalus, TCB 
would benefit from the lack of soft tissue injury, the potential to make a 
calibrating invasive measurement at the time of diagnosis, followed by the 
ability to trend non-invasive measures over time. 
 
5.6 Conclusions 
The pilot results from the BioTBI Study confirm some degree of relationship 
between TCB parameters and invasively measured ICP. The magnitude of this 
relationship is small and on the basis of the study, TCB is unlikely to provide a 
clinically useful estimate of ICP in patients admitted with TBI.  
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6 Pharmacokinetic Pharmacodynamic Modelling in 
Anaesthesia 
 
6.1 Overview 
Target controlled infusion (TCI) systems deliver intravenous drugs with the aim 
of achieving and maintaining set levels of drug in either the plasma or an effect 
site. In anaesthetic practice the effect site of interest is most commonly the 
brain. TCI systems apply population based pharmacokinetic (PK) models that 
attempt to account for inter-individual variability by adjusting model 
parameters according to covariates such as age, sex and weight(155). Most PK 
models in anaesthesia are compartment models, where drug is infused into a 
central compartment and can re-distribute to peripheral compartments as 
described by the rate constants. The delay between measured or predicted 
plasma concentrations and clinical effect can be accounted for by the 
incorporation of an effect site compartment, with an associated rate constant 
for elimination from this compartment (ke0). The resulting model is known as a 
pharmacokinetic pharmacodynamic, or PKPD model (Figure 6.1). 
 
In anaesthetic practice, the drug most commonly administered by TCI is 
propofol. A detailed discussion of the pharmacodynamic and pharmacokinetic 
features of propofol that make it ideally suited for TCI is provided below. There 
is a description of the PKPD models for propofol that are commonly used in 
clinical practice, alongside a consideration of their most significant differences. 
This is followed by an introduction of the Covariates Model, which is the subject 
of the PKPD study (VaSCoM) that forms the subsequent sections of this thesis. 
Finally there is a discussion of the modelling techniques available to determine 
the appropriate ke0 to use with a given PK model.  
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Figure 6.1: Three compartment mammillary model with model parameters V 
(compartment volumes) and k (microrate constants). The effect site is assumed to 
be infinitely small and does not effect the disposition of drug from the central 
compartment. Keo is the model parameter that describes the time course of clinical 
effect. 
6.2 Total Intravenous Anaesthesia 
Total intravenous anaesthesia (TIVA) has a number of theoretical advantages 
over inhalational anaesthesia that relate both to the drug delivery mechanism 
(Table 6.1) and the pharmacodynamic properties of the drugs used. TIVA is most 
commonly provided using a combination of a hypnotic agent (typically propofol) 
and a short acting opioid analgesic (typically remifentanil). In an audit of 
National Health Service (NHS) activity performed in 2013, 5.8% of anaesthetics in 
the United Kingdom are delivered by propofol infusion(156). The establishment 
of TIVA in routine anaesthetic practice has been facilitated by the development 
of PKPD models for propofol to allow its delivery via TCI systems. 
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Selected Advantages of Total Intravenous Anaesthesia 
No requirement for anaesthetic machine with vapourisers 
No risk of atmospheric pollution 
Continuous delivery of anaesthesia during airway surgery 
Continuous delivery of anaesthesia during patient transfer 
Safe for use in patients with malignant hyperthermia 
 
Table 6.1: Advantages of TIVA 
6.3 Propofol  
6.3.1 Chemistry 
Propofol (2,6-diisopropylphenol) is the most commonly used intravenous 
anaesthetic agent. It is a highly lipophylic compound and was initially introduced 
during the late 1970s formulated in Cremophor EL(157). Due to an association 
between Cremophor EL and anapylactoid reactions, this preparation of the drug 
was withdrawn and propofol has been subsequently formulated as a lipid 
emulsion. The first preparation chosen for development (Diprivan®) was based 
on the composition of the parenteral fat formulation Intralipid® (10% soybean 
oil, 2.25% glycerol, 1.2% egg yolk lecithin) with the pH adjusted by sodium 
hydroxide. The soybean emulsion in Diprivan® contains long chain triglycerides 
and these are thought to be responsible for the associated pain on injection. 
Alternative formulations containing mixed long and medium chain triglycerides 
(Propofol-Lipuro®) have been associated with similar pharmacokinetic and 
pharmacodynamic properties but with less injection pain(158). 
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Selected Effects of Propofol 
Airway    Haemodynamic response to intubation 
Respiratory     Central inspiratory drive 
    Minute volume 
    Tidal volume 
    Ventilatory response to increased ETCO2 
Cardiovascular    Arterial blood pressure  
    Systemic vascular resistance 
   Cardiac output 
   Stroke volume 
Cerebral physiology    CMRO2 
   Vascular reactivity 
   Autoregulation 
    Blood flow 
    Blood volume 
    ICP 
   CPP 
 
Table 6.2: Selected Effects of Propofol.    = consistently reduced across multiple 
studies,   = tendency towards reduction or a less significant effect,   = no change 
or conflicting evidence, ETCO2 = end tidal carbon dioxide, CMRO2 = cerebral 
metabolic rate for oxygen consumption, ICP = intracranial pressure, CPP = cerebral 
perfusion pressure. 
6.3.2 Pharmacodynamics 
Propofol induces unconsciousness through activity on the J-Aminobutyric acid A 
receptor (GABAA) on cortical and subcortical inhibitory interneurones(159).  The 
systemic effects of propofol have been well documented (160-162) and are 
summarised in Table 6.2. Propofol meets a number of the requirements of the 
ideal drug for intravenous anaesthesia by providing a rapid, smooth induction 
without excitation or respiratory distress and quick recovery to clear 
consciousness without post-operative nausea and vomiting. 
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6.3.3 General Pharmacokinetics 
The decline of plasma propofol concentration following an intravenous bolus 
dose or infusion has been well described and will be discussed in detail below in 
the context of disposition kinetics and existing PK models.  
 
Propofol is highly bound to plasma proteins with 97-98% binding (predominantly 
to albumin) in both control patients and patients with known cirrhosis but 
maintained plasma albumin levels(163). In contrast, clinical situations resulting 
in a reduction in the plasma protein concentration, such as cardiopulmonary 
bypass, have been associated with a rise in the concentration of unbound 
propofol(164). This rise in the free fraction of the drug is thought to result in 
increased pharmacodynamic effect despite a stable whole blood 
concentration(165). 
 
As well as being highly bound to plasma proteins, propofol is bound to 
erythrocytes. In whole blood samples, propofol has been shown to be 50% bound 
to erythrocytes, 48% bound to plasma protein and 2% free drug(166). 
 
The metabolism of propofol is thought to be primarily hepatic. There is likely to 
be at least some contribution from other organs due to the fact that apparent 
systemic clearance only reduced by around 40% during the anhepatic phase of 
liver transplant(167). Some authors have argued for a significant role of the 
kidney in propofol metabolism(168), although this could not be confirmed 
through measurement of propofol concentration in renal artery and vein in a 
swine experiment(169). Similarly there is some discussion over the relative 
contributions of the small intestine, lung and brain in propofol metabolism(167, 
170). 
 
Analysis of the urine metabolite profile for propofol has demonstrated an 
important contribution of both glucoronidation and hydroxylation prior to 
excretion(171). Only a small amount of propofol is excreted unchanged in the 
urine. 
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6.3.4 Disposition Kinetics 
The decline of the plasma concentration of propofol following an intravenous 
bolus dose can be mathematically modelled. The most commonly described 
pharmacokinetic model is the mammillary model(172). In this type of modelling, 
drug is delivered into a central compartment and then can either be 
redistributed to other tissue compartments or can be eliminated. The 
compartments do not represent real anatomical regions but rather groups of 
tissues that have similar blood flow and affinity for drug. Assumptions made by 
this type of modelling are that there is instantaneous mixing of drug delivered to 
the central compartment and there is uniform drug distribution within each 
peripheral compartment. 
 
Several early studies investigated the disposition kinetics of propofol following 
an intravenous bolus dose and all described the kinetics using a three-
compartment model(163, 173-175). These are a heterogeneous group of studies 
in that blood sampling was done from either arterial or venous systems, young 
and old patients were studied and propofol was either given alone or in 
combination with other drugs. However, key pharmacokinetic parameters were 
of a consistent magnitude and are summarised in Table 6.3. 
 
The structure of a three-compartment mammillary model has already been 
shown in Figure 6.1. A three compartment model was selected because of the 
triphasic decline of propofol concentration (Figure 6.2). The first phase 
represents rapid decline due to a combination of elimination, redistribution to 
the second compartment and slower redistribution to the third compartment. 
The second phase represent slower decline due to a combination of elimination 
and redistribution to the third compartment when the central and second 
compartments are in equilibrium. The third phase represents a terminal 
elimination phase when the central compartment is in equilibrium with both the 
second and third compartments. 
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Reference Sampling Group (n) V1 (l) Cl (l min-1) Cl (ml min-1 kg-1) 
Kay(173) Venous Males (6) 42.3 1.81 23.6 
  Females (6) 36.1 1.8 29.1 
Cockshott(174) Venous Control (6) 41.3 1.91 32.9 
  Fentanyl (6) 21.8 1.29 23.7 
  Halothane (6) 34.5 1.79 30.4 
Kirkpatrick(175) Venous Young (12) 26.3 NA 27.7 
  Elderly (12) 19.6 NA 23.2 
Servin(163) Arterial Control (10) 20.6 2.30 NA 
  Cirrhosis (10) 20.2 1.99 NA 
 
Table 6.3: Key pharmacokinetic parameters from studies of the disposition 
pharmacokinetics of propofol following an intravenous bolus. n = number of 
patients, V1 = central compartment volume, Cl = clearance from the central 
compartment. 
 
Figure 6.2: Simulated plot of the decline of propofol concentration following an 
intravenous bolus dose. 
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The tri-exponential decline of plasma propofol concentration according to the 
three compartment model can be described by the following equation:  
 
𝐶௣ = 𝐴𝑒ିఈ௧ +𝐵𝑒ିఉ௧ + 𝐶𝑒ି௖௧ (6.1) 
 
where Cp is the plasma concentration and t is time. Following fitting of the curve 
to identify the constants A, B, C and a, b, c, these can then be used to calculate 
the compartment volumes and the rate constants that predict the rate of 
elimination from the central compartment and transfer of drug between the 
central and peripheral compartments. For example: 
 
𝑉ଵ =
𝐷଴
𝐴+𝐵 + 𝐶 
(6.2) 
 
𝑘ଵ଴ =
𝑎. 𝑏. 𝑐(𝐴 + 𝐵 + 𝐶)
𝐴.𝑏. 𝑐 + 𝐵.𝑎. 𝑐 + 𝐶.𝑎. 𝑏 
(6.3) 
 
where V1 is the volume of the central compartment and D0 is the bolus dose of 
propofol administered and k10 is the rate constant for elimination from the 
central compartment (Cp or C1). Clearance from the central compartment (Cl) 
can subsequently be calculated as: 
 
𝐶𝑙 = 𝑘ଵ଴.𝑉ଵ (6.4) 
 
The two models currently available for TCI of propofol in clinical practice are 
the Marsh(6) and Schnider(176, 177) models. The development of these models 
and their significant differences shall be discussed in detail below.  
 
 
6.4 Pharmacokinetic Models for Propofol 
6.4.1 The Marsh Model 
The Marsh Model is an adaptation of the pharmacokinetic parameters described 
by Gepts et al in two studies investigating the disposition kinetics of propofol 
following fixed rate infusions(178, 179). In the first of these studies(178), 18 
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patients were allocated to receive propofol at 3, 6 or 9 mg/kg/hr (in 
combination with regional anaesthesia) depending on the perceived clinical 
need. A radial artery cannula was inserted in the contralateral arm to the 
intravenous access and arterial blood samples were taken for quantification of 
whole blood propofol concentrations at regular time intervals. The tri-
exponential model (Equation 6.1) was then fitted to the individual blood 
concentration datasets. Mean values calculated for Vc and Cl were 16.9 l and 
1.77 l/min respectively. 
 
In the second Gepts study(179), 11 patients received a constant rate propofol 
infusion (6 mg/kg/hr) in combination with an exponentially decreasing infusion 
of alfentanil to achieve general anaesthesia. As before, arterial blood samples 
were taken for propofol quantification and the tri-exponential model fitted. 
Mean values calculated for Vc and Cl were 19.7 l and 1.91 l/min respectively.  
White and Kenny described the process of incorporating a PK model into a 
computer controlled infusion device and using it to deliver propofol anaesthesia 
in 33 patients undergoing general surgery(180). In this publication they referred 
to the second Gepts paper(179) as the source of their PK model but did not print 
the exact model parameters. The publication by Marsh et al, the first paper to 
state the model parameters, was in fact a follow up study using the adult model 
to anaesthetise children(6). This “Marsh Model” was identical to the PK model 
published in the first Gepts paper(178), with the exception of a typographical 
error where the k12 was changed from 0.114 min-1 to 0.112 min-1 and a weight 
based value for Vc was incorporated (Table 6.3). 
 
The ‘Diprifusor¥’ was the first commercially available TCI device and used the 
Marsh Model (with a k12 of 0.114 min-1). The technological challenges of 
developing this system and the rationale for selecting the Marsh Model over 
other published PK models have been discussed in detail by Glen(181). To allow 
predictions of effect site concentration, a ke0 of 0.26 min-1 was implemented 
with the model, although the reasoning for this decision was never published.  
 
6.4.2 The Schnider Model 
The development of the Schnider Model for propofol was entirely different from 
that of the Marsh Model. It was derived from a combined PKPD study in 24 
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healthy adult volunteers and published as separate PK(176) and PD(177) papers. 
Each individual received a 2 mg/kg bolus of propofol (or 1 mg/kg if aged over 65 
years) and then one hour later received a randomly allocated fixed rate infusion 
of 25, 50, 100 or 200 mcg/kg/min for 60 minutes. Blood samples to quantify 
plasma propofol concentrations were taken from a radial artery cannula at 
frequent intervals following the bolus dose and during and after the fixed rate 
infusion. To assess the pharmacodynamic effects of propofol, the timing of loss 
of consciousness and return of consciousness were recorded along with a novel 
electroencephalogram (EEG) processing technique, known as semilinear 
canonical correlation, leading to calculation of a canonical univariate parameter 
for propofol CUPpropofol. 
 
One of the end points of this study was to compare the pharmacokinetics of 
propofol with and without Ethylenediaminetetraacetic acid (EDTA). All 
individuals were therefore studied on two separate occasions. The PK model was 
constructed using plasma propofol concentrations collected during the infusions 
phase of the EDTA containing preparation. Fitting of a three compartment model 
to the data and the influence of subjects’ covariates were calculated using non-
linear mixed effect modelling (NONMEM)(182). The final model had a fixed 
central compartment volume, while compartment two was adjusted according to 
subjects’ age (Table 6.4). k10 was adjusted according to subjects’ weight, lean 
body mass (LBM) and height, while k12 was adjusted according to subjects’ age. 
Calculation of LBM was done using the James formula: 
 
Females:  
 
𝐿𝐵𝑀= 1.07× 𝑤𝑒𝑖𝑔ℎ𝑡 − 148× ൬
𝑤𝑒𝑖𝑔ℎ𝑡
ℎ𝑒𝑖𝑔ℎ𝑡൰
ଶ
 
(6.5) 
 
Males:  
 
𝐿𝐵𝑀= 1.1×𝑤𝑒𝑖𝑔ℎ𝑡− 128× ൬
𝑤𝑒𝑖𝑔ℎ𝑡
ℎ𝑒𝑖𝑔ℎ𝑡൰
ଶ
 
(6.6) 
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and the implications of this will be discussed below(183). The PK study 
demonstrated that the pharmacokinetics of propofol differ after a bolus dose 
compared to an infusion. The presence or absence of EDTA did not effect 
propofol pharmacokinetics.  
 
One of the primary purposes of the PD study was to develop a rate constant for 
equilibration between the plasma and effect site (ke0). ke0 was calculated using 
both non-parametric and parametric techniques for each individual and then the 
median taken to represent the population value. For the non-parametric 
technique, measured plasma propofol concentrations were compared to the 
calculated CUPpropofol. For the parametric technique, plasma propofol 
concentrations predicted by their PK model were compared to the calculated 
CUPpropofol. The non-parametric ke0 was estimated to be 0.316 min-1, while the 
parametric ke0 was estimated to be 0.456 min-1. It was this parametric ke0 that 
the authors recommended for use with their PK model.  
 
6.4.3 Significant Differences Between the Marsh and Schnider Models 
There is considerable debate in the anaesthesia community over whether the 
Marsh or the Schnider PK Model is best suited to provide TCI of propofol in 
clinical practice. As mentioned above, the Diprifusor¥ was the first 
commercially available TCI device and was programmed with the Marsh model to 
be used in a plasma targeting mode. The device only accepted specially 
designed syringes pre-filled with the Diprivan£ formulation of propofol. 
Following the expiry of Diprivan£ patent protection in Europe, a new generation 
of “Open TCI” devices were developed that could accept any syringe(184). These 
devices allowed the user to select different drugs to deliver along with a choice 
of PKPD model. It thus became possible to select either the Marsh or Schnider 
Model to be used in a plasma or effect site targeting mode. 
 
The differences between the Marsh and Schnider Models have been discussed 
previously by Absalom et al(185). The structural components of the models are 
summarised in Table 6.3 and the most significant differences will be discussed in 
order below: 
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1. Central compartment volume (V1) 
The central compartment volume of the Marsh Model is proportional to total 
body weight. This means that the bolus dose of propofol required to achieve a 
chosen plasma target concentration will increase with weight. In the Schnider 
Model, the central compartment volume is fixed, meaning that for a chosen 
plasma target concentration, the bolus dose will be the same irrespective of 
weight, age or gender. 
 
2. Adjustment for multiple patient covariates 
The Marsh Model is a relatively simplistic PK model, where all body compartment 
volumes are proportional to weight, and all rate constants are fixed. The 
Schnider Model is a more complex model, which accounts for more patient 
covariates. The only compartment volume that varies with patient covariates is 
V2, which is adjusted according to patient age. Similarly the rate constants k12 
and k21 are influenced by patient age. The elimination rate constant k10 is 
adjusted according to body weight, lean body mass (and thus indirectly by 
gender, weight and height) and height. By accounting for more patient 
covariates, the Schnider Model could theoretically enable a more individualised 
dosing strategy. 
 
3. LBM calculation 
As mentioned above, the Schnider Model adjusts the elimination rate constant 
according to both body weight and LBM. A feature of the James formula for 
calculating LBM means that as body weight increases into the obese range, there 
is a paradoxical decrease in the calculated LBM. The consequence of this for the 
Schnider Model is that for a body mass index (BMI) of greater than 42 kg m-2 in 
males and 37 kg m-2 in females, there is an exponential increase in the 
magnitude of k10. The ways that pump manufacturers have compensated for this 
irregularity in the model, that could lead to dangerous overdosing in obese 
patients, is summarised in a letter by Engbers et al(186). 
 
4. Rate constant for effect site elimination (ke0) 
In their original, clinically implemented forms, the Marsh Model has a ke0 of 0.26 
min-1, while the Schnider Model has a ke0 of 0.456 min-1. The consequence of this 
difference is that the Schnider Model predicts more rapid equilibration between 
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the plasma and the effect site. This means that when using the Schnider Model 
in effect site targeting mode, TCI devices make more gentle manipulations of 
the predicted plasma concentration to achieve a desired effect site 
concentration. 
 
Model Parameter Marsh Schnider 
V1 0.228 litre kg-1  4.27 litre 
V2 0.463 litre kg-1 18.9 - 0.391 x (age - 53) litre 
V3 2.893 litre kg-1 238 litre 
k10 (min-1`) 0.119 0.443 + 0.0107 x (weight - 77) –  
0.0159 x (LBM-59) + 0.0062 x (height-177)  
k12 (min-1`) 0.112  0.302 - 0.0056 x (age - 53) 
k13 (min-1`) 0.042  0.196 
k21 (min-1`) 0.055  [1.29 – 0.024 x (age - 53)] / 
[18.9 – 0.391 x (age - 53)] 
k31 (min-1`) 0.0033  0.0035 
ke0 (min-1` ) 0.26 0.456 
 
Table 6.4: Structural parameters of the Marsh and Schnider Models for propofol. V = 
compartment volume, k = rate constant, LBM = lean body mass as calculated by the 
James formula. Age is measured in years, weight in kg and height in cm. 
A pragmatic approach recommended by most experts is to use the Marsh Model 
in plasma targeting mode and the Schnider Model in effect site targeting mode. 
Anaesthetists are encouraged to use the model with which they are most 
familiar and with caution if using TCI in a population of patients in whom the 
models have not been successfully validated. 
 
6.4.4 The Covariates Model 
The Marsh Model has been criticised for not taking into account patient 
covariates such as age and gender. Age is well known to have significant effects 
on body composition and hepatic and renal function, which influence the 
disposition and elimination of drugs(187). Indeed in one of the early studies of 
propofol pharmacokinetics following a bolus dose, Kirkpatrick et al compared 
patients aged 18 to 35 years old to those aged 65 to 80(175). The older patients 
had a significantly smaller central compartment volume and reduced clearance 
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of propofol. In a study of patients aged 65 to 91 years, who received a bolus 
followed by a fixed rate infusion of propofol, Vuyk et al demonstrated that 
compartment volumes and clearances were affected by gender(188) in this older 
age group. 
 
In an attempt to further improve the understanding of the effects of age and 
gender on the pharmacokinetics of propofol, White et al conducted a large 
population study in patients undergoing anaesthesia using TCI propfol(5). The 
study will be described in some detail, as a validation of the PK model proposed 
by the authors is presented later in this thesis.  
 
In 113 patients undergoing elective general surgery, anaesthesia was 
administered using the Marsh Model as implemented by the Diprifusor¥ TCI 
device. Precise details of the propofol infusion required for anaesthesia were 
automatically archived. Patients also received an infusion of alfentanil, 
breathed a mixture of 66% nitrous oxide in oxygen and were given a single bolus 
of atracurium if endotracheal intubation was required. After induction of 
anaesthesia, a cannula was inserted into the arm contralateral to the propofol 
infusion to allow removal of intravenous blood samples at regular intervals. 
Whole blood propofol concentrations were measured using a gas liquid 
chromatography-mass spectrometry technique. 
 
Using a NONMEM technique, the parameters of the Marsh model were optimised 
for each individual patient to provide the best prediction of the measured blood 
propofol concentrations. Only the volume of the central compartment and the 
clearance from the central compartment were adjusted as none of the other 
model parameters improved the goodness of fit by more than 2.5%. The 
relationship between age and central compartment volume for male and female 
patients volume is shown in Figure 6.3. The slopes of these regression lines are 
as follows:  
 
Females:  
 
𝑉ଵ = 191.78− 0.669×𝐴𝑔𝑒 (6.7) 
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Males:  
 
𝑉ଵ = 175.5+ 0.046× 𝐴𝑔𝑒 (6.8) 
 
where V1 is measured in ml kg
-1 and age in years. In this population there was a 
very clear decline in central compartment volume with age in females but not in 
males. 
 
 
Figure 6.3: Simulated plot of V1 against age for the Covariates Model in female (A) 
and male (B) patients. 
Similarly, the relationship between age and clearance from the central 
compartment is shown in Figure 6.4 for females and males. The slopes of these 
regression lines are as follows: 
 
  
86 
Females:  
 
𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 = 37.87− 0.198×𝐴𝑔𝑒 (6.9) 
 
Males:  
 
𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 = 26.88− 0.029×𝐴𝑔𝑒 (6.10) 
 
where clearance is measured in ml kg-1 min-1 and age in years. Again there is a 
very clear decline in clearance from the central compartment with age in 
females but not in males. 
 
 
Figure 6.4:  Simulated plot of clearance against age for The Covariates Model in 
female (A) and male (B) patients. 
The revised “Covariates Model” thus maintained the original Marsh Model 
parameters but was optimised by the addition of gender and age covariates to 
adjust central compartment volume and clearance. The propofol infusion data 
  
87 
for each patient were then used to perform pharmacokinetic simulation of the 
blood concentrations predicted by the new model. In the study population, the 
predictions made by the Covariates Model were closer to the measured blood 
propofol concentrations than those predicted by the Marsh Model. The VASCoM 
Study had the primary objective of confirming this robust performance of the 
Covariates Model. 
 
6.4.5 Physiologically Based Pharmacokinetic Models 
Despite attempts to optimise compartmental PK models, it is well known that in 
the early phase after a bolus dose, they do not perform well in predicting 
plasma concentrations of anaesthetic drugs(189, 190). This is in part due to the 
erroneous assumption that there is instantaneous mixing of drug within the 
central compartment. There is also a failure to consider the effects of cardiac 
output and differing blood flow between organ groups. The development of 
physiologically based PK (PBPK) models attempts to address these deficiencies 
and thus improve the understanding of drug disposition. 
 
An example of a PBPK model for propofol has been developed by Upton and 
Ludbrook(191). Their initial work was done using a chronically instrumented 
sheep model, where propofol concentrations were measured from the carotid 
artery and the sagital sinus following bolus injection into the right atrium(192, 
193). The effects of propofol on cerebral blood flow and metabolism were 
measured by Doppler flow of the sagital sinus and oxygen extraction between 
the carotid artery and sagital sinus. Analysis of the data from these experiments 
allowed them to build a six compartment model that could explain the kinetics 
and dynamics of induction of anaesthesia with propofol(194, 195).  
 
They subsequently developed the principles of their animal model using human 
data to define propofol kinetics and dynamics in a “standard” man. This model 
was a simplified version of the PBPK model, known as a recirculatory model. The 
necessary estimates of organ blood volume and blood flow for a 30 year old, 69 
kg man were averaged from those derived from the Third National Health and 
Nutrition Examination Survey(196). The final model consisted of brain and lung 
sub-models in parallel with liver and fast and slow distribution compartments. 
The brain sub-model represented cerebral kinetics and dynamics derived from 
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experiments where arterial and jugular venous propofol concentrations were 
measured, along with processed EEG following a propofol infusion in man(197). 
To derive the lung sub-model, data from a study involving simultaneous 
measurement of pulmonary and radial artery concentrations of propofol 
following a central venous infusion were used(198). The remainder of the 
systemic model was built to fit the propofol concentrations predicted by the 
Schnider Model following rapid and slow infusions in a standard man. 
 
One of the most interesting possibilities for PBPK models in general and for 
Upton and Ludbrook’s model in particular, is the potential to improve our 
understanding of how changes in cardiac output or regional blood flow can 
effect the kinetics and dynamics of anaesthetic drugs. The approach used by 
Upton and Ludbrook also introduces many of the concepts that are explored in 
this thesis including data sharing between research groups and the continuous 
evolution and optimisation of physiological models. 
 
6.4.6 Methodology for Pharmacokinetic Model Comparison 
If one PK model for propofol was clearly superior in all clinical situations, then it 
can be assumed that all TCI devices would exclusively implement this model. As 
this has not been the case, it is necessary to have a framework to allow PK 
model comparison so that newly defined models can be compared against those 
already used in clinical practice in terms of their predictive performance. 
Following such a comparison, if the performance of the new model was 
significantly better than the existing models, there would be a reasonable case 
to support its introduction into clinical practice.  
 
Varvel et al proposed an approach to allow systematic comparison of PK models 
used in TCI devices, referred to in the paper as computer controlled infusion 
pumps (CCIPs), that has become widely adopted in the anaesthetic 
literature(199). They tested their approach using a dataset collected during a 
study of CCIPs comparing the performance of two PK models for alfentanil(200). 
For 51 patients they had between 10 and 24 blood samples with measured 
alfentanil concentrations to compare to the concentrations predicted by the 
CCIP.  
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Central to their methodology was measurement of the performance error (PE). 
The PE represents the difference between the drug concentration measured in 
blood and the drug concentration predicted by the TCI device. It is calculated 
using the equation: 
 
𝑃𝐸௜௝ =
𝐶𝑏௜௝ − 𝐶𝑝௜௝
𝐶𝑝௜௝
× 100 
(6.11) 
 
where PEij is the percentage performance error i in the jth patient, Cb is the 
concentration measured in blood and Cp is the concentration predicted by the 
TCI device. 
 
The PE is expressed as a percentage of the predicted concentration because this 
is felt to be of more clinical utility. If a summary measure for the size of the PE 
is known, then for a given predicted concentration the clinician can estimate the 
range of the associated blood concentration. The same would not apply 
expressing the PE as a percentage of the measured concentration, which is not 
known at the time the TCI device is being used in clinical practice.  
 
Following calculation of the PEs for each sample in each individual, the authors 
advocate the calculation of four summary measures in each individual to 
describe the clinical utility of CCIPs. Firstly the median performance error 
(MDPE) represents the bias, or overall direction of the PEs, and thus the 
tendency of a CCIP to over or under-predict the blood concentration. Secondly 
the median absolute performance error (MDAPE) represents the inaccuracy, or 
overall magnitude of the PEs, and is not affected by the direction of the PEs. 
Thirdly divergence represents the tendency of PEs to either increase or decrease 
with time and is calculated from the slope of the linear regression of an 
individual’s PEs against time. Finally wobble represents the variability of an 
individual’s PEs and is calculated as the median absolute deviation of  PEs from 
the MDPE. 
 
The overall population performance of a CCIP requires further summarisation of 
the four summary measures described above. This can be done using either a 
two stage, pooled data or variance weighted approach. The two stage approach 
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simply takes a mean (or median) of all of the individuals summary measures. 
This inappropriately weights results towards individuals with fewer blood 
samples. The pooled data approach uses the number of samples for an individual 
to weight the contribution of that individual to the overall summary. Finally the 
variance weighted approach accounts for the intra-individual variability in PEs 
by weighting the contribution of an individual to the overall summary by the 
variance of the estimates for that individual. The authors suggest that in their 
analysis of several large datasets there is actually little difference in the 
summary measures calculated using each of the three approaches. 
 
6.4.7 Pharmacokinetic Model Comparison Studies 
The above methodology has been utilised in a number of studies to compare 
published PK models for propofol in their predictive performance. Coetzee et al 
randomly assigned 30 patients to receive propofol TCI by one of either the 
Tackley(201), Marsh or Dyck models(202). These were the same three models 
evaluated during the development of the Diprifusor¥ in 1993. Arterial and 
venous blood samples were collected at regular intervals and the summary 
measures of MDPE, MDAPE, divergence and wobble calculated. Although all 
models provided adequate clinical anaesthesia, the Tackley and Marsh Models 
were superior in terms of MDPE and MDAPEs. It was noted that arterial propofol 
concentrations were significantly greater than venous concentrations but that 
this difference decreased with time. 
 
Three recent simulation studies have compared the performance of the two PK 
models in common clinical use (Marsh and Schnider) and two of these included 
the Covariates Model introduced above(203-205). In the first, Glen et al used the 
standardised propofol infusion profiles from nine control patients (6 male and 3 
female) in a previous PK study(163) to simulate the plasma concentrations 
predicted by each of the Marsh, Schnider, Covariates and Schuttler(206) 
Models(203). PEs were then calculated for a total 286 arterial propofol 
concentration measurements. In terms of overall performance there was little to 
differentiate between the four models. In this group, the Covariates Model had a 
tendency to over-predict the plasma concentrations compared to the Marsh 
Model but compared favourably in terms of MDAPE. Although the Schnider Model 
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showed negligible overall bias, there was a tendency to over-predict during the 
early phases of infusion and under-predict during the recovery phase. 
 
In the second simulation study, Matsui et al used PK data from four previous 
studies, with distinct propofol infusion regimen(204). A total of 108 patients 
contributed PK data to the study, who had received propofol by either 
bolus(207), short infusion(208), long infusion(209) or TCI(202). Simulation studies 
were performed to calculate the plasma propofol concentrations predicted by 
each of the Marsh, Schnider and Schuttler PK models and an adaptation of the 
Upton physiologically based recirculation model(191). When all infusion regimen 
were taken into account, the Schnider Model more often displayed significantly 
better performance in terms of MDPE and MDAPE compared to the other models. 
This was particularly true when compared to the Marsh Model using data from 
the bolus and short infusion studies. All of the models performed with similar 
bias and inaccuracy when compared using data from the TCI study. 
 
In the third simulation study, Glen and White(205) used data from 41 patients in 
a previous study evaluating the predictive performance of the Diprifusor TCI 
system(210). Predicted plasma propofol concentrations for each of the Marsh, 
Schnider and Covariates Models were calculated and PEs measured for a total of 
530 arterial propofol samples. In this study, the MDPE of the Covariates Model 
was significantly improved compared to the Marsh and Schnider Models and the 
MDAPE was significantly improved compared to the Marsh Model. An important 
observation made by the authors was that for all three models, bias varied 
depending on whether plasma propofol concentration was increasing, steady or 
decreasing. 
 
6.5 Pharmacodynamic Models for Propofol 
6.5.1 Modelling the Effect Site 
As part of their review “Contributions of PK/PD Modelling to Intravenous 
Anesthesia”, Minto and Schnider described the theory of the effect site 
compartment in detail(155). The principles of the effect site and the techniques 
available to model its behaviour are central to the PD component of the VaSCoM 
study and will be considered below. 
  
92 
In response to the observation that the clinical effects of a drug are delayed 
relative to the plasma concentration (a fact that is well recognised by all 
practising anaesthetists), Sheiner et al proposed the concept of a hypothetical 
effect site compartment(211). The model parameter keo was introduced to 
characterise the delay between Cp and effect and therefore accounts for the 
processes of perfusion, diffusion, partition, drug-receptor interaction and the 
relationship between receptor occupancy and effect. In the original publication 
the nomenclature of keo was chosen to represent the rate constant for 
equilibration between the effect site compartment and “outside”. It is now 
more generally referred to using more standardised PKPD terminology as ke0 or 
the rate constant for elimination from the effect site. The structural model 
proposed has been illustrated in Figure 6.1 and the association between drug 
infusion rate and predicted plasma and effect site concentrations illustrated in 
Figure 6.5. 
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Figure 6.5: Lower panel provides details of propofol infusion regimen. Upper panel 
demonstrates associated plasma and effect site concentrations predicted by 
combined PKPD model. 
Sheiner et al applied their PKPD model to three datasets containing plasma 
concentrations and associated measures of effect for the drug d-tubocurarine. 
They modelled the relationship between concentration of drug in the effect site 
compartment and clinical effect using the adaptation of the “Hill Equation” 
previously proposed by Wagner(212): 
 
𝐸 =
𝐶௘ఊ
𝐶௘ఊ + 𝐶௘(50)ఊ
 
(6.12) 
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where E is the intensity of pharmacological effect expressed as a fraction of 
maximal effect, Ce is the concentration in the effect site, Ce(50) is a constant 
giving the value of Ce at 50% effect and J describes the sigmoidicity of the Ce to 
E relationship. For hypnotic anaesthetic drugs with an inhibitory effect on brain 
activity this can be expressed as:  
 
𝐸 = 𝐸଴ −
𝐸௠௔௫𝐶௘ఊ
𝐶௘ఊ + 𝐶௘(50)ఊ
 
(6.13) 
 
where E0 is the baseline effect with no drug present and Emax is the maximum 
difference from baseline. This sigmoid-Emax curve is demonstrated in Figure 6.6. 
 
Figure 6.6: Sigmoid-Emax Concentration-Effect relationship for a hypnotic anaesthetic 
drug where E0 = baseline effect with no drug present, Emax = the maximum 
difference from baseline, ec50 = a constant giving the value of Ce at 50% effect i.e. 
Ce(50). 
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The differential equation used to model the temporal relationship between Cp 
(or C1) and Ce was: 
 
𝛿𝐶௘
𝛿𝑡 = 𝑘ଵ௘𝐶ଵ − 𝑘௘଴𝐶௘ 
(6.14) 
 
where k1e is the rate constant for movement of drug between the plasma and 
the effect site. The effect site is considered to be of negligible volume and 
therefore does not influence the behaviour of any associated PK model. For this 
reason the rate constant k1e is inconsequential and the characterisation of the 
relationship between Cp and Ce can be described in terms of ke0 alone: 
 
𝛿𝐶௘
𝛿𝑡 = 𝑘௘଴𝐶ଵ − 𝑘௘଴𝐶௘ 
(6.15) 
 
In their study of d-tubocurarine, Sheiner et al successfully fitted a two-
compartment PK model to the data and determined the ke0 to describe the time 
course of the observed PD data. This is an example of parametric determination 
of the ke0, where the effect site is related to the plasma concentration predicted 
by a contemporaneous PK model and the magnitude of effect is modelled as a 
known function of Ce. 
 
It is also possible to determine ke0 using a non-parametric approach that makes 
no assumptions regarding the underlying PK model or the relationship between 
effect and Ce.(213). In this technique, ke0 is adjusted to account for the 
difference between measured plasma drug concentration and clinical effect. As 
for the parametric approach described above, this has the requirement to 
measure both plasma concentrations and pharmacodynamic effect within the 
same study. 
 
An alternative approach, referred to as the ‘time to peak effect site 
concentration’ (tpeak), has been proposed by Minto et al and allows PD 
parameters from one study to be combined with PK parameters from 
another(214). Following a submaximal intravenous bolus dose, tpeak is measured 
as the time taken to reach the maximum observed clinical effect (and thus 
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maximum Ce). Using an existing PK model, it is then possible to adjust the 
associated value of ke0 to preserve the measured tpeak. Minto et al performed a 
number of simulation studies using data from previous PKPD studies of 
thiopental, remifentanil and propofol and demonstrated that the tpeak method 
provided a better estimate of ke0 than simply extending a new PK model by 
combining a ke0 value from a previous PKPD study. 
 
In the Open TCI devices currently commercially available there are a number of 
very different implementations of ke0. A recent editorial by Cortinez has 
acknowledged the confusion that this can cause in the clinical use of TCI and 
discussed the implications of differing ke0s on the effect site concentrations 
predicted by these devices(215). In most of the studies estimating ke0, an index 
of the electroencephalogram (EEG) has been used as a surrogate for the clinical 
hypnotic effect of propofol. The use of differing EEG indices is likely to account 
for at least some of the difference in the calculated ke0s. 
 
As indicated above, a ke0 of 0.26 min-1 for the Marsh Model was implemented in 
the original Diprifusor TCI device. Although the rationale for selection of this k e0 
was never published, it was very similar to the ke0 of 0.2 min-1 calculated by 
Billard et al when comparing the Bispectral Index (BIS) to other indices of the 
EEG using a dataset from 12 patients who received a fixed rate propofol infusion 
(216). In a study using auditory evoked potentials (AEP) as a measure of the CNS 
effects of propofol, White et al used both parametric and non-parametric 
techniques to determine ke0. Successful fits of ke0 could be achieved in 14 of the 
22 patients using the population parametric approach and 15 of the 22 patients 
using the individual parametric approach. Mean ke0s for the parametric and non-
parametric approaches were 0.2 min-1 (median 0.16 min-1) and 0.22 min-1 
(median 0.24 min-1). 
 
The ‘adjusted’ ke0 often implemented with the Marsh Model is 1.21 min-1 and 
thus predicts much faster equilibration between the plasma and effect site 
compartments. This comes from using a tpeak for propofol of 1.6 minutes as 
reported by Schnider(177) to adjust the ke0. In a short TCI infusion study of 120 
female patients, with no period of decreasing plasma concentration, Struys et al 
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demonstrated that this adjusted ke0 more accurately predicts the measured 
changes in BIS(217). 
 
As has been outlined previously, the parametric ke0 of 0.456 min-1 is suggested 
for effect site TCI using the Schnider Model. With the common availability of two 
PK models and three Ke0s clinicians must exercise caution during the use of Open 
TCI to ensure that they are aware of the pharmacokinetic and pharmacodynamic 
consequences of their model selection. 
 
The PD component of the VaSCoM Study used the EEG index of BIS to estimate 
the appropriate ke0 to extend the Covariates PK Model. For this reason a brief 
summary of processed EEG (pEEG) and specifically BIS are provided below.  
 
6.5.2 Processed Electroencephalography 
The EEG is the measurement of bioelectric potentials resulting from the 
postsynaptic potentials produced by the dendrites of pyramidal neurones in the 
cerebral cortex(218). Needle or gel electrodes are required as transducers to 
convert the physiological ionic current to an electrical current for further 
processing by the EEG monitoring equipment. A formal EEG for diagnostic 
purposes uses a montage of electrodes attached across the whole scalp. For the 
purposes of monitoring the effect of anaesthetic drugs, gel electrodes connected 
across the forehead and temple are most commonly used. 
 
Unlike the electrocardiogram (ECG), the EEG has no fixed repeating pattern. If  
the signal is processed in terms of its time and frequency domain characteristics, 
there are however some constant statistical properties that can be correlated 
with differing levels of wakefulness or anaesthesia. A number of depth of 
anaesthesia monitors (DoA) have been developed in an attempt to quantify the 
hypnotic component of anaesthetic drugs on the EEG.  (219, 220). An effective 
device would help to prevent awareness under anaesthesia and avoid relative 
overdosing of anaesthetic drugs. Most DoA monitors attempt to provide an index 
of anaesthetic depth between 100 (fully awake) to 0 (no brain activity), with 
values of 40 to 60 often proposed to be adequate for surgical anaesthesia. In the 
ideal situation, these indices would correlate with clinical measures of 
anaesthetic effect and be stable across different anaesthetic drugs and clinical 
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populations. No DoA monitor yet meets these requirements but the BIS has 
become widely used in anaesthetic practice. Processing of the EEG signal is 
considered below in terms of BIS. 
 
6.5.3 Calculating the Bispectral Index 
The Bispectral Index is a complex parameter that integrates several separate 
descriptors of the EEG signal to provide a single index as above. It was 
developed by Aspect Medical Systems (subsequently owned by Covidien and now 
Medtronic) using data from 1500 anaesthetic administrations and was introduced 
in 1994. It uses a specialised four electrode sensor placed on the patients 
forehead to collect the raw EEG from one cerebral hemisphere. The underlying 
proprietary algorithm has never been published and has undergone continuous 
update, but the underlying principles of the signal processing have been 
described in detail by Sigl et al(221) and Rampil(218). The stages involved in 
calculating BIS are summarised in Figure 6.7.   
 
 
Figure 6.7: Summary of the processing steps involved in calculation of the Bispectral 
Index (BIS). BSR = burst suppression ratio, QUAZI detects burst suppression in the 
context of a wandering baseline voltage. 
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The first stage of EEG processing in BIS calculation involves filtering of high and 
low frequency artifacts and division of the signal into 2-s epochs. Further 
artifact filtering is then performed on these epochs to remove signals such as 
the ECG and electromyogram (EMG). Time domain analysis then uses two 
measures of burst suppression. During deep anaesthesia the EEG may develop 
the pattern of periods of normal or high voltage activity followed by periods of 
low voltage or isoelectricity. The burst suppression ratio (BSR) reports the 
periods of suppression of greater than 0.5 seconds as a fraction of the epoch 
length. In circumstances with a wandering baseline voltage, the “QUAZI” 
suppression index incorporates slow wave information to detect burst 
suppression that would be missed by the original BSR algorithm. 
 
Fourier’s theorem states that any complex repetitive waveform can be 
decomposed into the sum of simple sine or cosine waves (Figure 6.8). A 
computationally efficient method of performing this is known as the Fast Fourier 
transform (FFT). Each frequency component of the complex wave has an 
associated amplitude and phase component that can then be used for frequency 
domain analysis of the EEG. The frequency bands in the spectrum are named 
according to a generally accepted convention (Table 6.5). 
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Figure 6.8: An example of Fourrier theorem that a repetitive wave (A) can be 
deconstructed to a series of simple sine waves (B and C). 
Name Frequency Range (Hertz) 
Slow < 1  
Delta 1–4  
Theta 5–8  
Alpha 9–12  
Beta 13–25  
Gamma 26–80 
 
Table 6.5: Spectral frequency bands of the EEG 
The two measures of frequency domain analysis that contribute to the BIS Index 
are “BetaRatio” and “SynchFastSlow”. BetaRatio is the log ratio of power in the 
frequency bands 30-47 Hz and 11-20 Hz. SynchFastSlow is the contribution from 
bispectral analysis. The bispectrum is a complex measurement of the phase 
relationships between selected frequencies identified following FFT. It has been 
suggested that strong phase relationships are inversely related to the number of 
EEG pacemaker elements.  
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The BIS Index results from a combination of the subparameters of BSR, QUAZI, 
BetaRatio and SynchFastSlow, each of which was selected to have a specific 
range of anaesthetic depth where it performs best. SynchFastSlow predominates 
during the excitation phase and during surgical levels of hypnosis. BetaRatio is 
weighted more heavily during light sedation and BSR and QUAZI detect deep 
levels of anaesthesia. Ultimately a single number (BIS) is continuously produced 
using averaging of preceding epochs, which predicts the depth of anaesthesia.  
 
6.5.4 Clinical Validity of the Bispectral Index 
In the United Kingdom, use of BIS in anaesthetic practice is supported by 
guidance from the National Institute of Health and Care Excellence (NICE)(222). 
In the diagnostics guidance (DG6, 2012), pEEG depth of anaesthesia monitors, 
with specific reference to BIS, are recommended as an option during the 
following clinical situations: 
 
1. In patient groups at higher of risk of unintended awareness during general 
anaesthesia. These patients would include, but are not limited to, 
patients with a previous history of unintended awareness, patients with a 
history of drug or alcohol abuse or patients undergoing certain types of 
surgery such as airway surgery. 
 
2. In patient groups at higher risk of excessively deep levels of anaesthesia. 
These patients would include older patients and patients with a history of 
cardiac, renal or liver disease.  
 
3. In patients receiving total intravenous anaesthesia.  
 
In the NICE guidance, the recommendations regarding BIS were based on a 
Cochrane review on “Bispectral Index for improving anaesthetic delivery and 
post-operative recovery”(223). It included 31 randomised controlled trials (RCTs) 
of BIS monitoring compared with standard clinical practice, but the NICE 
guidance acknowledged a large amount of heterogeneity between the trials with 
unintended awareness as an end-point. Two of these trials, on the basis of being 
the largest and most influential, merit further discussion.  
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The B-Aware trial was a multicenter RCT of 2463 surgical patients aged 18 yr or 
older who were at higher risk of awareness(224). Patients were randomized to 
BIS monitoring with target range of 40 to 60 or routine care. BIS values were 
manually recorded by the anaesthetist in the intervention group and there was 
no BIS monitoring in the control group. The primary outcome measure was the 
incidence of confirmed awareness by use of a structured questionnaire. Until 30 
days after enrolment, the number of patients who reported awareness under 
anaesthesia was significantly less in the BIS group (2, 0.17%) than in the routine 
care group (11, 0.91%). This represented an odds ratio of 0.18 (95% confidence 
interval 0.02 to 0.84, p = 0.022) and absolute reduction in the risk of awareness 
of 0.74%, Therefore the number of high risk patients needed to treat to prevent 
one episode of awareness was 138. The rates of total intravenous anaesthesia 
with propofol were similar in the intervention and control groups (43% and 42%). 
 
The BAG-RECALL trial(225) was itself a follow up to the B-Unaware trial which 
was criticised for being single centre and underpowered to exclude a clinically 
significant benefit attributable to BIS(226). Therefore BAG-RECALL was a 
multicentre RCT of 5713 surgical patients aged 18 yr or older who were at higher 
risk of awareness. Patients were randomized to BIS monitoring with a target 
range of 40 to 60 or volatile anaesthesia with a targeted minimum alveolar 
concentration (MAC) of 0.7 to 1.3. BIS and MAC values were recorded at 
minimum intervals of 1 minute by means of an electronic recording of 
anaesthesia data. The primary outcome measure was the incidence of 
intraoperative awareness. Until 30 days after extubation, the number of patients 
who reported awareness under anaesthesia was not significantly less in the BIS 
group (7, 0.24%) than in the control group (2, 0.07%). This represented an 
absolute difference of 0.17% (95% confidence intervals -0.03 to 0.38, p = 0.98) 
and thus superiority for the the BIS protocol was not demonstrated. 
 
The BAG-RECALL study was performed only in patients undergoing volatile-based 
anaesthesia and thus does not exclude the possibility that BIS monitoring would 
lead to lower levels of unintended awareness during total intravenous 
anaesthesia. Indeed during the recently reported national audit project (NAP5), 
conducted by the Royal College of Anaesthetists, there was an approximate two-
fold over-representation of awareness cases where a propofol infusion was used 
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for maintenance than would have been expected(227). This led the report 
authors to suggest that depth of anaesthesia monitors should be considered in 
patients undergoing TIVA with associated neuromuscular blockade. 
 
One of the major limitations of all pEEG techniques used to monitor the depth of 
anaesthesia is the underlying assumption that all anaesthetic agents have the 
same effect on the EEG. Increasing doses of GABAergic anaesthetics (for 
example propofol) cause a shift in the spontaneous EEG from higher to lower 
frequency components and an increase in synchronisation. This is not necessarily 
the case for other agents that are known to increase the clinical depth of 
anaesthesia (for example ketamine and opioids). The EEG signatures of 
commonly used anaesthetic drugs and their neurophysiological bases have 
recently been reviewed in detail(228). 
 
On the basis of the variable effects of anaesthetic drugs on the EEG, some 
commentators have suggested that it would be more valuable for anaesthetists 
to be trained to observe the raw EEG waveform than be dependent on the 
output of a pEEG device(229). Barnard et al demonstrated that anaesthetists 
could be taught to recognise the basic EEG changes associated with GABAergic 
anaesthetic drugs(230). Following a 15 minute tutorial, anaesthetists were able 
to categorize EEGs as awake, sedated, or anesthetized with comparable 
accuracy to the BIS monitor. The authors therefore suggested that the 
combination of pEEG and a clinician able to interpret the raw waveform would 
be of more value than a DoA monitor alone. 
 
Despite the recognised limitations of BIS, the continuous nature of its output and 
its relatively well established place in clinical anaesthesia, mean that it was 
selected for monitoring of the effect site in the VaSCoM study. 
 
6.5.5 Non-linear Mixed Effect Modelling 
The standard technique used for the development of a PKPD model is known as 
non-linear mixed effect modelling (NONMEM)(231). The NONMEM software, 
now distributed by ICON Development Solutions, was initially released by Lewis 
Sheiner and Stuart Beal at the University of California and has been in use for 
over 30 years(232). There is an extensive product literature explaining the 
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ongoing development and instructions on the use of NONMEM(233). Owen and 
Fielder-Kelly have provided an excellent non-technical introduction to the 
principles underlying NONMEM analysis(234). 
 
Non-linear mixed effects models involve both fixed and random effects. The 
fixed effects are the structural parameters of the PKPD model (such as 
compartment volumes and rate constants) and can be scaled according to 
patient covariates. The random effects account for unexplained inter-patient 
variability and the difference between the individual predicted values and the 
observations.  
 
Therefore at the population level, the model predicted value (F) can be 
represented as a function: 
 
𝐹 = 𝑓(𝜃,𝑛,𝑥) (6.16) 
 
where the model parameter T, is scaled according to the covariates x, with 
inter-individual random variation K. At the individual level, the observation (Y) 
can be represented as a function of F: 
 
𝑌 = 𝑓(𝐹, 𝜀) (6.17) 
 
where H is the intra-individual variability. NONMEM estimates the fixed and 
random effects parameters using a maximum likelihood approach(235). 
 
While NONMEM remains the industry standard for PKPD modelling, open source 
alternatives are becoming increasingly refined. Using a standard PK dataset, 
Tornoe et al have demonstrated that the R package nlmeODE(236) provides 
accurate parameter estimates, which are consistent with NONMEM(237). This 
package was used in the VaSCoM study to provide population and individual 
estimates of the ke0 for the Covariates Model. 
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6.6 Summary of PKPD Modelling in the Context of the Covariates 
Model for Propofol 
Target controlled infusion of propofol represents a significant component of 
anaesthetic practice in the United Kingdom. While the physicochemical 
properties and clinical effects of propofol make it particularly suitable for 
intravenous infusion, it is the development of pharmacokinetic 
pharmacodynamic models that has been instrumental in facilitating its clinical 
use in TCI. There is considerable debate over whether the Marsh or Schnider 
PKPD model for propofol is better. The Covariates Model represents a potential 
alternative to these models and has the advantage over the Marsh Model of 
adjusting for the additional patient factors of age and gender. The VaSCoM Study 
presented in the coming chapters provides a systematic validation of the 
Covariates Model and comparison to the Marsh and Schnider Models.  
 
There has so far been no description of the pharmacodynamic component of the 
Covariates Model. The standard technique for extending a PK model to predict 
clinical effect is to describe the delay between plasma concentrations and 
clinical effect using the parameter of ke0, or the rate constant for elimination 
from a theoretical effect site. Quantifying the magnitude of anaesthetic effect is 
typically performed using depth of anaesthesia monitors that use specialised 
algorithms to process the raw electroencephalogram. BIS is the most established 
of these monitors and has been used is conjunction with a non-linear mixed 
effects modelling approach to determine the ke0 for the Covariates Model. 
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7 Materials and Methods for the VaSCoM Study 
 
7.1 Overview 
This chapter provides a detailed description of the patients and methods used in 
the Validation Study of the Covariates Model (VaSCoM). The study protocol and 
related documents are available on request. 
 
7.2 Objectives 
The primary objective of this study was to prospectively validate the predictive 
performance of the Covariates Pharmacokinetic Model for propofol in the study 
population. 
 
The secondary objectives were: 
a. Effect site modelling to obtain a ke0 value for the Covariate Model.  
b. Comparison of propofol concentrations measured in simultaneously 
sampled arterial and venous blood. 
 
Comparison of the Covariates Model performance to that of the commonly used 
Marsh and Schnider models was not a stated objective of this study. Throughout 
the course of the study the question of which model is “best” did naturally arise. 
For this reason, simulation studies were performed to compare the three 
models. 
 
7.3 Ethical Approval 
Ethical approval was granted for the study by the West of Scotland Research 
Ethics Service on 9th April 2010 (Reference Number: 10/S0709/8). The study was 
sponsored by The Golden Jubilee National Hospital and supported by funding 
from The Department of Anaesthesia and Peri-operative Medicine Endowment 
Fund.  
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7.4 Summary of Study Design 
The study was a single centre, randomised, non-comparative, validation study of 
the Covariates Model. The Medicines and Healthcare products Regulatory Agency 
confirmed that the study was not a Clinical Trial of an Investigational Medicinal 
Product. The aim was to enrol up to 50 adults with a goal of 30 completed cases. 
At least ten patients aged over 65 years were required to assess the validity of 
the model in an older population. The study protocol is summarised in Figure 
7.1. 
 
7.5 Patient Recruitment 
Study participants were prospectively recruited from patients attending the 
Golden Jubilee National Hospital, Glasgow for elective surgery between 26th 
January 2011 and 10th June 2014. Included patients were over 18 years of age 
and undergoing non-cardiac surgery requiring general anaesthesia and expected 
to last more than 30 minutes. 
 
Patients were approached during their pre-operative clinic attendance and 
provided with a Participant Information Sheet and a verbal description of the 
study procedure. They were either consented at this stage or allowed further 
time to consider their involvement prior to attendance on the day of surgery. 
 
Patients were excluded from the study if they refused consent or were unable to 
consent on the basis of lack of capacity. If a patient was due to receive pre-
medication or had received sedative or anaesthetic agents the preceding 12 
hours they were excluded because of the potential impact on depth of 
anaesthesia monitoring. For similar reasons, patients with a history of excessive 
alcohol intake or illicit drug use were excluded. Patients were excluded if they 
had a body mass index (BMI) of greater than 35, predictors of a difficult airway 
or a history of allergy to any of the constituents of propofol.  
 
7.6 Patient Monitoring 
During conduct of the study protocol, all patients were cared for in either an 
anaesthetic room or operating theatre by a minimum of two anaesthetists or one 
anaesthetist and one appropriately trained physician’s assistant for anaesthesia. 
  
108 
A skilled anaesthetic assistant was present at all times. Standards of monitoring 
provided by the Association of Anaesthetists of Great Britain and Northern 
Ireland (AAGBI) were followed(238). Monitoring was performed using the Draeger 
Primus anaesthetic machine with integrated monitoring (Draeger Medical UK 
Ltd.). 
 
7.7 Study Procedure 
7.7.1 Intravenous and Intra-arterial Access 
Following confirmation of stable vital signs, all patients had an 18G or 20G 
intravenous cannula inserted into a large forearm vein to allow infusion of 
propofol. In the contra-lateral arm, a second 18G intravenous cannula was 
inserted to allow sampling of venous blood. A further cannula was then inserted 
into the radial artery on this side to allow sampling of arterial blood and beat-
to-beat measurement of arterial blood pressure. 
 
7.7.2 Electroencephalographic Monitoring 
To allow modelling of the effect site, processed electroencephalography (pEEG) 
monitoring was performed. The monitor used in the study was the Bispectral 
Index (BIS XP A2000, Medtronic, Ireland) running software version 3.11 and with 
a smoothing rate of 15 seconds. 
 
7.7.3 Synchronised Electronic Data Capture 
Prior to initiation of the study protocol, the collection of continuous 
physiological data was confirmed. All routinely collected AAGBI standard 
monitoring data, invasive arterial blood pressure and details of all medications 
administered were recorded using the Recall digital anaesthetic record 
(Informatics, UK). pEEG data were streamed directly to a Dell Latitude 
Toughbook (Dell, USA) using the Anaesthesia Synchronisation Software 
(ASYS)(239) (provided by Nadja Bressan). 
 
7.7.4 Propofol Infusion Regime 
Propofol (Propofol Lipuro 2%, B. Braun Medical Ltd., UK) was infused using an 
Injectomat TIVA Agilia syringe pump (Fresinius Kabi, France) programmed with 
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the Covariates Model. Patency of the intravenous cannula was confirmed by 
concomitant slow infusion of compound sodium lactate solution. As described in 
the study protocol (Figure 7.1), patients were alternately randomised to either a 
2-5-2 infusion or a 5-2-5 infusion. In the 2-5-2 group, an initial propofol plasma 
target concentration of 2 Pg/ml was maintained for 15 minutes prior to an 
increase to 5 Pg/ml for 15 minutes and finally a reduction to 2 Pg/ml for 15 
minutes. The reverse was performed in the 5-2-5 group.  
 
The study procedure lasted around 45 minutes in total and was performed prior 
to the initiation of surgery. During this time, the patient remained 
spontaneously breathing via a face mask and the concentration of oxygen was 
titrated to maintain arterial oxygen saturations of at least 95%. Intravenous 
boluses of metaraminol 0.1 mg and glycopyrrolate 200 mcg were used to treat 
hypotension and bradycardia as clinically indicated. No medications that could 
interfere with the pharmacodynamics of propofol, such as volatile anaesthetics 
agents, benzodiazepines or opioids, were administered during the study 
procedure. 
 
7.7.5 Blood Sampling Schedule 
Throughout the study procedure, arterial and venous blood samples were drawn 
at pre-specified time points as indicated in Table 7.1. The sampling schedule 
was designed to allow comparison of arterial and venous propofol concentrations 
as well as to allow model validation close to plasma target changes and during 
stable anaesthesia.  
 
Following collection of the final blood sample, the patient was prepared for 
their surgical procedure. Anaesthetic management from this stage onwards 
followed local procedures and guidelines and participation in the study did not 
influence the patient’s ongoing clinical care.  
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Arterial Sample 
 
Venous Sample 
Patients Identified 
Patients Recruited 
Study Theatre 
GA Commenced 
Consent 
 
AAGBI Monitoring 
 
Venous/Arterial Access 
 
BIS Monitoring 
 
TCI Pump Connected 
 
Propofol Cp @ 2Pg/ml 
 
Propofol Cp @ 5Pg/ml 
 
Propofol Cp @ 2Pg/ml 
 
Patient Transferred to Operating Theatre for Surgery 
Propofol Cp @ 5Pg/ml 
 
Propofol Cp @ 2Pg/ml 
 
Propofol Cp @ 5Pg/ml 
 
2-5-2 
 
5-2-5 
 
1.5 Mins 
16.5 Mins 
5 Mins 
15 Mins 
20 Mins 
30 Mins 
31.5 Mins 
35 Mins 
45 Mins 
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Figure 7.1 (previous page): VaSCoM study algorithm. AAGBI = Association of 
Anaesthetists of Great Britain and Ireland, BIS = Bispectral Index, TCI = target 
controlled infusion, GA = general anaesthesia, Cp = target plasma concentration. 
Venous Samples Arterial Samples 
Sample 1 90 seconds Sample 1 90 seconds 
Sample 2 5 minutes Sample 2 5 minutes 
Sample 3 60 – 90 seconds 
after change of 
target 1 
Sample 3 60 – 90 seconds 
after change of 
target 1 
Sample 4 20 minutes 
 
Sample 4 20 minutes 
 
Sample 5 60 – 90 seconds 
after change of 
target 2 
  
Sample 6 35 minutes   
Sample 7 45 to 60 minutes   
 
Table 7.1: Schedule for sampling of venous and arterial blood 
7.7.6 Processing of Blood Samples 
Arterial and venous blood samples were collected into a blood gas syringe to 
heparinise. The sample was then transferred into a fluoride oxalate sample 
bottle to provide stability prior to storage at 4qC. Propofol concentrations in 
whole blood samples were analysed by C3P Analysis using a validated whole 
blood high performance liquid chromatography (HPLC) technique(231). 
 
7.8 Analysis 
7.8.1 Introduction 
The majority of data processing and analysis were performed using RStudio 
Version 0.98.1102 running R Version 3.1.2 (R Core Team, 2014)(7). Individual R 
Packages used for each stage of analysis are detailed in the appropriate 
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sections. The rationale for using R has already been discussed in the introduction 
to this thesis. All summary measures are reported as median (range). 
 
7.8.2 Data Preparation 
Infusion profiles from the Injectomat TIVA Agilia syringe pump were downloaded 
into Microsoft Excel (2007) using the software provided (Partner Agilia, Fresenius 
Kabi, France). The BIS recordings were exported from the ASYS software into 
Microsoft Excel. Similarly all arterial and venous blood results and individual 
patient demographic details were stored in Microsoft Excel. Data were then 
imported into R using the package gdata(240). Manipulation of data into a 
standardised format for ease of repeatable analysis was performed using the 
packages dplyr(135) and stringr(136). 
 
7.8.3 Approach to Pharmacokinetic Model Validation 
7.8.3.1 Introduction 
The approach to pharmacokinetic model validation published by Varvel et al and 
discussed in the introduction to this thesis was adapted for use in this 
study(199). The measures of performance felt to be most relevant were “bias” 
and “precision”. The calculations of these metrics as performed in this study are 
outlined below. 
 
7.8.3.2 Percentage Performance Error 
Prior to the calculation of bias and precision, it was first necessary to measure 
the percentage performance error for each of the arterial and venous blood 
samples. It was calculated using the equation:  
 
𝑃𝐸௜௝ =
𝐶𝑏௜௝ − 𝐶𝑝௜௝
𝐶𝑝௜௝
× 100 
(7.1) 
 
where PEij is the percentage performance error i in the jth patient, Cb is the 
concentration measured in blood and Cp is the concentration predicted by the 
TCI device. 
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7.8.3.3 Bias 
The bias of a TCI device is its tendency to over or under predict the actual drug 
concentration. For each individual this was measured through the median 
performance error (MDPE), calculated as: 
 
𝑀𝐷𝑃𝐸௜ = 𝑚𝑒𝑑𝑖𝑎𝑛൛𝑃𝐸௜௝, 𝑗 = 1,… , 𝑁௜ൟ (7.2) 
 
where Ni is the number of performance errors in the ith individual.  
 
7.8.3.4 Inaccuracy 
In a situation where a TCI device has the tendency to both under and over 
predict drug concentrations at different stages of the infusion, these PEs may 
compensate for each other and the bias may be negligible. The overall size of 
the PEs is thus better represented by the median absolute performance error 
(MDAPE), calculated as: 
 
𝑀𝐷𝐴𝑃𝐸௜ = 𝑚𝑒𝑑𝑖𝑎𝑛൛ห𝑃𝐸௜௝ห, 𝑗 = 1, … ,𝑁௜ൟ (7.3) 
 
7.8.3.5 Population estimates 
Following calculation of MDPE and MDAPE for each individual, the TCI device 
performance was measured for the entire population by finding the overall 
medians: 
 
𝑀𝐷𝑃𝐸 = 𝑚𝑒𝑑𝑖𝑎𝑛{𝑀𝐷𝑃𝐸௜, 𝑖 = 1, … ,𝑀} (7.4) 
 
and 
 
𝑀𝐷𝐴𝑃𝐸 = 𝑚𝑒𝑑𝑖𝑎𝑛{𝑀𝐷𝐴𝑃𝐸௜, 𝑖 = 1,… ,𝑀} (7.5) 
 
where M represents the number of study participants. The disadvantage of this 
two stage approach to finding the population estimates is that MDPE and MDAPE 
may be known in some participants with more certainty than others. This was 
accounted for by weighting the calculation by the number of blood samples 
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performed in each patient, but without adjustment for the intra-patient 
variability. 
 
7.8.3.6 Sample Size 
There is no consensus agreement on the required sample size for this type of PK 
validation study. Similar published studies have recruited around 30 
patients(241) and the same number was determined to be appropriate in this 
study.  
 
7.8.4 Model Simulation 
The TCI device infusion profile for each participant was used to simulate the 
propofol plasma concentrations predicted by each of the Covariates, Marsh and 
Schnider Models. For the interim analysis described below, this was first 
performed using the Tivatrainer software (Version 8.1)(242) to simulate the 
predictions made by the Covariates Model. Tivatrainer is a specialised 
pharmacokinetic simulation programme that has been used extensively in 
anaesthetic pharmacokinetic research. It does not however provide the 
flexibility of data manipulation and integration of multiple analyses that is 
provided by R. For this reason, the remainder of the simulation studies were 
performed using the deSolve Package in R, which provides the functions to solve 
ordinary differential equations as required in compartmental PK modelling(243). 
 
The models were represented in R based on the standard three compartment 
open model: 
 
𝛿𝐶ଵ
𝛿𝑡 = 𝑑𝑜𝑠𝑒 + 𝑘ଶଵ𝐶ଶ + 𝑘ଷଵ𝐶ଷ − (𝑘ଵ଴+ 𝑘ଵଶ + 𝑘ଵଷ)𝐶ଵ 
(7.6) 
 
𝛿𝐶ଶ
𝛿𝑡 = 𝑘ଵଶ𝐶ଵ − 𝑘ଶଵ𝐶ଶ 
(7.7) 
 
𝛿𝐶ଷ
𝛿𝑡 = 𝑘ଵଷ𝐶ଵ − 𝑘ଷଵ𝐶ଷ 
(7.8) 
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where dose is the quantity of propofol delivered, C1, C2 and C3 are the 
concentrations of propofol in the first, second and third compartments, k12, k13, 
k21 and k31  are the intercompartmental rate constants and k10 is the rate 
constant for elimination.  
 
To ensure that the deSolve Package was providing accurate solutions to the 
modelling studies, the predicted plasma concentrations for the Covariates Model 
in the interim analysis were compared to the predictions provided by 
Tivatrainer. This was done using the same methodology as described with 
calculation of MDPE and MDAPE as measures of bias and inaccuracy.  
 
7.8.5 Interim Analysis 
An interim analysis of the study was performed following recruitment of ten 
male and ten female patients to the study to ensure that MDPE and MDAPE for 
the Covariates Model were within the expected ranges. This analysis revealed 
that the PEs were markedly higher in female patients than was anticipated. The 
decision was therefore made to perform a simulation study at this stage to 
ensure that the implementation of the Covariates Model by the Fresenius 
Injectomat TIVA Agilia syringe pump was accurate. Simulation study using both 
Tivatrainer software and the desolve Package revealed that the TCI device 
programming had been mis-specified and was therefore not appropriately 
implementing the Covariates Model in female patients (details are provided in 
the results section). This mis-specification was corrected by the manufacturer 
and following discussion with the Research Ethics Service, an additional ten 
female patients were recruited to the study.  
 
7.8.6 Validation Study 
Validation of the Covariates Model as implemented by the syringe pump was 
performed only in the participants who received the correctly specified model. 
Overall values for bias (MDPE) and inaccuracy (MDAPE) were calculated. 
Wilcoxon Signed Rank Tests were performed to compare PEs measured using 
arterial and venous sampling. A p-value of < 0.05 was regarded as significant. 
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Again using the Wilcoxon Signed Rank Test, specific comparisons were made 
between male and female patients and younger and older patients to confirm 
that adjusting the model by the covariates of age and gender resulted in 
consistent bias.  
 
Finally, the effect of time since a change in target plasma concentration was 
explored. For arterial and venous samples, linear models were constructed to 
identify if there was a systematic change in bias with increasing time from a 
change in target concentration. The absolute difference was then calculated 
between each pair of PEs from arterial and venous samples (the a-v PE 
difference) and the magnitude of this difference modelled against time. All 
modelling was done using the stats Package in R(7) and details of the models 
selected are provided in the results section.  
 
7.8.7 Model Comparison Study 
Simulation studies were performed in the desolve Package using data from all 
patients to compare predictions made by the Covariates, Marsh and Schnider 
Models. Following calculation of the predicted plasma concentrations for each 
participant according to each of the models, their performances were compared 
using MDPE and MDAPE. The Friedman Rank Sum Test was used to compare all of 
the Covariates, Marsh and Schnider Models for a statistically significant 
difference in inaccuracy. The Nemenyi Multiple Comparison Test could then be 
used to determine which, if any, models were statistically different. Use of the 
Nemenyi multiple comparison test removes the need for post-hoc adjustment of 
p-values and therefore a p-value of <0.05 was regarded as significant. 
 
For each of the models, similar comparisons as for the validation study were 
performed between female and male and younger and older patients to 
determine if there were any systematic differences in bias. 
 
For arterial and venous blood sampling, models were compared at early (< 2.5 
minutes), intermediate (> 2.5 minutes) and late (> 5.5 minutes) time intervals 
following a change in target plasma concentration.  As above, statistical 
comparisons of model inaccuracies were performed using the Friedman Rank 
Sum Test with Nemenyi Multiple Comparison Test. For each of the PK models 
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there was then construction of linear models to determine systematic changes in 
bias with time and for a systematic change in the a-v PE difference. 
 
7.8.8 Effect Site Modelling 
The central role of the ke0 in effect site modelling and its determination using 
non-linear effect site modelling has been discussed in detail in the introduction. 
The appropriate ke0 for the Covariates Model had not been determined prior to 
this study. To perform effect site modelling using the standard parametric 
approach, it is necessary to simultaneously perform monitoring of the 
anaesthetic effect site while delivering anaesthesia using a validated PK model. 
In the first instance this meant using only data from patients in whom the 
correctly specified Covariates Model was delivered and an effect site monitoring 
profile (i.e. BIS) was available. The analysis was subsequently repeated using 
simulated PK data in all patients who had an effect site monitoring profile 
available. 
 
The relationship between anaesthetic effect and the effect site concentration 
was assumed to be represented by the sigmoid Emax model described by 
Hill(244): 
 
𝐸 = 𝐸଴ −
𝐸௠௔௫𝐶௘ఊ
𝐶௘ఊ + 𝐶௘(50)ఊ
 
(7.9) 
 
where E is drug effect, E0 is the baseline effect with no drug present, Emax is the 
maximum difference from baseline, Ce is the effect site concentration, Ce(50) is 
the drug concentration producing 50% of the maximum effect and J describes the 
slope of the concentration-effect relationship. To describe the relationship 
between the predicted plasma concentration and the effect site concentration, 
a further differential equation was added to the existing three-compartment 
model: 
 
𝛿𝐶௘
𝛿𝑡 = 𝑘௘଴(𝐶ଵ − 𝐶௘) 
(7.10) 
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where ke0 is the rate constant for elimination from the effect site and models 
the delay between changes in C1 and clinical effect.  
 
The standard software used for PKPD analysis, and thus estimation of the best 
ke0 to describe drug behaviour in a population is NONMEM£ (ICON Plc, Ireland). 
In this study, the R package nlmeODE(236) was used to perform non-linear mixed 
effect modelling using differential equations.  As discussed earlier, this package 
has been shown to provide accurate parameter estimates, which are consistent 
with NONMEM estimates(237). 
 
The analysis was performed in three stages. Firstly by allowing nlmeODE to fit 
the data by finding the best estimates of ke0, E0, Emax, EC50 and J. Secondly by 
fixing Emax to 100, as this is the maximum anaesthetic effect measurable by the 
BIS device. Finally by fixing both Emax and E0 to 100, as the theoretical BIS in all 
patients prior to starting anaesthesia is also 100. In each scenario, an overall 
population estimate (or fixed effect) as well as an individualised estimate (or 
random effect) for ke0 was provided.  
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8 Results of the VaSCoM Study 
 
8.1 Overview 
The principle results of the Validation Study of the Covariates Model (VaSCoM) 
for target controlled infusion of propofol are presented. The results are in four 
sections, relating firstly to an interim analysis, secondly to the pharmacokinetic 
(PK) validation study, thirdly to a pharmacokinetic PK comparison study and 
finally to the pharmacodynamic (PD) analysis. 
 
8.2 Data Collection 
8.2.1 Data Collection Period 
The initial plan for the VaSCoM study was to recruit up to 50 patients to achieve 
datasets for 30 patients. Data collection took place during the period 26th 
January 2011 and 10th June 2014. Recruitment was significantly slower than 
expected for two reasons. The first was the fact that the vast majority of 
patients undergoing non-cardiac surgery at the Golden Jubilee National Hospital 
are anaesthetised using regional rather than general anaesthetic techniques. 
This reduced the pool of eligible patients. The second reason related to the 
complex logistics of the study requiring three clinicians and a separate clinical 
area to complete the study procedure without impacting on the efficient running 
of the theatre list. 
 
As discussed in the methods section, the initial target sample size was increased 
to 40 to compensate for a calculation error programmed into the TCI device 
used. One patient was withdrawn from the study prior to any blood samples 
being collected because airway management became a priority. In addition, 
there was one female participant who was anaesthetised using the male 
algorithm. Ultimately there were 40 patients studied, with 29 participants 
anaesthetised using the correctly specified Covariates Model.  
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8.2.2 Patient Demographics 
25 female patients were studied with median age of 45 (38 – 63) years and 
median weight of 63 (61 - 71) kg. For the 14 females anaesthetised using the 
correctly specified Covariates Model, these values were 45.5 (43.25 – 65.25) 
years and 63 (60.25 – 73.25) kg. There were 15 male patients studied with 
median age of 51 (43 – 66) years and median weight of 86 (78 – 97) kg. Table 8.1 
summarises the demographic characteristics of each of the 40 participants and 
the infusion protocol that was used. 
 
8.2.3 Blood Samples and BIS Profiles 
Whole blood propofol concentrations were measured in 160 arterial blood 
samples and 274 venous blood samples. For patients who were anaesthetised 
using the correctly specified Covariates Model, there were 116 arterial samples 
and 199 venous samples. Bispectral index (BIS) profiles were available for 33 
patients, 24 of whom were anaesthetised using the correctly specified 
Covariates Model.
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ID Model Gender Age (Yrs) Weight (kg) Height (cm) Protocol 
1 Mis_spec f 54 66 160 a 
11 Covariates m 32 79 175 a 
20 Covariates m 29 86 180 b 
21 Covariates m 28 93 181 a 
23 Mis_spec f 43 62 161 b 
27 Mis_spec f 35 66 159 a 
30 Covariates m 53 117 185 b 
35 Covariates m 41 99 185 a 
39 Covariates m 51 99 175 b 
47 Mis_spec f 29 59 169 b 
49 Mis_spec f 52 62 166 a 
55 Covariates m 58 79 180 a 
56 Covariates m 46 95 175 b 
60 Mis_spec f 32 73 175 a 
61 Mis_spec f 49 80 171 b 
62 Covariates m 47 80 182 a 
63 Covariates m 45 120 192 b 
65 Mis_spec f 38 67 164 b 
71 Mis_spec f 30 61 171 a 
72 Mis_spec f 73 66 174 a 
78 Covariates f 51 49 156 a 
81 Covariates f 43 60 168 b 
83 Covariates f 46 58 171 a 
84 Covariates f 40 76 161 b 
85 Covariates f 45 63 162 a 
87 Covariates f 45 88 174 b 
88 Covariates f 44 63 159 a 
90 Covariates male f 69 51 164 a 
95 Covariates f 70 69 169 b 
101 Covariates m 65 68 173 b 
107 Covariates f 66 71 151 a 
108 Covariates m 75 75 172 b 
110 Covariates f 63 74 155 b 
112 Covariates f 35 62 167 a 
114 Covariates m 68 77 170 a 
117 Covariates m 67 95 179 a 
119 Covariates f 32 82 176 b 
130 Covariates m 67 73 177 b 
132 Covariates f 70 61 160 b 
137 Covariates f 68 54 158 a 
 
Table 8.1: Demographics, PK model details and study protocol for each of the 40 
patients studied in the VaSCoM study.  
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8.3 Interim Analysis 
An interim analysis of data from the first ten male and ten female patients 
studied was performed and these were presented in June 2012 at the 
Anaesthetic Research Society Meeting, Aberdeen(245). MDPE and MDAPE were 
first calculated for the full cohort of patients. MDPE and MDAPE for venous 
samples were 10 (-49 to 52) and 23 (9 to 54), while MDPE and MDAPE for arterial 
samples were 27 (-33 to 89) and 34 (13 to 89). The bias and inaccuracy 
calculated were of a greater magnitude than was anticipated given the 
optimisation of the Covariates Model through the inclusion of age and gender 
covariates. To explore this further, separate analyses of male and female 
patients were performed and the results revealed a much larger performance 
error in female patients (Table 8.2 and Figure 8.1). 
 
Measure Female Male 
MDPE Arterial 49 (-33 to 89) 16 (-11 to 72) 
MDAPE Arterial 49 (26 to 89) 23 (13 to 72) 
MDPE Venous 8 (-49 to 52) 15 (-6 to 29) 
MDAPE Venous 40 (12 to 54) 23 (9 to 31) 
 
Table 8.2: Interim results with MDPEs and MDAPEs for venous and arterial sampling 
in males and females. 
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Figure 8.1: Boxplots demonstrating the range of MDPEs and MDAPEs for arterial and 
venous sampling for females (A) and males (B) in the interim analysis of pump 
performance. 
On the evidence of the MDPE for arterial sampling in females there seemed to be 
a systematic under prediction of the measured propofol concentrations by the 
Covariates Model as implemented by the Fresenius Injectomat TIVA Agilia syringe 
pump. Sample plots of predicted concentrations with measured arterial and 
venous blood concentrations for female patients anaesthetised using both 
protocol a (2-5-2) and protocol b (5-2-5) supported this hypothesis (Figure 8.2). 
This systematic error could be related to either a bias within the Covariates 
Model itself, or a mis-specification of the Covariates Model within the syringe 
pump. To elucidate this further, it was necessary to perform simulation studies 
for each of the patients so far recruited and compare the predicted 
concentrations from the simulations to those downloaded from the syringe pump 
(Figure 8.2). 
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Figure 8.2: Predicted concentration profiles for female patients who had propofol 
infusions delivered according to protocol a (A) and b (B) for the mis-specified 
Covariates Model. The measured arterial and venous blood concentrations have 
been plotted to indicate the significant discrepancy between measured and 
predicted values. The concentrations predicted by a simulation of the correctly 
specified Covariates Model are plotted for comparison. 
The simulation studies were performed using both the Tivatrainer software and 
the deSolve Package in R with identical input parameters. Performance errors 
between the concentration predictions made by Tivatrainer and those made by 
the syringe pump were plotted against time (Figure 8.3). It became immediately 
clear that in female patients the syringe pump was systematically predicting 
lower concentrations than those expected by Tivatrainer. This was supported by 
a MDPE of 35 (23 to 69) and a MDAPE of 35 (23 to 69) in females. There was 
systematic under prediction of concentrations in males but to a much smaller 
degree with a MDPE of 5 (3 to 6) and a MDAPE of 5 (3 to 6) (Figure 8.4). 
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Figure 8.3: Performance error plotted against time for ten male and ten female 
patients comparing simulated predictions made by Tivatrainer and (A) the 
predictions made by the syringe pump and (B) the simulated predictions made by 
the deSolve Package. 
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Figure 8.4: Comparison of MDPE and MDAPE for female and male patients between 
predictions made by Tivatrainer and (A) the predictions made by the syringe pump 
and (B) the simulated predictions made by the deSolve package. 
On the basis of the significant and systematic error between propofol 
concentration predictions made by the syringe pump and both the measured 
values and the predictions made by Tivatrainer, the VaSCoM study was put on 
hold. A review of the input parameters to the Covariates Model as implemented 
by the syringe pump was performed and revealed a simple arithmetic error. 
Calculation of the central compartment volume should have been implemented 
as: 
 
𝑉ଵ = 191.78− 0.669×𝐴𝑔𝑒 (8.1) 
 
but had instead been implemented as: 
 
𝑉ଵ = 191.78+ 0.669×𝐴𝑔𝑒 (8.2) 
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with the consequence of increased doses of propofol being delivered to fill the 
larger compartment volume. All of the syringe pumps used in the study were re-
programmed with the correctly implemented model, and following liaison with 
the Research Ethics Committee a plan was made to recruit an additional 10 
female patients to the study. 
 
The results of the simulation studies performed comparing the predictions made 
by the deSolve Package to those made by the syringe pump gave essentially 
identical results to those using Tivatrainer. Indeed when the performance error 
between predictions made by Tivatrainer and those made by deSolve were 
plotted against time there was no real systematic difference identified (Figure 
8.3). This conclusion was supported by calculation of a MDPE of 0 (-2 to 1) and 
MDAPE of 1 (0 to 2) (Figure 8.4). On the basis of these results, all subsequent 
simulation studies were performed using the deSolve Package due to the ability 
to more quickly and efficiently perform multiple simulations. 
 
8.4 Validation Study Results 
8.4.1 Overall Validation Results 
The results presented below relate to a comparison between the measured 
arterial and venous propofol concentrations and the concentrations predicted by 
the syringe pump. Only data from the 29 patients anaesthetised using the 
correctly specified Covariates Model with the correctly implemented Covariates 
Model were included in the analysis. These results were presented in part in 
September 2016 at the World Congress of Anesthesiologists, Hong Kong(246). 
Overall the implemented model seemed to perform with a reasonable degree of 
bias and inaccuracy with a MDPE of 9 (-45 to 82) and MDAPE of 24 (9 to 82) for 
arterial samples and MDPE of -8 (-64 to 70) and MDAPE of 23 (9 to 70) for venous 
samples (Figure 8.5). There was a statistically significant difference between PEs 
for each arterial and venous blood sample (p < 0.0001) and between the arterial 
and venous MDPEs for each patient (p < 0.001) as tested by the Wilcoxon Signed 
Rank Test. 
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Figure 8.5: Validation study results showing MDPE and MDAPE for arterial and venous 
samples in (A) the overall population, (B) female patients and (C) male patients. 
8.4.2 Female and Male Patient Comparison 
On examination of the results for female and male patients, there appeared to 
be a tendency for the predicted concentrations to be higher than the measured 
concentrations in female patients but lower than predicted concentrations in 
male patients (Table 8.3 and Figure 8.5). This was confirmed by significant 
Wilcoxon Signed Rank Tests comparing MDPEs for female and male patients on 
arterial (p < 0.001) and venous (p < 0.0001) samples. The result of these 
opposing biases (over prediction in females and under prediction in males) was 
that the overall population bias was reduced to nearer to zero.  
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Measure Female Male 
MDPE Arterial -14 (-45 to 28)* 19 (-11 to 82)* 
MDAPE Arterial 23 (9 to 45) 24 (13 to 82) 
MDPE Venous -20 (-64 to -8)* 12 (-9 to 70)* 
MDAPE Venous 21 (11 to 64) 23 (9 to 70) 
 
Table 8.3: Final validation results with MDPEs and MDAPEs for venous and arterial 
sampling in females and males. * Denotes statistically significant difference between 
MDPEs in females and males. 
8.4.3 Younger and Older Patient Comparison 
There was no clear systematic difference in the bias of model predictions 
between younger (aged under 65 years) and older patients (Table 8.4). This was 
confirmed by non-significant Wilcoxon Signed Rank Tests comparing MDPEs for 
younger and older patients on arterial (p = 0.36) and venous (p = 0.80) samples. 
There was a tendency for older age to emphasise existing differences in bias 
between female and male patients as supported by arterial MDPEs of -12 (-43 to 
18) and -23 (-45 to 28) in younger and older females and 16 (-11 to 72) and 27 
(13 to 82) in younger and older males (Figure 8.6). 
 
Measure Younger Older 
MDPE Arterial 1 (-43 to 72) 20 (-45 to 82) 
MDAPE Arterial 22 (9 to 72) 27 (13 to 82) 
MDPE Venous -6 (-64 to 29) -9 (-51 to 70) 
MDAPE Venous 22 (9 to 64) 24 (10 to 70) 
 
Table 8.4: Final validation results with MDPEs and MDAPEs for venous and arterial 
sampling in younger and older patients. 
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Figure 8.6: Validation study results showing MDPE for arterial and venous samples in 
(A) younger females, (B) younger males, (C) older females and (D) older males.  
8.4.4 Early and Late Sampling Comparison 
On visual inspection of the data, there appeared to be a systematic change of 
PEs with increasing time from an increase in the target plasma concentration. 
With increasing, time arterial PEs appeared to become more negative and 
venous PEs appeared to become more positive. This was formally investigated 
using a linear modelling technique with the model: 
 
𝑃𝐸 = 𝛼ଵ∆𝑡+ 𝛼ଶ𝐺 + 𝛽 (8.3) 
 
where PE is the arterial or venous PE, 't is the time since an increase in plasma 
target concentration and G is gender (Table 8.5 and Figure 8.7). There was a 
significant negative correlation between time from an increase in target plasma 
concentration and the performance errors measured using arterial samples (p < 
0.0001, r-squared = 0.29). In contrast, using performance errors measured using 
venous samples, the overall model demonstrated statistical significance (p < 
  
131 
0.0001, r-squared = 0.23) but there was no significant relationship between 
performance errors and time (D1 p = 0.302). 
 
Sampling Constant Estimate Lower Upper p-value 
Arterial E 0.37 -0.26 15.61 0.946 
D1 -0.03 -0.05 -0.02 0.001 
D2 38.10 16.92 37.31 0.000 
Venous E -32.98 -42.41 -23.55 0.000 
D1 0.01 0.00 0.02 0.302 
D2 40.00 29.69 50.3 0.000 
 
Table 8.5: Estimates for constants in Equation 8.3 for venous and arterial sampling 
with upper and lower 95% confidence intervals and associated p-values. 
 
Figure 8.7: Plots of PE against time since an increase in the target plasma 
concentration for arterial (A) and venous (B) samples. Linear models are displayed 
as fit +/- 95% confidence interval. The lighter shaded area represents 95% 
confidence interval of model predictions. 
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From Figure 8.7, there is a suggestion that the differences between PEs 
calculated using arterial and venous sampling reduce with time from an increase 
in plasma target concentration. To explore this further, the difference was 
calculated between every pair of arterial and venous blood samples (Figure 8.8). 
After visual inspection of the data, the following linear model was fitted:  
 
𝑙𝑜𝑔(𝑃𝐸௔ − 𝑃𝐸௩) = 𝛼∆𝑡+ 𝛽 (8.4) 
 
where PEa is performance error calculated from arterial sampling, PEv is 
performance error calculated from arterial sampling and 't is the time since an 
increase in plasma target concentration (Table 8.6). There was a significant 
relationship between log(PEa - PEv) and time since an increase in target plasma 
concentration (p < 0.0001, r-squared = 0.32). 
 
Figure 8.8: Plot of the difference between arterial and venous PEs against time 
since an increase in target plasma concentration. Linear models are displayed as fit 
+/- 95% confidence interval. The dashed line represents 95% confidence interval of 
model predictions. 
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Constant Estimate Lower Upper p.value 
D 3.643 3.385 3.847 0.000 
E -0.002 -0.002 -0.001 0.000 
 
Table 8.6: Estimates for constants in Equation 8.4 with upper and lower 95% 
confidence intervals and associated p-values. 
8.5  Model Comparison Results 
8.5.1 Introduction 
All of the validation study results presented above have used the Fresenius 
implementation of the Covariates Model. For consistency in comparison, the 
Covariates Model, Marsh Model and Schnider Model were all re-simulated using 
the deSolve Package in R from the Fresenius Agilia Pump infusion profile for all 
40 patients. In the simulations performed for the interim analysis results above, 
predictions made using deSolve were very close to those made by the well-
established Tivatrainer software. 
 
8.5.2 Model Comparison Based on Overall Performance Error 
Comparison was first made between the arterial and venous blood propofol 
concentrations and the concentrations predicted by each of the Covariates, 
Marsh and Schnider Model Simulations in all study patients and at all study time 
points. The summary results for these simulations are displayed in Table 8.7 and 
Figures 8.9 and 8.10. On the basis of arterial sampling, the overall bias of the 
Covariates Model was closest to zero, with accuracy similar to that of the 
Schnider Model. The Marsh Model tended to over-predict with lower accuracy 
than the other two models. This was confirmed statistically using a Friedman 
Rank Sum Test to confirm a difference between the MDAPEs for each of the 
models (p < 0.0001). Pairwise comparisons using Nemenyi Multiple Comparison 
Test confirmed the similarity of the Covariates and Schnider Models, but a 
significant difference between the Marsh Model and the Covariates and Schnider 
Models respectively (p < 0.01 and p < 0.0001). On the basis of venous sampling, 
the Covariates Model had a greater tendency to under-predict but there was no 
significant difference in the accuracies of the models (p = 0.20). 
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Model MDPE Art MDAPE Art MDPE Ven MDAPE Ven 
Covariates 3 (-45 to 73) 25 (3 to 73)* -11 (-64 to 56) 20 (9 to 64) 
Marsh 18 (-44 to 112) 34 (9 to 112)* -5 (-56 to 84) 25 (9 to 84) 
Schnider 9 (-40 to 68) 22 (7 to 68)* -6 (-59 to 40) 26 (9 to 59) 
 
Table 8.7: Summary of results for prediction errors in simulation studies for each of 
the Covariates, Marsh and Schnider Models. * Denotes statistically significant 
difference between MDAPEs calculated for each model. 
 
Figure 8.9: Summary of results for prediction errors based on arterial blood 
sampling in simulation studies for each of the Covariates, Marsh and Schnider Models 
in all patients (A), females (B) and males (C). 
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Figure 8.10: Summary of results for prediction errors based on venous blood 
sampling in simulation studies for each of the Covariates, Marsh and Schnider Models 
in all patients (A), females (B) and males (C). 
8.5.3 Model Comparison By Gender 
The predictive performance of the Covariates, Marsh and Schnider Models in 
female and male patients was compared. The results are summarised in Table 
8.8 and Figures 8.9 and 8.10. In line with the Validation Study results, the 
simulation studies using the Covariates Model confirmed the tendency to over-
predict in females and under-predict in males. Again this was confirmed by 
significant Wilcoxon Signed Rank Tests comparing MDPEs for female and male 
patients on arterial (p < 0.0001) and venous (p < 0.0001) samples. The tendency 
for the Marsh Model to under-predict was consistent across both female and 
male patients on arterial but not venous samples. There was a statistically 
significant difference in bias between female and male patients in both arterial 
(p < 0.0001) and venous samples (p < 0.0001). In contrast, there was no 
significant difference in bias between female and male patients in the 
predictions made by the Schnider Model in either arterial (p = 0.55) or venous 
samples (p = 0.12). 
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Model Gender MDPE Art MDAPE Art MDPE Ven MDAPE Ven 
Covariates Female -7 (-45 to 47)* 24 (3 to 47) -26 (-64 to 16)* 26 (12 to 64) 
Male 14 (-15 to 73)* 25 (8 to 73) 3 (-18 to 56)* 18 (9 to 56) 
Marsh Female 12 (-44 to 74)* 32 (10 to 74) -13 (-56 to 27)* 25 (9 to 56) 
Male 36 (0 to 112)* 36 (9 to 112) 20 (-7 to 84)* 24 (17 to 84) 
Schnider Female 7 (-40 to 43) 24 (7 to 48) -6 (-59 to 33) 27 (9 to 59) 
Male 11 (-21 to 68) 20 (9 to 68) -7 (-26 to 40) 24 (10 to 59) 
 
Table 8.8: Results for prediction errors in simulation studies for each of the 
Covariates, Marsh and Schnider Models for female and male patients. * Denotes 
statistically significant difference between MDPEs in females and males. 
8.5.4 Model Comparison By Age 
The predictive performance of the Covariates, Marsh and Schnider Models was 
compared between older and younger patients. The results are summarised in 
Table 8.9 and Figures 8.11 and 8.12. With the exception of the Schnider Model 
as assessed on venous blood sampling (p < 0.05), there was no statistical 
difference between the model biases in younger and older patients. There was a 
non-significant trend for increased under-prediction in older patients for the 
Marsh Model.  
 
Model Age Group MDPE Art MDAPE Art MDPE Ven MDAPE Ven 
Covariates Younger 4 (-45 to 67) 25 (3 to 67) -8 (-64 to 24) 20 (11 to 64) 
Older 1 (-45 to 73) 24 (8 to 73) -15 (-51 to 56) 21 (9 to 56) 
Marsh Younger 15 (-44 to 97) 34 (9 to 97) -6 (-56 to 47) 25 (9 to 56) 
Older 31 (-23 to 112) 36 (10 to 112) 5 (-43 to 84) 22 (10 to 84) 
Schnider Younger 11 (-34 to 43) 19 (8 to 46) -7 (-59 to 27)* 24 (9 to 59) 
Older -4 (-40 to 68) 29 (7 to 68) 3 (-31 to 40)* 33 (13 to 58) 
 
Table 8.9: Results for prediction errors in simulation studies for each of the 
Covariates, Marsh and Schnider Models for younger and older patients. * Denotes 
statistically significant difference between MDPEs in younger and older patients. 
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Figure 8.11: Summary of results for prediction errors based on arterial blood 
sampling in simulation studies for each of the Covariates, Marsh and Schnider Models 
in all patients (A), younger patients (B) and older patients (C). 
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Figure 8.12: Summary of results for prediction errors based on venous blood 
sampling in simulation studies for each of the Covariates, Marsh and Schnider Models 
in all patients (A), younger patients (B) and older patients (C). 
8.5.5 Model Comparison By Timing Of Blood Sampling 
At set times following an increase in plasma target concentration, the predictive 
performances of the Covariates, Marsh and Schnider Models were compared.  The 
time periods selected were less than 2.5 minutes, greater than 2.5 minutes and 
greater than 5.5 minutes. The results are summarised in Table 8.10 and Figure 
8.13. 
 
For both the Covariates and the Marsh Models there was a trend from the early 
to the late time window from model under-prediction to over-prediction on the 
basis of arterial sampling. The reverse was true for the Schnider Model and these 
trends were explored in detail through linear modelling. 
 
 
 
  
139 
Time Measure Covariates Marsh Schnider 
< 2.5 Mins MDPE Art 9 (-46 to 113) 43 (-22 to 166) -15 (-50 to 44) 
MDAPE Art 31 (0 to 113)* 47 (2 to 166)* 27 (1 to 50)* 
MDPE Ven -20 (-79 to 61) 1 (-73 to 95) -34 (-77 to 18) 
MDAPE Ven 53 (7 to 79)* 56 (9 to 95)* 47 (7 to 77)* 
> 2.5 Mins MDPE Art 0 (-52 to 80) 2 (-55 to 118) 11 (-34 to 93) 
MDAPE Art 25 (8 to 80)* 30 (5 to 118)* 25 (4 to 93)* 
MDPE Ven -12 (-58 to 56) -4.5 (-56 to 84) 3.5 (-52 to 54) 
MDAPE Ven 18 (2 to 58) 21 (6 to 84) 22 (6 to 59) 
> 5.5 Mins MDPE Art -22 (-53 to 59) -17 (-58 to 80) 26 (-29 to 135) 
MDAPE Art 26 (6 to 59) 22 (3 to 80) 29 (6 to 135) 
MDPE Ven -14 (-53 to 50) -8.5 (-56 to 74) 13 (-27 to 107) 
MDAPE Ven 18 (2 to 53) 21 (6 to 74) 25 (3 to 107) 
 
Table 8.10: Results for prediction errors at specified time intervals in simulation 
studies for each of the Covariates, Marsh and Schnider Models. * Denotes statistically 
significant difference between MDAPEs calculated for each model at given time 
interval. 
At the early time window, on the basis of arterial sampling there was a 
significant difference between the accuracy of the three models as assessed by 
Friedman Rank Sum Test of the MDAPEs (p < 0.0001). Pairwise comparisons using 
Nemenyi Multiple Comparison Tests confirmed the similarity of the Covariates 
and Schnider Models, but a significant difference between the Marsh Model and 
the Covariates and Schnider Models respectively (p < 0.001 and p < 0.01). A 
significant difference was also seen between the accuracy of the three models 
on the basis of venous sampling (p < 0.01). Again the similarity of the Covariates 
and Schnider Models was confirmed, with a significant difference between the 
Marsh Model and each of the Covariates and Schnider Models (p < 0.01 and p < 
0.05).  
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Figure 8.13: Summary of results for prediction errors based on arterial (A) and 
venous (B) blood sampling in simulation studies for each of the Covariates (red), 
Marsh (green) and Schnider (blue) Models at set time points following an increase in 
target plasma concentration. 
At the intermediate time window, there was a persisting statistically significant 
difference in the accuracies of the three models on the basis of arterial (p < 
0.05) but not venous sampling (p = 0.50). On pairwise comparison, the statistical 
difference on the basis of arterial sampling was only present between the Marsh 
and Schnider Models (p < 0/05). 
 
At the later time window there was no statistically significant difference 
between accuracies of the three models on arterial (p = 0.25) or venous 
sampling (p = 0.71). 
 
As for the Fresenius implementation of the Covariates Model, there was further 
exploration of the relationship between increasing time from a plasma target 
increase and bias for each of the three simulated models. The same linear model 
described in Equation 8.3 was used with estimated constants in Table 8.11 and 
fits in Figures 8.14 and 8.15.  
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Sampling Model Constant Estimate Lower Upper p-value 
Arterial Covariates E 7.67 -0.26 15.61 0.058 
D1 -0.03 -0.05 -0.02 0.000 
D2 27.12 16.92 37.31 0.000 
Marsh E 37.73 28.3 47.15 0.000 
D1 -0.06 -0.07 -0.04 0.000 
D2 30.97 18.86 43.08 0.000 
Schnider E -11.09 -19.41 -2.78 0.009 
D1 0.04 0.02 0.05 0.000 
D2 0.49 -10.2 11.17 0.928 
Venous Covariates E -29.19 -36.51 -21.86 0.000 
D1 0.00 0.00 0.01 0.398 
D2 30.31 21.45 39.17 0.000 
Marsh 
 
E -12.71 -21.37 -4.06 0.004 
D1 -0.01 -0.02 0.00 0.135 
D2 36.79 26.31 47.26 0.000 
Schnider E -35.16 -43.51 -26.81 0.000 
D1 0.04 0.03 0.05 0.000 
D2 12.76 2.66 22.86 0.014 
 
Table 8.11: Estimates for constants in Equation 8.3 for venous and arterial sampling 
with upper and lower 95% confidence intervals and associated p-values. 
Using arterial sampling, there was a significant negative correlation between the 
time since an increase in the target concentration and the performance error for 
the Covariates and Marsh Models, (p < 0.0001, r-squared = 0.24 and p < 0.0001, 
r-squared = 0.33). The opposite was true for the Schnider Model, where there 
was a significant positive correlation (p < 0.0001, r-squared = 0.14). 
 
Using venous sampling the overall model demonstrated statistical significance 
for the Covariates and Marsh Models (p < 0.0001, r-squared = 0.14 and p < 0.0001 
and r-squared 0.15) but there was no significant relationship between 
performance errors and time (D1 p = 0.398 and 0.135). There remained a 
significant positive correlation for the Schnider Model (p < 0.0001, r-squared  = 
0.21 and D1 p = 0.000). 
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Figure 8.14: Plots of PE for arterial samples against time since an increase in the 
target plasma concentration for the Covariates (A), Marsh (B) and Schnider (C) 
Models. Linear models are displayed as fit +/- 95% confidence interval. The lighter 
shaded area represents 95% confidence interval of model predictions. 
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Figure 8.15: Plots of PE for venous samples against time since an increase in the 
target plasma concentration for the Covariates (A), Marsh (B) and Schnider (C) 
Models. Linear models are displayed as fit +/- 95% confidence interval. The lighter 
shaded area represents 95% confidence interval of model predictions. 
The difference was calculated between every pair of arterial and venous PEs for 
each of the three simulated models. The linear model from Equation 8.4 was 
fitted and demonstrated a significant relationship in each of the Covariates (p < 
0.0001 and r-squared 0.32), Marsh (p < 0.0001 and r-squared 0.37) and Schnider 
Models (p < 0.0001 and r-squared 0.15), (Table 8.12 and Figure 8.16). 
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Model Constant Estimate Lower Upper p-value 
Covariates E 3.616 3.385 3.847 0.000 
D -0.002 -0.002 -0.001 0.000 
Marsh E 3.875 3.385 3.847 0.000 
D -0.002 -0.002 -0.001 0.000 
Schnider E 3.34 3.385 3.847 0.000 
D -0.001 -0.002 -0.001 0.000 
 
Table 8.12: Estimates for constants in Equation 8.4 for each of the simulated models 
with upper and lower 95% confidence intervals and associated p-values. 
Figure 8.16: Plot of the difference between arterial and venous PEs against time 
since an increase in target plasma concentration for the Covariates (A), Marsh (B) 
and Schnider (C) Models. Linear models are displayed as fit +/- 95% confidence 
interval. The dashed line represents 95% confidence interval of model predictions. 
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8.6 Pharmacodynamic Model Development 
8.6.1 Introduction 
The Covariates Pharmacokinetic Model was extended to a pharmacokinetic 
pharmacodynamic (PKPD) model by calculation of an overall population estimate 
for ke0. As described in the methods section, this was performed firstly for the 
patients who received the correctly specified Fresenius implementation of the 
Covariates Model and secondly for all patients using predicted plasma propofol 
concentrations simulated by the Covariates Model. The results were presented in 
part in September 2016 at the World Congress of Anesthesiologists, Hong 
Kong(247). 
 
8.6.2 Fresenius Implementation 
Of the 29 patients who were anaesthetised according to the correctly specified 
Covariates Model, there were 24 with BIS data available for PKPD model 
development. Using the nlmeODE Package it was possible to successfully provide 
a population based estimate for ke0 with or without fixed values for E0 and Emax. 
Table 8.13 provides a summary of the population variable estimates in each of 
the three scenarios. Estimates for ke0 were all similar and ranged from 0.21 to 
0.25 min-1. 
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Model Variable Estimate Lower Upper p-value 
Fresenius 
 
ke0 (min-1) 0.25 0.20 0.31 0.00 
E0 (BIS) 106 102 110 0.00 
Emax(BIS) 144 0 2.01e+63 0.94 
EC50 (Pg/ml) 4.39 0.00 9.65e+85 0.99 
J 2.36 0.00 1.19e+07 0.91 
Fresenius with fixed E0 and Emax ke0 (min-1) 0.22 0.18 0.27 0.00 
E0 (BIS) 105 101 108 0.00 
EC50 (Pg/ml) 2.48 2.14 2.86 0.00 
J 2.80 2.37 3.31 0.00 
Fresenius with fixed Emax ke0 (min-1) 0.21 0.18 0.25 0.00 
EC50 (Pg/ml) 2.83 2.53 3.17 0.00 
J 2.33 1.78 3.07 0.00 
 
Table 8.13: Estimates for variables in Equation n for each of the described scenarios 
with upper and lower 95% confidence intervals and associated p-values. 
8.6.3 Covariates Simulation 
There were 33 patients with BIS data available for PKPD model development 
using simulated plasma propofol predictions for the Covariates Model. It was 
again possible to successfully provide a population based estimate for ke0 with or 
without fixed values for E0 and Emax. Table 8.14 provides a summary of the 
population variable estimates in each of the three scenarios. Estimates for ke0 
were similar to those calculated using the Fresenius implementation of the 
Covariates Model and ranged from 0.22 to 0.27 min-1. Figure 8.17 displays the 
fits achieved for population (fixed) and individual (random) estimates for ke0 
without fixed values for E0 and Emax. Figure 8.18 provides a more detailed display 
of the fits for a single patient (ID = 137). 
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Model Variable Estimate Lower Upper p-value 
Covariates ke0 (min-1) 0.27 0.23 0.32 0.00 
E0 (BIS) 104 102 106 0.00 
Emax(BIS) 124 96 160 0.00 
EC50 (Pg/ml) 4.13 2.50 6.82 0.00 
J 2.56 1.77 3.70 0.00 
Covariates with fixed Emax ke0 (min-1) 0.24 0.22 0.27 0.00 
E0 (BIS) 104 101 107 0.00 
EC50 (Pg/ml) 2.77 2.53 3.04 0.00 
J 2.21 1.94 2.53 0.00 
Covariates with fixed E0 and Emax 
 
ke0 (min-1) 0.22 0.20 0.25 0.00 
EC50 (Pg/ml) 3.05 2.81 3.30 0.00 
J 2.40 1.89 3.05 0.00 
 
Table 8.14: Estimates for variables in Equation n for each of the described scenarios 
with upper and lower 95% confidence intervals and associated p-values. 
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Figure 8.17 (preceding page): Fixed (red) and random (blue) nlmeODE fits for all 
patients with suitable BIS data. Model fits are plotted over the measured BIS values 
for each patient.  
 
Figure 8.18: Upper panel shows fixed (red) and random (blue) nlmeODE fits for an 
example patient (137). Model fits are plotted over the measured BIS values for each 
patient. Lower panel shows the associated Covariates Model predictions for plasma 
propofol concentration. 
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9 Discussion and Conclusions for the VaSCoM Study 
 
9.1 Overview 
A discussion of the results from the VaSCoM Study is presented below. 
Limitations of the study are addressed and the results are considered in terms of 
those of similar pharmacokinetic (PK) and pharmacodynamic (PD) studies of 
propofol. There is then a description of work performed as a direct result of the 
VaSCoM Study with suggestions for future directions of pharmacokinetic 
pharmacodynamic (PKPD) modelling in anaesthesia. 
 
9.2 Rationale for the Study 
The relative advantages and disadvantages of the Marsh and Schnider Models for 
target controlled infusion (TCI) of propofol have been discussed in the 
introductory section. There is currently no overall consensus on which is the 
more generally applicable model to a wide range of clinical situations. The 
Covariates Model described by White et al represents an update to the Marsh 
Model that adjusts for the patient covariates of age and gender(5). The VaSCoM 
Study aimed to prospectively validate the PK component of the Covariates 
Model, while extending the model to include a PD component by estimating the 
rate constant for elimination from the effect site (ke0). 
 
9.3 Data Collection 
9.3.1 Study Population 
All study patients were undergoing anaesthesia to facilitate elective non-cardiac 
surgery. In this respect they were representative of the population of patients in 
whom TCI of propofol is used in clinical practice. While patients with significant 
co-morbidities were excluded, the study was designed to recruit a reasonable 
number of patients who were aged over 65 years. This was particularly 
important as firstly this age group represents a significant proportion of 
anaesthetic caseload(156) and secondly it allowed comparison of model 
performance in younger and older age groups. 
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9.3.2 Infusion Regime and Blood Sampling 
The infusion regime used in the VaSCoM Study was chosen to be representative 
of the use of TCI in clinical practice. There were multiple step changes in target 
plasma concentration of propofol with patients randomised to either a 2-5-2 
Pg/ml protocol or 5-2-5 Pg/ml protocol. Therefore model performance was 
tested at several target plasma concentrations and also while plasma 
concentration was both increasing and decreasing. Following a change in target 
plasma concentration, there were no further target changes for at least 15 
minutes to allow time for PD effects to reach a steady state and thus assist with 
modelling of the effect site compartment. 
 
During the study period there was no administration of any other hypnotic drugs 
or analgesic drugs. Therefore the risk of other drugs influencing the distribution 
and metabolism of propofol or modulating the pharmacodynamic effects of 
propofol were minimised. 
 
In previous studies comparing PK models for propofol, both arterial and venous 
blood-sampling methods have been used. Some commentators believe that 
arterial sampling is of more value in PK modelling on the basis of the ‘front-end 
kinetics’ delivering the drug to its sites of action. Front-end kinetics refers to 
early drug distribution following intravenous administration and determines the 
relationship between the plasma concentration of drug delivered to various 
tissue groups and time(190). Three compartment PK models, such as the 
Covariates, Marsh and Schnider Models, ignore the complexity of this early phase 
and assume instantaneous mixing of drug within the whole of the central (i.e. 
plasma) compartment. To effectively model this dynamic phase of drug 
disposition, physiology based pharmacokinetic (PBPK) or recirculatory models, 
for example the model described by Upton and Ludbrook(191), are required. 
PBPK models are far more complex and are yet to be implemented in clinical 
practice.  
 
The development of the Covariates Model was based on venous blood samples 
taken during anaesthesia delivered using the Marsh Model(5). In the VaSCoM 
Study, the decision was made to collect a combination of arterial and venous 
samples. This allowed the comparison of the performance errors (PEs) between 
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sampling methods and also, as is discussed below, an examination of how 
arterial and venous PEs change with time. The study schedule involved sampling 
arterial blood at four specified time points during the first 20 minutes of 
anaesthesia and sampling venous blood at seven specified time points during the 
45 to 60 minutes of the study. In retrospect, a schedule involving paired arterial 
and venous sampling for the entire duration of the study would have allowed 
better comparison of the two methods. 
 
9.3.3 BIS Monitoring 
The most commonly used approach to modelling the effect site concentration 
(Ce) of a hypnotic anaesthetic drug in PKPD studies is through processed 
electroencephalography (pEEG). On the basis of endorsement by national 
guidelines(222) and use in routine clinical practice at the Golden Jubilee 
National Hospital, the Bispectral Index (BIS) was selected for the VaSCoM Study. 
The disadvantages of using BIS to model Ce include the fact that it is a surrogate 
marker of clinical effects and, as is the case with all pEEG monitors, there is a 
time delay associated with processing the EEG signal(248). There was no attempt 
to account for this time delay in the PD modelling study. 
 
Alternative approaches using clinical end-points to estimate the magnitude of 
the effect site concentration in PKPD studies have been suggested. For example, 
Lim used the loss of eyelash reflex during different propofol administration 
regimes to derive a ke0 of 0.8 min-1(249). Use of a fixed end-point means that 
the PKPD model will be dependent upon a single clinical observation in each 
individual.  
 
More recently Thomson et al have described a novel technique for estimating ke0 
while assessing clinical effect using visual reaction time (VRT)(250). This is an 
attractive technique as it provides a continuous measure of a true clinical end-
point. Unfortunately it is only practical at sedating doses of propofol and cannot 
be applied to the recovery phase from deeper anaesthesia. 
 
Using the above approach, Thomson et al tested several ke0s with the Marsh 
Model in effect site controlled TCI to see which provided the highest probability 
of achieving stable clinical effect(250). A ke0 of 0.61 min-1was most likely to 
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maintain a stable VRT when a fixed Ce was programmed. In a subsequent 
randomised study, they demonstrated that compared to TCI with the Marsh 
Model in plasma controlled mode or effect site controlled mode with a ke0 of 1.2 
min-1 and the Schnider Model in effect site controlled mode, the Marsh Model 
with a ke0 of 0.6 min
-1 achieved faster induction but with no associated increase 
in haemodynamic instability(251). 
 
9.4 Interim Analysis 
In the interim analysis performed of data collected in the VaSCoM Study, a 
marked deviation from expected PEs was identified in female patients. Further 
investigation revealed a significant Covariates Model mis-specification in the 
Injectomat TIVA Agilia syringe pump based on a typographical error. Following 
discussion with the device manufacturer, the model was adjusted and 
subsequent female patients were anaesthetised using the correct specification 
of the model. Events like this underline the need for formal testing of PK models 
in a clinical context before implementation in Open TCI devices and introduction 
to clinical practice.  
 
Interestingly the plasma concentrations predicted for male patients by the TCI 
device were not identical to those estimated by the Tivatrainer software (Figure 
8.3). However, the deviations were within an acceptable margin of error 
following import of infusion rates into an external program along with the 
necessary interpolations of missing values. 
 
Outputs for Covariates Model predictions provided by Tivatrainer were compared 
to those provided the desolve Package in R. The results suggested that this open 
source alternative provides a suitable means of accurately simulating predictions 
for multiple PK models from infusion profiles. desolve is more suited to batch 
processing than Tivatrainer and should therefore be considered for future 
comparative PK studies. 
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9.5 Validation Study 
9.5.1 Overall Validation 
Schuttler et al suggested that a mean variation in measured drug plasma 
concentrations of 20 to 30%, with a total bias of 10 to 20% from TCI device 
predictions, represented acceptable performance(252). At the time of this 
publication, the use of PEs and the summary measures of median performance 
error (MDPE) and median absolute performance error (MDAPE) had not yet 
become established but similar ranges have been suggested by subsequent 
authors(202). Therefore the VaSCoM Study has demonstrated that the Injectomat 
TIVA Agilia syringe pump implementation of the Covariates Model achieved an 
acceptable level of predictive performance, as assessed by both arterial and 
venous sampling, for use in clinical practice. Whether or not there is a sufficient 
improvement in performance compared to the Marsh and Schnider Models to 
justify a shift towards usage of the Covariates Model shall be discussed with 
consideration of the comparison study results below.  
 
9.5.2 Specific Patient Populations 
The overall minimal bias of the Covariates Model (MDPE of 9 for arterial samples 
and -8 for venous samples) was not consistent across patient subgroups. On both 
sampling methods there was a consistent and statistically significant tendency to 
under-predict plasma concentrations in females and over-predict in males. This 
is a disappointing finding, given that in the development of the Covariates Model 
the Marsh Model was updated with a specific aim to account for gender 
differences. The Covariates Model was more successful in adjusting for the 
covariate of age and there was no significant difference in bias between younger 
and older patients.  
 
9.5.3 Relationship Between PE and Time 
The importance of the choice of blood sampling site (arterial or venous) and the 
influence of timing since dose on measured drug concentrations has undergone 
detailed general discussion elsewhere(253, 254). In their comparative study of 
PK models for propofol, Coetzee et al noted marked differences in calculated 
model performance based on arterial or venous sampling and changes in the 
  
155 
differences between arterial and venous propofol concentrations over time(202). 
Similar results were noted in the VaSCoM Study. 
 
When explored with a linear modelling technique, performance errors based on 
arterial samples showed a statistically significant tendency to change from more 
positive to more negative with time. There was no significant relationship 
observed for venous samples, although PEs tended to change in the opposite 
direction. In line with these observations, the difference between arterial and 
venous PEs (a-v PE difference) could be fitted with an exponentially decreasing 
model over time. From Figure 8.8 it can be suggested that by between 15 and 20 
minutes after an increase in target plasma concentration, arterial and venous 
PEs will have reached some sort of equilibrium. This has significant implications 
for planning blood sampling site and sampling schedule for future PK studies of 
TCI of propofol.  
 
9.6 Model Comparison 
9.6.1 Overall Comparison 
Simulations of the plasma concentrations predicted by the Covariates, Marsh and 
Schnider Models were performed using the propofol infusion profile from each 
patient. This allowed a comparison of each of the model’s predictions to the 
measured blood propofol concentrations. As suggested from the above results, 
the model biases were different depending on whether venous or arterial 
sampling was used. On arterial sampling, the Covariates Model had the bias 
closest to zero, suggesting the least tendency to over or under-predict plasma 
concentrations. The opposite was true for venous sampling. Statistical 
comparison between models was performed on the basis of inaccuracy (MDAPEs). 
This meant that the direction of any bias was irrelevant and models were 
compared only on the overall magnitude of PEs. The Marsh Model was 
significantly more likely to provide PEs of greater magnitude than either the 
Covariates or Schnider Models based on arterial sampling. 
 
9.6.2 Comparison by Specific Patient Population 
Statistical comparisons between female and male patients and between younger 
and older patients were performed for each model based on bias. The reason for 
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this was that when using a PK model clinically it is important to know if it has a 
difference in tendency towards over or under-prediction depending on the 
covariates of the individual patient. Both of the Covariates and Marsh Models, on 
the basis of both arterial and venous sampling, showed a significant tendency 
towards more positive bias in male patients. The Schnider Model did not 
demonstrate any significant difference in bias between female and male 
patients and therefore can be considered to more effectively account for the 
covariate of gender than the other models.  
 
In contrast, only the Schnider Model, on the basis of venous sampling, showed a 
significant tendency towards increased positive bias in older patients. The Marsh 
Model had a non-significant tendency towards more positive bias in older 
patients on the basis of arterial sampling. This difference in bias is negligible in 
the Covariates Model and supports the rationale for adjustment of the central 
compartment volume (V1) and clearance (Cl) for age. 
 
9.6.3 Comparison of Relationships Between PE and Time 
In the simulation studies, both of the Covariates and Marsh Models showed a 
similar pattern of arterial and venous PE changes over time as described above 
for the validation study. The Schnider Model showed distinctly different results. 
As assessed by linear modelling, on the basis of both arterial and venous 
sampling, PEs showed a significant tendency to become more positive over time. 
This is likely related to the fact that the relatively small fixed central 
compartment volume specified by the Schnider Model resulted in over-prediction 
of plasma concentrations in the early phase after an increase in target 
concentration. 
 
Comparisons between model performances were made at early, intermediate 
and late sampling periods. During the early sampling period, on the basis of both 
arterial and venous samples, the Marsh Model was associated with significantly 
increased inaccuracy compared to the other two models. By the late sampling 
period this difference is no longer significant and indeed the Schnider Model is 
trending towards increased inaccuracy.  
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For all three PK models, the relationship between a-v PE difference and time 
can be fitted with an exponentially decreasing model. The a-v PE difference is 
relatively smaller for the Schnider Model in the early phases because the model 
tends to over-predict both arterial and venous blood concentrations.  
 
All of the above results need consideration when using any of the above models 
in clinical practice. The anaesthetist must be aware of how the bias of the 
selected model will change with time and be prepared to adjust target plasma 
or effect site concentrations based on this knowledge. 
 
9.7 Pharmacodynamic Model 
The VaSCoM Study has provided a range of estimates for the appropriate ke0 to 
use with the Covariates Model using an adaptation of the parametric approach. 
In the classic study by Sheiner et al, they described fitting a PK model for d-
tubocurarine while explaining the time course of the PD effects with the 
ke0(211). In the current study there was no new PK model fitted to the available 
data but there was simultaneous validation of the predictions made by the 
Covariates Model. 
 
Depending on whether the analysis was restricted to patients who had received 
the correctly specified Covariates Model or performed in all patients with 
simulated plasma propofol concentrations predicted by the Covariates Model, 
the range of ke0 estimations were 0.21 to 0.25 min-1 and 0.22 to 0.27 min-1 
respectively. There was minimal effect in restricting the allowed BIS values for 
E0 (baseline value with no drug present) and Emax (maximum change from 
baseline). Indeed all estimates were around the value of 0.26 min-1 that was 
originally implemented with the Marsh Model in the Diprifusor¥. This is 
reassuring given that the non-linear mixed effect modelling (NONMEM) was not 
performed using the standard NONMEM software but instead the nlmeODE 
Package in R. Further reassurance comes from Figures 8.17 and 8.18 that show 
the fixed and random effects models provide good fits to the available BIS data. 
The nlmeODE Package therefore provides a realistic alternative to NONMEM for 
PKPD modelling that avoids the need to purchase proprietary software.  
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9.8 Results in the Context of Similar Studies 
9.8.1 PK Model Comparison 
There are only two prior studies that have compared performance of the 
Covariates Model to that of Marsh and Schnider Models(203, 205). The first of 
these studies used data from nine patients who had received a propofol infusion 
and the second used data from 42 patients undergoing surgery with TCI of 
propofol via the Diprifusor¥.  
 
In terms of assessing the performance of the Covariates Model, the VaSCoM 
Study has several theoretical advantages over the previous studies. To begin 
with, the VaSCoM Study is the first to provide a new PK dataset and validated 
the Covariates Model by directly testing it with a demanding schedule of 
increasing and decreasing target plasma concentrations. Patients recruited to 
the VaSCoM Study received no pre-medication and during the study period, 
anaesthesia was provided only by TCI of propofol. In the two prior studies, 
patients were routinely pre-medicated and received multiple other drugs that 
could potentially affect the PK profile of propofol.  
 
Despite the technical differences between the studies, there are important 
similarities in the results. In common with both the infusion and TCI studies 
above, the VaSCoM Study highlighted the favourable overall performance of the 
Covariates Model as assessed by MDAPE compared to the Marsh Model. As was 
demonstrated in the previous TCI study, the tendency of the Marsh Model to 
under-predict in males relative to females remained present (albeit to a lesser 
degree) in the Covariates Model despite the adjustments made to the model on 
the basis of gender.  
 
The VaSCoM Study confirmed the observation of both earlier studies that the 
Schnider Model tends to over-predict in the induction phases and under-predict 
in the later phases of anaesthesia. Indeed the VaSCoM Study also agreed with 
the finding of the previous TCI study that the bias of all three models did not 
remain constant across increasing, stable or decreasing target plasma 
concentrations. 
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In recognition that all of the published PK models for propofol have been derived 
from quite distinct patient or volunteer populations, Eleveld et al attempted to 
derive a general purpose PK model with robust performance across multiple 
patient populations(255). They used PK data from 21 previous studies, obtained 
either from the Open TCI Initiative or through personal communication with 
authors. The Open TCI Initiative provides a forum for the discussion of issues 
related to PKPD modelling and a platform for the sharing of open source code 
and data for model development(256). A comment on the importance of this 
type of initiative is included in the concluding remarks of this thesis.  
 
The final PK model constructed by Eleveld et al could theoretically be used to 
deliver propofol TCI in patient groups ranging from neonates to the elderly and 
from normal to high to body mass index (BMI). To remain applicable across such 
a diverse population, the model was necessarily complex and accounted for the 
patient covariates of gender, age and weight in a scaled manner. The model also 
distinguished between individuals depending on whether they were patients or 
healthy volunteers. Despite the complexity, and assessing predictive 
performance in the same population it was derived from, the Eleveld model 
actually showed only modest improvement in inaccuracy in an adult population 
compared to the Covariates Model.  
 
9.8.2 PD Model Development 
As stated above, the range of ke0 estimates calculated in the VaSCoM Study are 
very similar to the ke0 implemented with the Marsh Model in the Diprifusor¥. 
Furthermore, the range is also similar to the ke0 of 0.2 min-1 calculated by Billard 
et al using BIS to monitor drug effect during increasing and decreasing plasma 
concentrations of propofol(216). 
 
Studies using different methodology to calculate ke0 have provided markedly 
different estimates. For example in the study by Thomson et al outlined above 
the ke0 was faster than calculated in the VaSCoM Study. The Thomson study has 
the strength of having used a clinical measure of drug effect. However, in terms 
of general applicability, the VaSCoM Study monitored drug effect at a wider 
range of predicted effect site concentrations and also studied the decline in 
drug effect with decreasing concentrations. Only patients between the ages of 
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21 and 65 years were recruited to the Thomson study and therefore the 
applicability of the ke0 to an older population cannot be assumed(250). 
 
Minto et al advocated a ‘time to peak effect site concentration’ (tpeak) approach 
to estimating ke0(155) and Struys et al used the technique to estimate an 
‘adjusted ke0’ for the Marsh Model of 1.2 min-1(217). By definition the tpeak 
approach only accounts for the pharmacodynamics relating to onset of drug 
effect and therefore is unlikely to provide as full a description of PD behaviour 
as the more detailed approach adopted in the VaSCoM Study.  
 
Inter-individual variation of pharmacokinetics and pharmacodynamics means 
that a single ke0 value will not accurately predict effect site compartment 
concentrations in all patients. It remains the responsibility of the anaesthetist to 
monitor the clinical effects of target Cp or Ce and adjust infusions appropriately.  
 
9.9 Related and Future Work 
9.9.1 Introduction 
In similar with the BioTBI Study, the high-resolution data collected as part of the 
VaSCoM Study have become a valuable research resource. Examples of recent 
and ongoing projects that are using the data in PKPD analysis are provided 
below. 
 
9.9.2 Non-Parametric Estimation of Ke0 
To confirm the parametric ke0 estimated in the VaSCoM Study, the arterial blood 
propofol concentrations and BIS profiles were used to estimate a non-parametric 
ke0(257). The overall population estimate was 0.27 and thus within the range 
estimated in the VaSCoM Study.  
 
9.9.3 Unique Modelling Approaches to PKPD 
Physiology based pharmacokinetic models provide an alternative to 
compartmental PK models by attempting to incorporate existing knowledge of  
physiological behaviour. The opposite of this approach is a purely data driven or 
‘machine learning’ system (Figure 1.1). Data from the VaSCoM Study have been 
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used in an input-output non-linear dynamical system to model pharmacodynamic 
behaviour of multiple physiological effects in individual patients(258). The need 
to consider multiple effect site compartments was acknowledged in early work 
by Fuseau and Sheiner(213) and the delay between hypnotic and haemodynamic 
effects of propofol has previously been explored(217, 259). Attempts to apply 
input-output non-linear dynamical systems beyond the individual patient level 
are currently underway. 
 
9.9.4 The Future of PKPD Modelling in Anaesthesia 
The Food and Drug Administration (FDA) has never approved the use of TCI 
devices to deliver anaesthesia in the United States of America. A recent series of 
editorials in Anesthesia and Analgesia detailed the history, technology and 
safety of TCI and concluded with a review of the potential pathways to FDA 
approval(184, 260-262). Licensing of TCI in the United States would undoubtedly 
lead to a substantial rise in usage and further increase the demand for more 
refined and generally applicable PKPD models.  
 
One approach to this challenge, as demonstrated in the Eleveld study above, is 
to use bigger datasets with more patients, to develop increasingly complex 
compartmental models. Alternative modelling approaches may include the 
adaptation of PBPK models or machine learning models for clinical practice. A 
final methodology that is likely to influence the future of PKPD modelling in 
anaesthesia is the concept of ‘feedback control’(263). Closed-loop TCI for 
hypnotic drugs in anaesthesia would involve using the PK models as the starting 
point for drug delivery and adapting the infusion rate based on some observation 
of the system. The observations may be pharmacodynamic, for example a pEEG 
measure of hypnosis, or pharmacokinetic, for example bed-side measurement of 
blood propofol concentration(264). A suitable measurement device has been 
evaluated in comparison to reference techniques(265, 266) but it is as yet 
unclear if it will become adopted into clinical practice. Similarly, for any closed-
loop control systems to be introduced into routine use in anaesthesia there will 
need to be extensive assessment of their safety and value. 
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9.10 Conclusions 
The VaSCoM Study has validated the Covariates Model for target controlled 
infusion of propofol and confirmed that it improves inaccuracy compared to the 
Marsh Model. There remains a difference in bias between female and male 
patients such that anaesthetists would need to respect this if using the model in 
clinical practice. A ke0 in the range of 0.21 to 0.27 min-1 has been estimated for 
implementation with the Covariates Model. 
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10 Overall Conclusions to the Thesis 
 
The management of patients with traumatic brain injury (TBI) on the 
neurological intensive care unit (NICU) and the use of target controlled infusions 
(TCI) in the operating theatre provide two excellent examples of how 
mathematical modelling can enhance knowledge and influence the practice of 
anaesthesia and critical care. As has been demonstrated with the BioTBI and 
VaSCoM Studies the modelling approaches and techniques can be adapted to suit 
the particular clinical questions. There is however one underlying theme that 
can unite all modelling studies of critically ill patients. An increasing quantity of 
high-frequency physiological data are collected from these patients with a 
correspondingly high financial and resource cost. It is therefore imperative that 
these data are appropriately used.  
 
To facilitate the most effective exploitation of physiological data, networks of 
clinicians and scientists must share the data and the associated analytic 
techniques. Examples of such networks have already been discussed in terms of 
TBI (BrainIT(96), CENTER-TBI(97), IMPACT(142)) and TCI (Open TCI 
Initiative(256)). The most well established repository for sharing data and code 
in the critical care domain is the Medical Information Mart for Intensive Care 
(MIMIC) Database(267, 268). Now onto its third iteration it is an openly available 
dataset comprising de-identified health data associated with around 40,000 
patients. Collaboration such as this represents one of the keys to leveraging 
technology to improve the care of critically ill patients. 
 
In support of the above theme, all of the analyses in this thesis have been 
performed using the open source statistical programming environment ‘R’(7). 
Ultimately the code will be made available via BrainIT for the BioTBI Study and 
via the Open TCI Initiative for the VaSCoM Study. 
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